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ABSTRACT
The elderly are increasingly retaining natural teeth into old age and many require regular
long-term medication for chronic medical problems. If these medicines contain sugars and have a
prolonged clearance time from the mouth, they may threaten dental health. The extent of regular
and long-term use of these medicines in the elderly was the subject of this study comprising five
surveys.
A general medical practice survey identified 2002 elderly patients aged 260 years taking 143
prescribed medicines with prolonged oral clearance (POC) long-term representing a prevalence of
use of 9.8%, with females aged 275 years more likely to be taking poe medicines long-term
(p<0.001). The main medical problems reported were cardiovascular and musculoskeletal,
however antacids, laxatives and minor analgesics were the most commonly prescribed poe
medicines. The prevalence of over-the-counter poe medicine use long-term was 1.1%.
Analysis of prescription numbers and quantities of medicines dispensed in primary care
identified 613 poe medicines representing 13% of the 457 million items dispensed in England in
1994, of which 30.4 million items (51%) were for medicines potentially used regularly and long-
term by the elderly. poe medicines prescribed in primary care represented the main area of use;
secondary care accounted for only 1% of the overall quantities prescribed in the Northern Region
and the contribution of OTemedicines to overall consumption of poe medicines was also low
«1 %). The influence of generic prescribing and dose form on the sugar content of the medicines
dispensed was substantial; over 80% of generic liquid oral medicines were sugars-containing
compared with 7% of proprietary liquid oral medicines.
Efforts should be made to draw the attention of government, manufacturers, prescribers and
dispensers as well as consumers to the major influences of dose form and specificity of
prescribing on the sugars content of medicines. This is crucial in those increasing number of
dentate individuals whose dental health is at risk through regular and long-term use of poe
medication.
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Introduction
CHAPTER 1
INTRODUCTION
The elderly are a growing population in the UK. In 1997 the population of the UK was 59
million individuals, of which 10.7 million (18%) were of a pensionable age, that is, aged 60 and
over (Office of Population Censuses and Surveys, 1998). The elderly population of the Northern
Region of England in 1995 was 0.62 million (21% of the overall Northern Region population),
which had increased from 0.44 million in 1979, when the elderly represented 14.2% of the
population (Office for National Statistics, 1995).
In a ten year period (1978 to 1988) the percentage of the UK population (16 years and over)
who were edentulous fell from 30% to 21% (Todd & Lader, 1991). During the same period, the
percentage of people aged 65 to 74 years, who were edentulous had decreased from 75% to 56%
(Downer, 1991). The increase in the elderly population, together with improved dental health, has
resulted in increased numbers of elderly persons retaining their own teeth.
The elderly suffer from more medical problems than younger members of the population;
individuals over the age of 65 years report twice as much chronic or long-standing illness as
persons under 65 years, however older people consult their doctor only one and a half times as
often (HMSO, 1996). Medicines prescribed to the elderly in England accounted for 49% of all
500 million items dispensed in 1997 (Department of Health, 1998). These medicines are mainly
administered orally, with the solid oral dose (e.g. tablets and capsules) being the most common
formulation. However, solid doses are not always suitable and other oral formulations available
for use include liquids, syrups, emulsions, pastilles, lozenges, chewable, buccal and sublingual
tablets. These may be used because they are more acceptable to the patient, for example, when
the patient may be too ill to swallow or if the solid oral dose causes local irritation. In addition,
the efficacy of certain medicines is optimised with certain dose forms. Antacids offer fastest relief
when formulated as liquids, and cough and sore throat products are most effective as pastilles and
lozenges.
Medicines formulated as liquids, syrups, pastilles, lozenges, and chewable and effervescent
tablets, buccal and sublingual oral slow release tablets all have an increased clearance time from
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the oral cavity compared with oral doses designed to be swallowed immediately. For the purposes
of this study they will be referred to as medicines with prolonged oral clearance (POC).
The role of sugar in the aetiology of dental caries has been well researched and it is clear that
frequent intake of sugar may cause dental caries. Studies have also shown that liquid oral
medicines which contain sugar and are used long-term, cause dental caries in children. If other
medicines with prolonged oral clearance also contain sucrose or other sugars with acidogenic
properties, they also may constitute a threat to dental health.
The elderly, who have higher morbidity and take more medicines are already a vulnerable
group of the population. Good oral health has many positive benefits including improved general
health as individuals with an intact dentition are able to consume healthier foods such as fibre. As
more elderly individuals retain their natural teeth into old age, dental health concerns which have
previously not required consideration are increasingly having to be addressed. The effects of the
long-term use of medicines upon dental health is just one of these concerns.
"I do not want two diseases: one made by nature and one made by the doctor" (Napoleon
Bonaparte 1820). The role of the health professionals is to cure and treat disease to the best of
their ability and use a holistic approach to treatment, considering all aspects of the patients health.
There are a number of issues to be considered with regard to medicine use in the elderly.
• Do medicines with prolonged oral clearance form a significant part of the overall
consumption of medicines in the elderly?
• Is the use of medicines with prolonged oral clearance restricted to acute short-term
treatments or are such medicines being used long-term on a regular basis?
• What are the prescribing and dispensing issues relating to medicines with prolonged
oral clearance?
• What proportion of medicines with prolonged oral clearance currently used overall and
by the elderly are sugars-containing and pose a threat to dental health?
• Are there any wider general health and dental health concerns resulting from the use of
medicines with prolonged oral clearance in the elderly?
2
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The use of liquid oral medicines and dental health in children has been studied previously but
research on the overall use of medicines prolonged oral clearance and their use in the elderly is
sparse and mainly anecdotal. An assessment of the prevalence of use of all medicines with
prolonged oral clearance in the elderly would provide valuable information which has been
previously unavailable.
These issues formed the background to the planning and the subsequent undertaking of the
series of surveys, which comprised this study.
3
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CHAPTER2
OVERVIEW OF MEDICINES CONTROL IN THE UNITED
KINGDOM
2.1 INTRODUCTION
This chapter will give an overview of the control of medicines in the United Kingdom (UK)
and mechanisms behind prescribing and dispensing in the UK.
2.2 REGULATION OF MEDICINES USED IN THE UK
The pharmaceutical industry is the UK's largest manufacturing industry, accounting for a
gross output of over £6500 million per year (Stone & Curtis, 1995), with sales to the British
National Health Service (NHS) of £2927 million, representing 10% of the gross cost of the NHS
(Association of British Pharmaceutical Industry, 1992). Medicines manufactured by the
pharmaceutical industry are subject to strict regulations and controls to ensure that the fmal
product is safe. A major catalyst for the imposition of these strict regulations was the 1961
thalidomide tragedy when it was discovered that the drug thalidomide prescribed for morning
sickness during pregnancy, caused foetal abnormalities (Ministry of Health, 1964). As a result of
this and other adverse events due to drug therapy, the government implemented medicines control
through the publication of the Medicines Act 1968 (HMSO, 1969).
Currently a new drug has to undergo a series of studies and clinical trials before it is granted
a product licence by the Licensing Authority (via the Department of Health) (Figure 2.1). Initially
a drug undergoes Phase 1 studies to look at biopharmaceutical data such as stability and
formulation, as well as the drug's toxicology and pharmacology (Harman, 1999). Once these data
have been collected and analysed, they are presented to the Medicines Control Agency, who can
allow Phase 2 and 3 studies (clinical trials on human subjects) to begin. Once these are complete,
evidence of safety and efficacy is submitted to the Committee on the Safety of Medicines (CSM)
who can then recommend whether a drug should or should not be granted a product licence by the
Department of Health.
The CSM is an independent advisory committee established under the Medicines Act 1968
(HMSO, 1969) which advises the UK Licensing Authority (Government Health Ministers) on the
quality, efficacy and safety of medicines in order to ensure that appropriate public health
4
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I standards are met and maintained. The Committee's responsibilities are broadly, two-fold; to
provide advice to the Licensing Authority on whether new products (new active substances)
submitted to the UK Medicines Control Agency (MCA) should be granted a marketing
authorisation, and to monitor the safety of marketed medicines, in close association with the
MCA's Post-Licensing Division to ensure that medicines continue to meet acceptable standards of
safety and efficacy. This is achieved through a system of licensing and monitoring medicines after
a licence has been granted. The MCA has separate divisions dealing with licensing, post-
licensing, inspection and enforcement of medicines, executive support and finance.
Once a product licence has been obtained, the manufacturer may bulk produce their drug for
distribution into primary and secondary care. These new drugs are subject to post marketing
surveillance in the form of the Yellow Card Scheme, where prescribers are asked to report any
adverse drug reaction (ADR) to the new drug. Data from these reports are analysed to assess the
probability of a reaction being caused by the drug. The CSM provide regular bulletins for health
care professionals, updating them on potential ADRs. Figure 2.1 shows the pre- and post-
marketing controls on manufacturing and marketing of new drugs.
2.3 CLASSIFICATION OF MEDICINES USED IN THE UK
2.3.1 Prescription only medicines (POM)
Prescription only medicines (POM) are usually potent drugs which have to be prescribed by
a qualified medical or dental practitioner in the UK. These medicines are generally available to
the UK public, prescribed on a NHS prescription. However in April 1985, in a bid to reduce
costs, the government selected a list of medicines it felt were not efficacious and created a NHS
blacklist of drugs it was not prepared to fund using budgets and amended the NHS Regulations to
limit the range of preparations available within therapeutic groups (Department of Health, 1995).
As well limiting the range of drugs in a therapeutic section, drugs with limited clinical value were
also blacklisted. Blacklisted products cannot be prescribed on NHS prescription forms. They
have to be prescribed privately on a private prescription and the patient will usually incur a fee for
this service.
5
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I 2.3.1.1 Branded and generic medicines
All new medicines are generally manufactured by large multinational companies who either
produce and sell the medicine directly or sell the chemical entity or product to another company.
These medicines are assigned brand or proprietary names. As well as this name, the medicine will
also have a chemical name which can be either the British Approved Name (BAN), recommended
International Non-proprietary Name (rINN) or the scientific name (Kopp-Kubel, 1995). This
chemical name is generally referred to as the generic name and the Medicines Act 1968 (HMSO,
1969) states that it must be included on the medicine label.
Most new medicines are given a patent for a number of years (usually 10 to 15 years) so that
the developers of the drug can recoup the research and development costs incurred in getting the
drug licensed for use. Once the patent expires, any pharmaceutical manufacturer can produce the
drug as long as it complies with strict quality guidelines regarding bioavailability, stability and
palatability. These generic formulations are also subject to the strict regulations and control
imposed on new medicines, however, as these generic manufacturers have not incurred the
research and development costs, they tend to be cheaper than the proprietary equivalent. Although
there may be many generic formulations of a medicine, not all companies distributing them are the
manufacturers; some buy the product and then pack it into their own packaging and it may be that
the source of the raw material for the medicine may vary from time to time. Currently, European
Community guidelines do not require the excipients (the inert ingredients in the formulation) in
generic formulations to be identical (Feely, 1996).
The spiralling costs of the NHS drugs bill has forced government to seek ways of reducing
this expenditure and this prompted the publication of the 1982 Greenfield report, which stated that
there were advantages to be gained from generic prescribing but, in particular, highlighted the cost
savings (Greenfield, 1982). As a result of this, generic prescribing and dispensing has increased
dramatically over the last 15 years, with 60% of all prescribing in England in 1997 being generic
compared with 39% in 1987 (Department of Health, 1998). The proportion of drugs generically
dispensed however, forms a lower proportion of use since not all drugs prescribed generically are
available in a generic form.
6
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I 2.3.1.2 Parallel imports
The manufacture of medicines in other countries is sometimes considerably cheaper than in
the UK and this has led to their increased import into the UK for dispensing. This has obvious
financial advantages for community pharmacists in that they can buy a branded product more
cheaply abroad and be paid the higher price of the original UK brand. This loophole in NHS
regulations has necessitated further control of these medicines and now only those with a Parallel
Importing Product License (PL[PID can legally be dispensed. Pharmacists using unlicensed
products are open to disciplinary action for professional misconduct (Royal Pharmaceutical
Society of Great Britain, 1998).
2.3.2 Over the counter (OTC) medicines
Medicines that can be bought 'over the counter' (OTC) are generally safe, well established
preparations, many of which have been available for a number of years. OTe medicines can be
classified either as 'pharmacy only' (P) or general sales list (GSL). Pharmacy only (P) medicines
are those that can be bought without a prescription but have to be sold under the supervision of a
pharmacist. GSL medicines can be sold in any retail outlet without any restrictions or supervision
from a healthcare professional.
All P medicines are governed by strict regulations compiled by the Royal Pharmaceutical
Society of Great Britain which states that a pharmacist must at all times be on the premises during
the sale of a P medicine (Royal Pharmaceutical Society of Great Britain, 1998). The pharmacist
does not have to be directly involved in the sale as long as a pharmacy sales assistant has been
trained to a National Vocational Qualification (NVQ) level and there is a protocol on the sale ofP
medicines displayed in the pharmacy. However, the pharmacist must also be present to deal with
any problems associated with the sale. P medicines are price protected by the Resale Price
Maintenance (RPM) scheme which, as the name suggests, maintains the cost of all P medicines to
ensure community pharmacies cannot compete with each other and that smaller rural pharmacies
providing a vital service to the community can continue as a viable business.
To optimise the use of general medical practitioners time and cut down on waiting times,
patients are being encouraged to seek advice from community pharmacists on healthcare matters
(National Pharmaceutical Association, 1990). Pharmacists are being encouraged to assess a
medical complaint identifying any serious underlying problems, in which case the patient would be
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I referred to the general medical practitioner. If the condition was minor then the pharmacist could
treat it using the appropriate OTe medicine with counselling and guidance. OTe medicines sold
to patients are not currently recorded, although some of the latest computer software used in some
pharmacies can record a sale of a OTe medicine in a patients record. This allows the pharmacist
to check any interactions with prescribed medicines, ensuring that the OTe medicine is safe for
that patient.
Medicines classed as GSL medicines can also be bought at supermarkets and other retail
outlets and are normally sold without any supervision or counselling. Recent pressure from the
pharmaceutical profession led to reclassification of two such GSL medicines (paracetamol and
aspirin) as P medicines, so that packs of 16 and above could only be bought from pharmacies
(National Pharmaceutical Association, 1998), requiring pharmacists to supervise the sale and
appropriate use of these potentially harmful products.
2.4 PRESCRIBING AND DISPENSING OF MEDICINES IN THE UK
2.4.1 Primary health care (Figure 2.2)
In the UK, the National Health Service allows the public access to free healthcare from their
general medical practitioner. The patient will present with a complaint and after assessment, the
general medical practitioner may prescribe a treatment with a medicine by issuing a prescription
to the patient. This is usually a NHS prescription which is taken to a community pharmacy for
dispensing. The pharmacy must have a contract with the Family Health Services Association
(FHSA) before it can dispense a NHS prescription, the most common of these being the FP 10
which is the script used by general medical practitioners for prescribing in primary care. The
dentist uses the FP14 and the FPI0(HP) and FPI0(S) are used by hospital doctors and the armed
forces, respectively.
If a general medical practitioner prescribes a proprietary product, then the dispensing
pharmacist must dispense that brand. If the medicine is prescribed by the generic name then any
brand which is chemically equivalent may be dispensed.
The pharmacist is responsible for ensuring that the prescription has been correctly written,
with the correct dose, that the drug does not interact with other therapy and that the drug has not
been blacklisted, after which the medicine is dispensed and the script filed. Most pharmacies keep
8
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I patient medication records (PMRs) for each patient, however this is not a requirement within the
terms ofNHS pharmacy services and the quality of information recorded can vary from pharmacy
to pharmacy.
The NHS prescription will either be exempt from the NHS prescription charge or the patient
will have to pay this charge (currently £5.80) for each item dispensed. Those exempt must
indicate on the back of the script the reason for their exemption; for example, being aged over 60
years, or being entitled to income support. Some medicines prescribed are 'over the counter'
(OTC) products; if their cost is less than the prescription charge and the indication is appropriate,
a pharmacist will usually suggest that the patient buy the OTC pack and will give the appropriate
counselling regarding to administration and dosage.
At the end of each month the NHS scripts (e.g. FPIO and FP14) from each community
pharmacy are sent to the Prescription Pricing Authority (PPA); the special health authority
responsible for paying community pharmacy contractors. The PPA calculates the cost of the
drugs dispensed and this fee is reimbursed to the pharmacy contractor along with a dispensing fee
for each item dispensed. Additional fees for prescriptions for controlled drugs and
extemporaneous dispensing are also paid where the pharmacist has endorsed the prescription to
claim these fees. Once payment has been made, the PPA collate the data to produce prescribing
reports called Prescribing Cost and Analysis (PACT) and Prescribing Cost Analysis (PCA)
reports. PACT reports are produced quarterly for each general medical practitioner and give a
summary of the prescribing costs for that quarter. They are also available six monthly and yearly
and are available to various health professionals for prescribing research.
2.4.2 Secondary health care
In hospitals the control and dispensing of medicines is managed by the hospital pharmacy
service. For inpatients, the hospital pharmacy dispenses to wards following requests from doctors
or nursing staff. The ward pharmacist consults with doctors and is responsible for checking the
dose and any interactions or contraindications for use. For outpatients, following a consultation
and a change in medication, a first prescription is issued for 7 days, which is dispensed at the
outpatients pharmacy in the hospital. If the treatment is long-term, the consultant will write to the
general medical practitioner, who will continue prescribing the medicine. Unlike community
9
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pharmacies, dispensing information in hospital pharmacies IS not recorded and there IS no
equivalent information on prescribing or dispensing.
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I Figure 2.1 Pre- and post-marketing control of new drugs.
( UNLICENCED JNEW DRUG
1
( PHASE I STUDIES )
1
MEDICINES CONTROL AGENCY
REJECTED ACCEPTED
APPEAL PHASE II HUMAN STUDIES
COMMITTEE on the SAFETY
of MEDICINES
DEPARTMENT OF HEALTH
LICENCING AUTHORITY
LICENSED
NEW DRUG
YELLOW CARD SCHEME
for Adverse Drug Reactions
reporting
J Figure 2.2 The prescribing and dispensing of medicines in primary care, in the
UK
General medical or
dental practitioners
Prescription
Pricing
Authority
(PPA)Health Authority,
Prescribing Advisors,
Prescribing Units
Review of the literature
CHAPTER3
REVIEW OF THE LITERATURE
3.1 INTRODUCTION
The population of elderly individuals is increasing and not only are there more older people,
but they also form a larger proportion of the population. The proportion of persons over the age
of65 years worldwide in 1950 was 5.l%, which had increased to 6.4% by 1994 and is estimated
to reach 8.8% by the year 2020 (Office for National Statistics, 1998). In Europe and the USA
this proportion of elderly (aged 65 years and over) in the general population is higher; it ranged
from 12.6% in the USA to 16% in the UK, in 1994, and is estimated to rise to 16.1% and 18%
respectively in 2020 (Office of Health Economics, 1997). The UK population in 1994 stood at
57.8 million individuals of whom 48.7 million were living in England. Of these 48.7 million, 7.7
million (16%) were aged 65 years and over (Office of Population Censuses and Surveys, 1995)
and of these, 4.4 million (57%) were aged 65 to 74 years and 3.3 million (43%) aged 75 years and
over. As the elderly make more demands on the healthcare services, this steady increase in the
population has serious implications for healthcare and the future planning of services for the
elderly.
The review of the literature will cover four major Sections. Section 3.2 will consider the
ageing process and the theories and mechanisms of ageing. The physiological and
pharmacological changes as a result of ageing are also discussed in this Section. Common health
problems in the elderly, the use of healthcare services, together with the types of medication used
by the elderly and the associated problems are reviewed in Section 3.3. Section 3.4 will consider
the oral health of the elderly, their nutritional status and, in particular, oral problems caused by
medication. Section 3.5 discusses sugars, sugars-containing medicines and medicines with
prolonged oral clearance and the impact of their use on oral health.
3.2 MECHANISMS AND PHYSIOLOGY OF AGEING
3.2.1 Introduction
"How old would you be if you didn't know how old you was" Satchel Paige (Cristofalo,
1990).
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Why do we grow old? This question must be one of the most commonly addressed issues for
mankind. It has been postulated that God or Evolution caused animals to age to make room for
younger, fitter off-spring to inherit the earth (Comfort, 1965) suggesting that the older individuals
are not required once they have fulfilled their role in producing off-spring. However, it can be
argued that the old offer an indirect evolutionary advantage by offering their experience to the
young. Examples of this include certain moths that are foul tasting to birds. The older moth
offers itself to the bird, saving the lives of the young moths (Comfort, 1965). This theory of
ageing suggests a pre-programmed mechanism, but what processes cause organisms to age? Do
animals simply 'wear out' during their lives, or are there processes which control the ageing
process?
There have been many attempts to define ageing. Bromley (1988) defined ageing as "a
complex cumulative, time-related process of psycho-biological deterioration occupying the adult
phase of life" (Bromley, 1988). Ageing has also been described as a "decline in fertility and
vitality, with an increase in mortality" (Comfort, 1965), as a "process which brings about an ever
increasing age-specific mortality" (Fairweather, 1991) and an "increasing vulnerability to
environmental change" (Comfort, 1965).
These many definitions reflect the difficulties involved in research into ageing when one
considers the many ageing scenarios that occur in nature, as well as the impact of various
environmental and intrinsic mechanisms occurring independently.
3.2.2 Ageing Mechanisms
There are a number of theories regarding the ageing process, and many of these attempt to
identify a single cause for senescence. However, it has been argued that ageing is unlikely to be
the result of a single factor (Cristofalo, 1990). Ageing may be a result of environmental factors or
it may be an intrinsic process, involving changes in the body over time that are independent of
extrinsic interactions (Harman, 1998). The following theories look at possible intrinsic
mechanisms for the process of senescence.
3.2.2.1 Intrinsic Ageing
Research into intrinsic ageing has focused on three major areas: (a) 'programmed' ageing,
(b) stochastic theories which consider the concept of error accumulation and (c) reactive oxygen
and free radicals theory.
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I 3.2.2.1.1 Programmed Ageing
Programmed ageing involves the concept of a decaying biological clock, with each organism
having a specified lifetime (Baillie & Woodhouse, 1988; Wilson, 1974). Like other lifetime
events (e.g. puberty, menopause), it has been suggested that ageing is genetically determined
within a species. Man has an approximate life-span of eighty five years. Other organisms such
as the ocean quahog (Arctic islanica) may live for two hundred years, whilst certain bird species
are thought to live for approximately forty years (Fairweather, 1991). This implies that individual
species have been 'programmed' to live to a certain maximum age, after which they will die. It
has been suggested that the development of maximum life-spans could be a part of the
evolutionary process; senescence being required to provide 'space' for future generations
(Fairweather, 1991).
Genetic control of senescence after menopause has been suggested (Wilson, 1974), and the
possibility of a 'deleterious' gene or genes has also been considered, along with hypotheses that
these genes may be associated with fertility, and in later life (post-reproduction) be involved in
ageing (Cristofalo, 1990). This would suggest that ageing is the price we pay for successful
reproduction and evolution, however these theories have yet to be scientifically proven.
3.2.2.1.2 Stochastic theories
The group of stochastic ageing theories are based upon the knowledge that within the internal
environment, cell components are constantly being damaged. Over time this damage accumulates,
until a threshold is reached when the cell can no longer function and a level of damage
incompatible with life is reached (Cristofalo, 1990).
Error accumulation is the result of mutation, due to external factors such as radiation, in
mitochondrial (mtDNA). As mitochondrial DNA, is used to produce mitochondrial RNA
(mtRNA), these mutations produce incorrect sequences of mtDNA which is then incorrectly
transcribed into incorrect mtRNA, thus producing faulty enzymes and proteins. Over time this
will result in the gradual loss of efficiency of the mitochondrial energy production system, with
pathological consequences (Linnane et al., 1989).
Using DNA isolated from aged monkeys, it has been shown that mitochondrial DNA
deletions do occur and the incidence of these increase with age (Lee et al., 1993). Experiments
involving skeletal muscle mitochondria have shown that there is a reduction in their function as a
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I result of ageing (Lee et al., 1993). The central point ofthis theory is that the cumulative effect of
these errors will build up over time, reducing the efficiency of the various organs and systems in
the body.
3.2.2.1.3 Free radicals theory
Normal metabolic reactions in the body result in the formation of free radicals which are
reactive molecular fragments. Normally these free radicals are destroyed by enzyme systems such
as superoxide dismutase, however some free radicals escape destruction and cause damage to
inter-cellular contents. Damage accumulates and can eventually interfere with the normal
function of the cell. It has been postulated that these effects cause ageing (Cristofalo, 1990;
Harman, 1998), and that advancing age is also associated with a reduced capacity to limit this
damage, due to a reduced function of the cells' enzyme repair systems, resulting in more free
radicals and more damage (Horan & Pendleton, 1995). NoW (1993) reviewed the research into
the production of free radicals and concluded that ageing is associated with an increase in free
radical production, however it was unclear whether free radicals contributed to the initiation or
propagation of ageing (Nohl, 1993).
A lower metabolic rate is associated with lower production of free radicals. In a species of
mammals, the bigger the animal, the lower the metabolic rate. An inverse relationship has been
shown between metabolic rate and life-span suggesting that the production of free radicals may be
related to the life-span of a species (Harman, 1998). However, if the free radical theory was
entirely correct it would mean that exercise resulting in an increased metabolic rate and greater
caloric expenditure would produce more free radicals and reduce life-span (Dhahbi et al., 1998).
Experiments using antioxidants such as Vitamin E have failed to prove that reducing free radicals
increases life expectancy (Cristofalo, 1990).
There is now a growing consensus, largely based on the results of measures to minimise more
or less random endogenous free radicals, that such creations are a major cause of ageing (Harman,
1998).
3.2.2.1.4 Other intrinsic theories
The immune system forms the basis for another intrinsic theory of ageing (Cristofalo, 1990).
This theory suggests that reduced T-cell numbers and function, which occur with age, lead to
reduced resistance to infection, and the emergence of age-associated auto-immune disease. In
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I addition, as a result of mutation described by the stochastic theory of ageing (Section 3.2.2.1.2),
the body's own cells may not be recognised and be attacked by auto-antibodies (Comfort, 1965;
Harman, 1996).
3.2.2.2 Extrinsic ageing
There is great inter-species and intra-species variation in life-span. For example, humans
have an average life-span of eighty five years, yet may live up to one hundred and twenty years or
die at fifty years or younger. Intrinsic theories have tried to explain the mechanisms of ageing and
the programmed ageing theory has suggested that we live up to a certain genetically predefined
point. These theories cannot however explain the variation in life spans within the same species.
This intra-species variation is more likely to be due to exposure to environmental and
lifestyle factors which vary from person to person. For example, twins separated at birth and
brought up in different environments will show different physical characteristics and differing life
expectancy. Environmental conditions such as early exposure to disease, accidents during
childhood or geographical location can cause a person to age or die before others.
In summary, ageing appears to be multifactorial in aetiology, involving a complex interaction
of many intrinsic and extrinsic factors which are still not fully understood, although the most
recent literature on ageing theories suggest that free radicals are the major cause of ageing.
3.2.3 The effects of physiological changes due to ageing upon pharmacokinetics
3.2.3.1 Introduction
Age-associated changes can be found in most adult body systems. The possible causes of
these ageing effects have been discussed in the previous section. The effects of age differ between
those structures and systems which are rapidly replaced (e.g. the skin) and those which are non-
renewable (e.g. teeth).
Pharmacokinetics is the study of the mechanisms by which drugs are absorbed, distributed,
metabolised and excreted from the body. The pharmacological effects of drugs are usually
dependent upon interactions between drugs and receptors. Over recent years research on the
effects of age upon pha~acokinetics has focused on the three areas of absorption, distribution
and excretion. This Section will review this research and discuss the major findings.
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'3.2.3.2 Drug absorption and the Gastrointestinal System
Ageing is associated with secretory and morphological changes in the gastrointestinal system.
After the age of 50 years, about 80% of stomachs show muscular atrophy. This is due to a
cumulative effect of surface injury and repair and is accompanied by reduction in mucus
production (Lamy, 1991). Stomach function is further impaired by a reduction in splanchnic
blood flow by as much as 50%, by the age of 65 years. To add to these effects, the influence of
psychosomatic and behavioural factors such as fear of disease and death, depressive illness and
anxiety have a negative effect on gastric motility and secretory function (Lamy, 1991). Ageing is
associated with a decline in gastric secretions, especially acid secretions, with secretory volumes
as low as 50% in some elderly patients, compared with younger individuals (Geokas &
Haverback, 1969). In addition, the elderly may have a reduced splanchnic blood flow, increase in
gastric pH, impaired intestinal motility and decreased gastric motility (Geokas & Haverback,
1969; Ouslander, 1981) and as a result of these effects, chronic gastritis, irritable colon, spastic
colitis, heartburn, and nausea are frequent problems. As gastritis increases with age, there is a
reduction the number of chief and parietal cells in the mucosa (Lamy, 1991), resulting in an
ageing stomach which is vulnerable to insult by exogenous substances, especially drugs and in
particular, non-steroidal anti-inflammatory and corticosteroid drugs.
Although one would expect an age-related change in the absorption of pharmacological
agents, evidence from investigative studies has shown that few drugs have altered absorption in
the elderly (Avorn & Gurwitz, 1990). Drugs that are affected include digoxin and
chlordiazepoxide, where absorption is slightly delayed in the elderly.
3.2.3.3 Drug distribution
There is a decrease in total body water and lean body mass, with a proportionate increase in
body fat, with age. With the decline in muscle mass and power, conditions such as arthritis and
osteoporosis become common in the elderly (Lamy, 1991). A decreased bone turnover in the
elderly leads to a lower bone density which accounts for the increased incidence of fractures in
this population, particularly the hip and pelvis (Diggory et al., 1991). Also as a result of the
decrease in lean body mass, by the age of 65 years the average man will have lost 12kg, and the
average woman 5kg in weight (Ouslander, 1981). These changes can either increase or decrease
the volume of distribution of drugs, depending on the type of drug. For example water-soluble
(polar) drugs (e.g. diazepam and nitrazepam) have a reduced volume of distribution and therefore
increased initial concentrations in the blood. The main exceptions to this are the antibacterial
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.tobramycin and the muscle relaxant pancuronium (Williams & Lowenthal, 1992). Conversely the
fat-soluble (non-polar) drugs (e.g. cimetidine and digoxin) have a greater volume of distribution
and therefore a lower initial concentration, however the volume of distribution is not affected for
some non-polar drugs, such as lorazepam and amobarbital (Williams & Lowenthal, 1992).
Drugs can only act if they are in the free, unbound form. Proteins such as serum albumin
bind with certain drugs, reducing the drugs concentration in plasma. Lower serum albumin levels
may be found in the elderly due to age, disease or malnutrition, causing lower drug protein binding
(Avorn & Gurwitz, 1990; Williams & Lowenthal, 1992), allowing more free drug to circulate,
leading to a larger pharmacological effect. As a result, drugs such as acetozolamide, diazepam,
naproxen, phenytoin, tolbutamide and warfarin, which normally bind to serum albumin, have a
more marked pharmacological response in the elderly (Piraino, 1995).
3.2.3.4 Excretion
The excretion of drugs from the body is through either the kidneys or the liver and age related
changes in these systems can affect the breakdown of these drugs, potentiating side effects or
resulting in sub-therapeutic plasma levels.
Age-related changes in hepatic function will affect the distribution of drugs as the liver is
responsible for the breakdown of a number of drugs using a system of enzymes known as the P-
450 system. Drugs such as cimetidine, propranolol, metoprolol and labetalol are primarily
deactivated during first pass metabolism through the liver. With age, the efficiency of this process
is reduced, resulting in increased circulating levels of these drugs (Piraino, 1995).
Age and disease are the major contributors to renal changes. The kidneys of elderly
individual tend to be smaller in size, and have a reduced blood flow. The decrease in the renal
blood flow and number of functional glomeruli results in a drop in the glomerular filtration rate
which makes the kidneys to become less efficient at clearing metabolites and other waste products
from the blood (Beck & Burkart, 1985). Glomerular filtration rate decreases by between 35 per
cent and 50 per cent from the age of 70 to 90 years (Ouslander, 1981; Williams & Lowenthal,
1992). In addition, there is a fall in creatinine clearance by the kidneys, however the creatinine
levels in plasma remain the same suggesting that creatinine production has also decreased.
This change in renal function and its impact on pharmacokinetics has been well documented
(Beck & Burkart, 1985; Ouslander, 1981; Williams & Lowenthal, 1992). As a result of this
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.reduction in renal function, drugs eliminated by the kidneys (e.g. digoxin, ranitidine, atenolol) are
retained at higher plasma levels, leading to potential toxicity and adverse drug reactions in the
elderly.
3.2.4 Other physiological changes in the elderly
The skin is the largest human organ and shows the most visible changes during chronological
ageing. The reduction in subcutaneous fat, increased collagen and fragmented inelastic elastin
cause the skin to wrinkle (Diggory et al., 1991). The cells of the stratum corneum tend to hold
less moisture, making them more brittle (Balin, 1990). The decreased renewal rate of skin
increases the time taken for wounds to heal. The number of melanocytes decrease with age,
causing graying of the hair and more importantly, decreased protection from exposure to
ultraviolet radiation.
Age-related changes in the cardiovascular system, include hypertrophy of smooth muscle
cells, a decrease in connective tissue elasticity, as well as an increase in atherosclerosis; changes
which may result in increasing blood pressure with age (Applegate, 1990; Horan & Pendleton,
1995). The function of the resting heart does not vary with increasing age (Lakatta &
Gerstenblith, 1990), however changes in the peripheral circulation associated with age are
compensated for by hypertrophy of the left ventricle.
Ageing is associated with several changes in pulmonary physiology. The diameters of the
trachea and central airways increase, increasing the anatomical dead space. The lung weight
decreases by 20%, and there is a loss of alveolar elastic recoil (Lamy, 1991). These changes to
the airways result in a decrease in maximum expiratory flow and an increased risk of respiratory
failure.
Age also affects the central nervous system. Although there is approximately a 2% decrease
in the mass of the brain per decade after 50 years, the most important changes are observed at a
microscopic level. There is neuron loss from all areas of the brain which may be related to the
neurological conditions associated with ageing (Horvath & Davies, 1990).
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3.2.5 Summary
The process of ageing has attracted extensive research and many theories have been
postulated as to why we age. More important in the management of the health of the elderly is the
effect of these changes on their physiology. In addition to the broad circulatory, respiratory and
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gastrointestinal changes with ageing, there are changes in the distribution and excretion of drugs,
which will affect the final plasma levels of these drugs. These effects must be accounted for in the
prescribing and dispensing of medicines to the elderly and may require changes in dosage or dose
form as a result. The following section will look at the general health of the elderly as a result of
ageing and discuss the pharmacological treatment and control of any health problems.
3.3 GENERAL HEALTH OF THE ELDERLY
3.3.1 Introduction
Since the tum of the century there have been major improvements in the health of the UK
population. With regard to life expectancy, only 332 males and 599 females per thousand were
expected to reach the age of sixty five years in 1896, but by 1945 this number had increased to
398 males and 725 females per thousand (Stocks, 1950). The approach of the Second World War
prompted major social and healthcare reforms and major scientific advances were made with
introduction of the first drugs effective against life-threatening infections. Diseases such measles,
rubella, whooping cough, smallpox, chicken-pox, syphilis and mumps were all major causes of
death at the tum of the 19thCentury (Stocks, 1950). However, Salvarsan for the treatment of
syphilis and 'Sulfa Drugs' for the treatment of pneumonia were introduced in the late 1930s.
Penicillin became available after 1941. Major healthcare reform during and following the second
world war resulted in the publication of the Beveridge Report in 1942, which formed the basis for
the foundation of the Labour Party's National Health Service in 1948 (Abel-Smith, 1978)
providing comprehensive healthcare for all ages. The free NHS was not to remain so for long,
with the introduction of prescription charges to try and reduce the burden on the Health Service.
In 1948, in the UK, life expectancy at birth was 66.4 and 7l.2 years for males and females
respectively and the life expectancy for a 65 year old male and female was 12.8 years and 15,3
years respectively. By 1994, life expectancy at birth had increased to 74.3 and 79.6 years and life
expectancy for a 65 year old had increased to 14.6 and 18.2 years for males and females
respectively (Office of Health Economics, 1997).
3.3.2 The elderly as health care users
Elderly persons have a higher morbidity than younger members of the population; chronic ill
health being reported by 62% of persons aged sixty five years and over, compared with only 17%
and 31% of persons aged under sixteen and sixteen to sixty four year olds, respectively, in 1994
(Office of Health Economics, 1997). In 1993, 15% of the UK population of all ages consulted a
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NHS general medical practitioner. This proportion was greater in the elderly population, with
20% and 21% of 65-74 year olds and 275 year olds respectively consulting a doctor (Office of
Health Economics, 1997). Of the 45.6 million consultations with a NHS general medical
practitioner in 1994, 7.9 million (17%) were by persons 65 years and older, of which 3 million
were for cardiovascular conditions, 2.6 million for musculoskeletal problems and 2.1 million for
central nervous system disorders (Office of Health Economics, 1997).
Expenditure on health in the UK was £1 billion in 1960, and rose to £46 billion (£4l.4 billion
was for NHS expenditure) in 1994. Of the £41 billion NHS expenditure, 49% was for patients
aged 65 years and over. The cost of this drug therapy in 1994 was £l.5 billion pounds, which
represented 44% of the total drugs expenditure of £3.4 billion in England in 1994 (Prescription
Pricing Authority, 1995).
In developed countries, the elderly use more health resources than younger members of the
population. Studies in the United States (Williams & Lowenthal, 1992) have calculated that
individuals aged sixty five years and over account for 25 per cent of the total drug expenditure, a
figure which is estimated to reach 40 per cent by the year 2030 (Williams & Lowenthal, 1992).
The elderly population also account for 25-30% of all healthcare expenditure (Ouslander, 1981).
3.3.3 Drug prescribing to the elderly
3.3.3.1 In the UK
Medical problems in the elderly are managed mostly by drug therapy prescribed by their
general medical practitioner in primary care. Even those individuals referred for secondary care
in hospitals as outpatients have their drug therapy prescribed by general medical practitioners
under the guidance of a consultant.
Analysis of prescriptions dispensed shows that, in terms of number of drugs dispensed, the
elderly require relatively more than a younger population. The elderly in the UK were dispensed a
mean of 22.2 prescription items per head of population in 1997 (Department of Health, 1998).
This amounted to 245 million prescriptions, 49 per cent of all prescription items in 1997, an
increase of 4% from 1984 (Department of Health, 1998).
Other studies in the uk have looked at more specific areas of prescribing. Of 1003 patients
aged 69 years and over taking part in a longitudinal study looking at prescribing trends in
Nottingham, 71% were found to be taking at least one prescribed medication in 1985, with a mean
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of 1.8 drugs per patient being taken. By 1989, this proportion of elderly taking at least one
medication per patient had increased to 75.2%, with a mean of 2.1 drugs per patient (Rumble &
Morgan, 1994). Of the 1003 patients, the proportion taking 2 or more medicines were 49.4% and
54.4% in 1985 and 1989 respectively. These results were consistent with a study by the
Consumers Association (Consumers Association, 1990) which surveyed the medication of 805
elderly persons in ten parliamentary constituencies in England and showed that 70% were
prescribed at least one medicine on a long-term basis, with an average of 2.8 medicines per
person. The Rumble and Morgan study (1994) also showed that with increasing age the number
of drugs taken also increased (Rumble & Morgan, 1994), with patients aged 69-72 years taking a
mean of 1.3 medicines each, which increased to 3 medicines per person in the 89 years and over
group, in 1989 (Rumble & Morgan, 1994). There was no data for patients under the age of69.
3.3.3.2 Worldwide
Drug prescribing to the elderly in Germany has shown a higher level of utilisation. When the
drugs of 300 elderly patients aged 75 years and over attending a geriatric clinic in Heidelberg,
Germany from 1984 to 1989 were examined, 94% of patients were taking one or more medicine,
with a mean of 4.3 medicines per patient (Kruse et al., 1991). The study showed that
institutionalised patients were on a significantly higher number of medicines than non-
institutionalised patients (5 medicines per person compared with 4.1). Of the 300 patients, in the
study 118 (43%) were prescribed five drugs or more.
Drug utilisation research in 324 elderly patients aged 55 years and over in four nursing
homes and central hospitals in urban Harare, Central Africa showed that 210 (65%) were taking
at least one medicine (Nhachi et al., 1994). The group were taking 1117 different medicines, with
each person taking a mean of 3.4 medicines.
3.3.4 Drugs commonly used in the elderly
3.3.4.1 Introduction
Increased morbidity in the elderly accounts for large numbers of drugs taken by this group of
the population. Table 3.1 shows some of the common groups of drugs dispensed in England
during a one year period (1994), the number of prescriptions written and the total cost for
prescribing these drugs to elderly exempt patients.
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,Table 3.1 Prescription Cost Analysis data for Elderly Exempt Patients in England
1994 (prescription Pricing Authority, 1995)
BNF Therapeutic Items Dis pensed cosr
Section' Group Millions % £ millions %
01 Gastrointestinal 19 10.5 234 12.0
02 Cardiovascular 51 27.6 343 25.8
03 Respiratory 14 7.5 145 10.9
04 Central Nervous System 36 19.5 133 10.0
05 Infections 10 5.6 48 3.6
06 Endocrine 10 5.5 60 4.5
09 NutritionIBlood 5 2.9 35 2.6
10 Musculoskeletal 12 6.2 94 7.1
Others 27 14.6 45 23.3
Total 184 100 1,544 100
lBritish National Formulary No. 34 (British Medical Association & Royal
Pharmaceutical Society, 1997)
2Net Ingredient Cost (the cost of drugs, excluding any other charges such as
dispensing and other fees)
3.3.4.2 Cardiovascular drugs
Table 3.1 shows that in 1994, 27.6% of all drugs prescribed to the elderly (those exempt
from prescription charges) in England were drugs used in cardiovascular conditions. Other
studies have also confirmed that the most prevalent conditions in the elderly are those that affect
the cardiovascular system. In a study of 300 patients in Germany (Kruse et al., 1991),276 were
taking 782 drugs, with 28.5% of these drugs being cardiovascular medicines. In the study looking
at medication use in the four nursing homes and central hospitals in urban Harare, Central Africa,
over 20% of the drugs used were for cardiovascular medicines, of which hydrochlorothiazide and
frusemide were the most common (Nhachi et al., 1994). Of the 1409 drugs highlighted as being
used by patients 65 years and over in a UK longitudinal study (Rumble & Morgan, 1994),30.4%
were for cardiovascular medicines.
Diuretics and beta-adrenoceptor blocking drugs (B-blockers) are commonly used as first line
drugs in the treatment of hypertension (Beard et al., 1992) and these groups of drugs along with
vasodilators (nitrates, calcium channel blockers) were the three most commonly dispensed sub-
groups of cardiovascular drugs dispensed to elderly exempt patients in 1994 (Prescription Pricing
Authority, 1995).
3.3.4.3 Central nervous system (CNS) drugs
Central Nervous System drugs, particularly hypnotics, anxiolytics and analgesics, account
for the second major area of drug use in the elderly, with 19.7 per cent of all drugs dispensed in
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England, in 1994, having effects in this therapeutic area (Prescription Pricing Authority, 1995).
The longitudinal study in Nottingham also highlighted Central Nervous System medicines as
commonly used by the elderly, with 29.1 % of 1409 drugs being for CNS medicines (Rumble &
Morgan, 1994). CNS medicines were also widely used by the elderly in the study undertaken in
urban Harare, Central Africa (Nhachi et al., 1994).
Hypnotics, particularly benzodiazepines have formed a traditional drug therapy for insomnia,
a clinical problem commonly found in the elderly as average sleep time decreases with age
(Mulligan & Sobel, 1994). In 1971, a total of 41.7 million items were written for hypnotics for
all ages (Conrad, 1982). However with concerns over physical and psychological drug
dependency, there has been a decrease in hypnotic use over recent years. Hypnotics currently
represent approximately 23% of all CNS drugs dispensed to the elderly in England 1994
(Prescription Pricing Authority, 1995).
Depression, a psychiatric disorder which is diagnosed fairly commonly in the elderly (World
Health Organisation, 1985) is managed with antidepressants which represent approximately 12%
of CNS prescription items dispensed to the elderly in the UK. Traditional treatments include
tricyclic antidepressant drugs (e.g. amitriptyline, imipramine, nortriptyline and clomipramine).
However their use in the elderly is limited to some extent by the large number of side effects
associated with their use including xerostomia (Bertram et al., 1979; Peters, 1989). Older
antidepressants have now been replaced by newer, more selective drugs which have fewer side
effects associated with them. These drugs are referred to as SSRls and are now commonly used
in the elderly (Mulligan & Sobel, 1994).
Analgesics were another area of common use by the elderly, with almost 45% (16 million
items) being dispensed to the elderly in 1994, in England (Prescription Pricing Authority, 1995).
The analgesics prescribed ranged from minor analgesics such as paracetamol, to stronger opoid
pain killers such as morphine based products.
3.3.4.4 Drugs used in musculoskeletal andjoint disorders
Musculoskeletal complaints are common in the elderly and were responsible for
approximately one third of all GP consultations in patients over 65 years of age in the UK (Nuki,
1990). Non-steroidal anti-inflammatory drugs (NSAIDs) are the first line treatment for rheumatic
and muscular pain. NSAIDs represent around 5% of all prescriptions written in the UK, with
50% of the patients using these drugs aged 60 years or over (Goorah & Wynne, 1995). Aspirin
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was the original and most commonly used NSAID, but its use has been superseded by newer
products such as ibuprofen and naproxen, which are associated with fewer side effects.
Currently, there are approximately fourteen different NSAIDs on the market (British Medical
Association & Royal Pharmaceutical Society, 1997). Major variations in the therapeutic response
of these drugs between patients often necessitate medication with different types before the most
suitable formulation is found (Lamy, 1988)
3.3.4.5 Respiratory drugs
Respiratory problems tend to increase during ageing and as Table 3.1 shows, respiratory
medicines accounted for 7.5% of all prescription items dispensed to elderly exempt patients in
1994 (Prescription Pricing Authority, 1995). Drugs are a common adjunct to other therapies,
such as oxygen and physiotherapy in the treatment of congestive obstructive airways disease such
as bronchitis and emphysema. Bronchodilators such as salbutamol and terbutaline which are
taken for wheezing and cough, are the most common respiratory drugs used, accounting for over
50% of all respiratory drugs (Prescription Pricing Authority, 1995). Steroidal products such as
beclomethasone and budesonide (inhaled) and prednisolone (oral) are also used in moderate to
severe respiratory disease.
Drug utilisation studies which have been carried out have concentrated on the analysis of a
particular medicine or medicines within a particular therapeutic area or cohort of the population
rather than considering the dose form used. With regard to medicines taken orally, no studies
have analysed drug utilisation by dose form.
3.3.5 Problems with drug use in the elderly
3.3.5.1 Polypharmacy and adverse drug reactions (ADRs)
Elderly persons suffer from more medical conditions than younger and take a wide range of
drugs to alleviate these problems (Stewart & Cooper, 1994). The term 'polypharmacy' describes
the co-administration of two or more drugs. As the number of drugs taken by the patient
mcreases, so do the possibility of drug-drug interactions, where one drug may modify the action
of, or have its actions modified by, another drug. These modifications may result in toxicity or
under-dosing and the outcome of such an interaction may result in an adverse drug reaction
(ADR). Although drug-drug interactions can happen in any patient, they are of particular concern
in the elderly as they take large numbers of medicines and may be frail. Stewart and Cooper
(Stewart & Cooper, 1994) reviewed the results of several studies of multiple drug regimes, and
26
Review of the literature
ooncluded that as the number of medications increased, the potential for interactions between
drugs increased. They described studies where the use of combinations of prescribed and OTC
medicines ranged from 3.1 to 7.9 drugs per person and showed that the use of these drugs was
often inappropriate, with 72.8% of all drug reactions being caused by the use of drugs which were
unnecessary for that patient in the first place.
In another review of adverse drug reactions in the elderly (Walker & Wynne, 1994), the
authors estimated a prevalence of between 1.5% to 35% in hospitalised patients (Walker &
Wynne, 1994). Williamson and Chopin (Williamson & Chopin, 1980) monitored 1998 patients
admitted to 42 geriatric medical units in the UK and reported adverse drug reactions in 248
(12.4%) of them at the time of admission. In 209 of these elderly patients the ADR was thought
to have contributed to the admission. The use of NSAIDs is common in the elderly, with over
50% of all NSAID users being 60 years and over (Goorah & Wynne, 1995). These drugs were
responsible for 25% of all ADRs reported and were highlighted as a particular risk to elderly
patients.
The problems of inappropriate prescribing have been further highlighted by practice
pharmacists who have been employed primarily to reduce practice costs, but now have a role in
rationalising prescribing.
3.3.5.2 Patient compliance problems in the elderly
Some 2500 years ago, Hippocrates said "patients often lie when they state they have taken a
certain medicament". The problem of patients taking their medicines is one that has a number of
implications, not only for their healthcare and financial costs to the NHS, but also to drug
utilisation studies. Information on drug use obtained through prescription analysis relates to what
is prescribed or dispensed to the patient. However what proportion of this quantity is actually
consumed by the patient is less clear. A recent working party set up by the Royal Pharmaceutical
Society of Great Britain has suggested that as many as 50% of patients identified in studies of
compliance may not be taking their medication (Royal Pharmaceutical Society of Great Britain,
1997).
Other studies have determined non-compliance rates to be as high as 40% to 75%, with non-
compliance being higher in females than males (Salzman, 1995). Salzman et al (1995) suggested
that possible reasons for such high non-compliance could be the large number of medicines used
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by the elderly, forgetfulness and confusion, and intentional non-compliance to avoid the side-
effects resulting from the use of particular medicines (Salzman, 1995).
A review of non-compliance by Gillum et al (Gillum & Barsky, 1974) reported that a third
of patients failed to comply with doctors orders, with 50% of patients reporting non-compliance.
The proportion of patients who did not follow advice for six types of medicines, in 68 studies
ranged from 37.5% to 54.6% (Stahelin, 1982). However, a study looking at 156 patients aged 70
years and over who were hospitalised with congestive heart failure, in Washington, USA, showed
that intervention and patient counselling improved compliance in the elderly (Rich et al., 1996).
A survey looking at prescriptions written over three months from a health centre in Tayside,
Scotland found that 14% of the 4854 patients who were issued a prescription were not redeeming
it at a pharmacy (Beardon et al., 1993). Of the 1638 elderly patients in this study, 10% failed to
redeem their prescription.
Compliance with a medication regime is an important issue as non-compliance will lead to
under-dosing and possible ill health as the patient is not receiving effective medication. Other
issues such as cost are also important as the patient may be 'hoarding' medicines. Non-
compliance has been recognised as a major issue by the Royal Pharmaceutical Society of Great
Britain, who recently published a report ('From compliance to concordance'), in which they
recommended that medication taking should take a partnership approach between the general
medical practitioner and the patient (Royal Pharmaceutical Society of Great Britain, 1997).
3.4 THE ORAL HEALTH OF THE ELDERLY
3.4.1 Introduction
Over fifty years ago it was common for an elderly person to have no natural teeth, however,
with major improvements in dental care and preventative dental policies most aspects of the oral
health of this group of the population have improved dramatically. A number of studies have
observed a positive relationship between oral and general health amongst elderly people (Agerberg
& Carlsson, 1981; Mattsson et al., 1990; Osterberg et al., 1984) and the maintenance of dental
health in the elderly is important in the maintenance of good quality of life in the elderly
population.
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3.4.2 Dental caries
National adult dental health surveys have been carried out in the UK every 10 years since
1968 and have documented the improvements in dental health over the last 30 years (Todd &
Lader, 1991; Todd & Walker, 1980; Todd et al., 1982). This trend has been seen in all age
groups. In the 1988 survey, the elderly had a mean of 0.7 decayed teeth, compared with a mean
for all ages of 0.2. More recently, a study (Steele et al., 1996) of 2280 subjects aged 60 to 64
years undertaken in three areas of England (Richmondshire, Darlington and Salisbury), showed
that elderly in Richmondshire, Darlington and Salisbury had a mean of 0.8, 1.0 and 0.8 mean
decayed teeth respectively.
3.4.3 Periodontal disease
Periodontal disease is a chronic disease characterised by gingival inflammation which can
result in destruction of the periodontal connective tissue (Hugoson & Jordan, 1982). It is
primarily a disease of adulthood; the 1988 national UK dental health survey (Todd & Lader,
1991) reported higher levels of periodontal disease in the older age groups with 16% of
individuals aged 65 years having one or more periodontal deep pockets (>6mm). The proportion
of elderly patients aged 55 and over with some periodontal disease was 96% in 1978 and had risen
slightly to 97% in 1988 (Todd & Lader, 1991; Todd et al., 1982). The 1968 dental health survey
did not give information on periodontal disease (Todd & Walker, 1980).
In Sweden, 600 individuals were assessed for severity of periodontal disease in 1973, which
was compared to a similar cohort of 597 persons in 1983 (Hugoson et al., 1992). The study
showed that in 1973 younger members of the group (20 to 50 years) had more mild to moderate
periodontal disease than 60 year and 70 year olds, where only 12% and 4% respectively were
affected. In 1973 moderately severe periodontal disease affected only 2% of the sample and 3%
and 6% of those aged 60 years and 70 years respectively, which had increased to 26% and 38% of
these age groups respectively, in 1983.
A US survey looking at a sample of 14,690 dentate Americans aged 15 to 74 years reported
an increase in periodontal disease with age (Abdellatif & Burt, 1987). The highest percentage of
persons with periodontitis was in the 55 to 59 year age group. Of those aged between 60 and 69
years, almost 17% had periodontitis, the prevalence in the 70 years and over, was lower at 13.4%,
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which was due to a higher rate of edentulousness in the older group. The authors concluded that
where oral hygiene was poor the incidence of the disease was higher.
3.4.4 Tooth wear
Tooth wear describes the three processes of attrition, abrasion and erosion (Nunn et al.,
1996). Attrition is the loss of tooth substance caused by contact between teeth which occurs
during normal functions. Abrasion is the progressive loss of tissue caused by mechanical factors
other than tooth-tooth interactions (e.g. tooth-brushing and chewing). Erosion is the chemical
dissolution of tooth enamel and dentine. Its aetiology may be intrinsic (e.g. due to acid
regurgitation) or extrinsic (e.g. due to dietary factors) (Donachie &Walls, 1996).
Dental erosion is common with acidic drinks, particularly carbonated soft drinks which are
now very widely available, although their use tends to be more prevalent in the younger
population (Milosevic, 1993). There has been an increase in the consumption of such drinks by
700% since the 1950s (Nunn et al., 1996). There is very little literature on dental erosion
associated with the use of acidic medicines, however, it would appear that such medicines could
adversely affect tooth wear. A report on a case study linked dental erosion to the use of chewable
vitamin C tablets (Giunta, 1983) and a study looking at 42 children with Juvenile Rheumatoid
Arthritis (Sullivan & Kramer, 1983) which compared 25 children taking chewable aspirin with 12
children taking swallowed aspirin only found tooth erosion in those children that were taking the
chewable tablets and concluded that the erosion was due to the topical effect of the medicine.
3.4.4.1 Tooth wear in the elderly
As tooth wear is an irreversible process and cumulative, older adults have more wear than
younger members of the population. In the Adult Dental Health Survey of 1988 (Todd & Lader,
1991) an investigation of root surfaces showed that there were 0.8 worn teeth per person.
However there were major age differences, with persons aged 65 years having an average of 2.4
worn teeth whilst the mean for the youngest group was only 0.1 worn teeth.
Hugoson et al (Hugoson et al., 1992) studied a population of 20 to 80 year olds in 1983 and
studied incisal and occlusal wear. They concluded that with increasing age there was an increase
in the number of teeth with .incisal or occlusal wear, with 77% of60, 70 and 80 year olds affected,
compared with 65% of 20 year olds. There was extensive occlusal wear in the group aged 60
years and over.
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In a study of 148 subjects composed of three ethnic groups in Northern Borneo (Milosevic,
1993), with 32% each of Chinese and Malay and 36% of Kadazan groups, 95% of all subjects
showed tooth wear, with 41% showing severe tooth wear. The rate of tooth wear in Kadazan was
accounted for by a more frequent use of chewable tablets.
3.4.5 Edentulousness
3.4.5.1 In the UK
Edentulousness or the complete absence of teeth becomes more prevalent with ageing as
natural teeth are lost due to dental caries or periodontal disease. The national dental surveys
undertaken in the UK since 1968 have shown a steady decrease in the prevalence of
edentulousness in the UK adult population, but with regional differences for both young and older
adults.
The national dental health survey undertaken in the UK in 1978 reported that 30% of adults
aged 16 years and over had no natural teeth (Todd et al., 1982), with 28% of adults in England as
a whole and 35% in the North and North East of England having no natural teeth. Of the elderly
population (65 years and over) in the UK, England and the North and North East of England,
79%, 78% and 88% respectively were edentulous. The national survey also took into account the
differences in rates of edentulousness between the North and South of England; 80% of the elderly
(aged 65 years and over) in the North of England in 1988 were edentulous, compared with only
57% in the south.
The most recent national dental health survey in the UK, was undertaken in 1988. This
showed a further reduction in the number of edentulous adults and especially edentulous elderly.
From 1978 to 1988 the number of adults in the UK with no natural teeth fell from 30% to 21%.
There was a significant decrease in the number of edentulous elderly (aged 65 years and over),
with 67% having no natural teeth in 1988, compared with 79% in 1978 (Todd & Lader, 1991).
A more recent study under taken in three English communities of Richmondshire, Darlington
and Salisbury showed that of the 2280 subjects aged 60 years and over sampled, 47% (1069)
were edentulous (Steele et al., 1998). The study also showed that edentulousness was higher in
the North of England compared to the South, with 39%, 55% and 76% of the three elderly groups
(aged 60-64y, 65-74y and ~75y) in Darlington being edentulous compared with 15%, 32% and
47% in Salisbury.
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3.4.5.2 Worldwide
Studies which have looked at the dental health of the elderly in terms of edentulousness have
mainly been confined to developed countries. An oral health review of individuals aged 3 to 70
years in Jonkoping, Sweden in 1973 (n = 1000), 1983 (n = 1024) and 1993 (n = 1007) showed
that only persons aged 40 years and over were edentulous in 1973,50 years and over in 1983 and
60 years and over in 1993 (Hugoson et al., 1995). Of the adults aged 60 years and 70 years in
1973 (n = 200), 1983 (n = 197) and 1993 (n = 192) 28%, 22% and 16% respectively, were
edentulous.
Tooth loss and edentulousness was investigated in institutionalised elderly in four nursing
homes in Naples, Italy (Angelillo et al., 1990). Of the 234 individuals aged 65 years and over, in
the study, 140 (60%) were edentulous.
Weintraub et al (Weintraub & Burt, 1985) reported on 7 studies conducted in the USA from
1957 to 1980 and showed that over time the proportion of edentulousness in the 65 to 74 year age
group had fallen from 55.4% in 1957-58 to 33.8% in 1980. A more recent study which
determined the prevalence of edentulousness in the elderly in the USA was the New England
Elders Dental Study. This was undertaken to assess the dental health of non-institutionalised
elders aged 70 years and over, living in six states of New England. Of the 1151 persons in the
survey 433 (38%) were found to be edentulous (Douglass et al., 1993).
Progressive diseases like periodontal disease and untreated dental and root caries result in
irreversible dental damage, often leading to tooth loss. However in recent decades, as the national
dental health survey in the UK and surveys in other developed countries, such as the USA, have
shown, the dental health of the elderly has improved, the prevalence of edentulousness in the
elderly has reduced and this trend continues.
A table of surveys showing the prevalence of edentulous ness both in the UK and worldwide
shows a range from 16% to 78% in the elderly (Table 3.2).
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'Fable 3.2 Surveys showing the prevalence of edentulousness in the UK and worldwide
Area of Survey n Age group no. Reference
edentulous
(%)
United Kingdom 574 ~65y 574 (65%) (Downer, 1991)
Richmondshlre, 2280 ~60y 1069 (47%) (Steele et al., 1996)
Darlington & Salisbury,
UK
West Essex, UK 414 Male ~65y & 323 (78%) (Tobias, 1988)
Female ~60y
Oslo, Norway 371 ~67y 202 (55%) (Ambjomsen, 1986)
Naples, Italy 234 ~65y 140 (60%) (Angelillo et al., 1990)
New England, USA 2057 ~7Oy 782 (38%) (Douglass et al., 1993)
Jonkoping, Sweden 192 60y to 79y 93 (16%) (Hugoson et al., 1995)
3.4.6 Nutrition and oral health in the elderly
Nutrition, amongst other biological factors may playa role in ageing. As well as having a
role in health and fitness, nutrition may also contribute to the development and progression of
degenerative diseases that are associated with ageing (Munro, 1981). As nutrition has such a
major role in health, the appropriate management of health problems should take into account the
links between health, nutrition and ageing (Watkins, 1978).
Nutritional status has a direct effect upon general and oral health in individuals of all ages.
In addition, nutrition has an important and complex relationship with dental health. In particular,
food consumed by the elderly may adversely affect their dental health or conversely oral health
problems may force the elderly to adversely change their eating habits.
There is evidence that nutritional deficiency at an early stage in life may affect health later in
life (Schlenker et al., 1973). Screening for dietary deficiencies in the elderly in the USA has been
taking place for many years (Kuczmarski et al., 1994), with the US Department of Agriculture
funding food composition records compiled in 1892 and the national dietary surveys of the 1930s.
A number of studies have suggested that the elderly may have a poorer nutritional state than
younger individuals (Beveridge et al., 1965; Blass, 1980; Brown et al., 1977; Grandjean et al.,
1981; Posner et al., 1993; Stiedemann et al., 1978). A number of dietary nutrients have been
identified as being below the standard recommended levels in the elderly. These include vitamin
A, thiamin, riboflavin, iron; calcium and pyridoxine, which are all associated with a lower mean
caloric intake.
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A survey carried out in Great Britain during 1994-95 on behalf of the Ministry of
Agriculture, Fisheries and Food of diet and nutrition in the elderly aged 65 years and over (Finch
et al., 1998), studied two groups of elderly individuals, one free-living and one institutionalised.
Intake of vitamins A, B6, B 12, C and E were well above the reference levels for the majority of
subjects, however lower levels of vitamin D were consumed. Analysis of the data from this study
by Steele et al (Steele et al., 1998) found that for the free-living sample there were differences
between edentate and dentate groups, with fewer of the edentate eating certain foods such as
apples, compared with the dentate group. The authors reported that there were more dietary
restrictions for institutionalised elderly with some foods such as nuts and raw carrots not being
eaten at all.
Factors that may influence nutritional state in the elderly include lower physiologic functions
(Masoro, 1976), as well as alterations in olfactory and taste thresholds (Cohen & Gitman, 1967;
Schlenker et al., 1973), which may affect appetite. Oral problems such as xerostomia, sore gums,
loose teeth, dental pain may also affect nutritional intake. Regional differences also have their
impact upon diet and nutritional status in the elderly. The study by Finch et al (Finch et aI.,
1998) on diet and nutrition showed the average intake of vitamins to be higher in London and the
South East than in Scotland and the North of England.
Tooth loss may be of concern as it can interfere with foodstuffs the edentate elderly
population may be consuming. Moynihan (Moynihan, 1995) reviewed the relationship between
tooth loss, diet and nutritional status found that the elderly have a lower masticatory ability and as
a result digestion was impaired. This problem was increased if the patient was edentate. The
review highlighted edentate people as being unable to digest hard fibrous foods such as fruit, raw
vegetables, meat and cheese, having instead to rely on soft foods such as porridge. Lack of high
fibre foodstuffs has health implications; restriction of fibre in the diet may lead to constipation and
possibly higher cholesterol levels.
Nutrition has a major role in the ageing process and is an important component of health care
in the elderly, due to the important relationship between diet, ageing and health.
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3'.4.7 Saliva and oral health
3.4. 7.1 Introduction
In the 16th century, salivary glands were thought to have a sieve-like role in straining of
excrementous substances from the blood, such as 'emunctories' (bad spirits of the brain) (Garrett,
1975). It was common for physicians to administer substances such as mercurous chloride to
increase saliva production and cleanse the system (Mandel, 1987). Ancient judicial systems also
used saliva as a early version of the lie detector; the accused was given some rice and if they could
not form a bolus as a result of inhibition of saliva secretion (due to fear or guilt?) then 'off with
his head'. It was not until 1856 and the publication of 'Adenographia' by Thomas Wharton that
the concept of salivary secretion was born. It is now understood that saliva has two basic roles: to
digest food and protect the mouth (Mandel, 1987).
3.4.7.2 Formation and/unction of saliva
Saliva is produced from three major glands: the submandibular, sublingual and parotid,
along with contributions from other minor glands (Levine, 1989). Its secretion is controlled by a
complex supply of nerves to the glands (Whelton, 1996).
The protective function of saliva is the result of a number of mechanisms. Salivary mucins
have low solubility, high viscosity, high elasticity and adhesiveness (Tabak et al., 1982), which
allows saliva to concentrate on the oral mucosal surfaces and offer protection against
environmental insult. Mucin glycoproteins produce a high strength film which coats areas of the
mouth (Mandel, 1987), however strong acids such as aspirin can destroy this layer and cause
damage to the epithelial cells below (Levine, 1989). Salivary mucins are also involved in the
control of the permeability of mucosal surfaces, limiting the penetration of potential irritants and
toxins in foods and beverages (Tabak et al., 1982).
Saliva exerts a direct bactericidal effect (Bowen, 1996), through salivary proteins such as
lysozyme, lactoferrin, and lactoperoxidase which interfere with bacterial growth or kill the
bacterial cells directly. The histidine-rich peptide of parotid saliva has been shown to have
inhibitory and bactericidal effects (MacKay et al., 1984). It also has been shown that
hypothiocyanate ions produced from salivary thiocyanate by an oxidation process will inhibit
plaque acid production (Tenovuo et al., 1981).
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Another major protective role of saliva is the maintenance of salivary pH at a normal resting
level of between 6 and 7 (Edgar & Higham, 1996). This is important for the protection of the
enamel and dentine of teeth from the demineralising effects of acid produced by the metabolism of
fermentable carbohydrates by bacteria, which is achieved through a series of buffer systems.
These are primarily bicarbonate, calcium and phosphate buffering systems. In stimulated saliva
the bicarbonate ion is the most important buffer and is responsible for about 80% of saliva
buffering capacity (Helm et al., 1982). At rest, the levels of bicarbonate are low and the
buffering action is mainly from histidine-rich peptides and phosphates (Edgar & Higham, 1996).
3.4.7.3 Saliva and oral clearance
"Clearance" in terms of pharmacokinetics describes the removal of drugs from the body,
usually through the hepatic or renal systems. The term "oral clearance" is used to describe the
removal of substances from the oral cavity following intake. This is important in terms of
assessment of risk to the teeth from foods and drinks which may contain sugars and other
substances detrimental to dental health. It also helps to explain some of the susceptibility to
disease amongst individuals. A high salivary concentration of sucrose and long periods of
retention in the oral cavity will increase the risk of dental caries therefore it is important that
fermentable carbohydrates are removed or 'cleared' from the oral cavity as quickly as possible.
Some studies comparing the prevalence of dental caries to rates of oral clearance of fermentable
carbohydrates have produced equivocal results with both positive (Adorjan & Stack, 1976; Miura
et al., 1991) and negative (Keene et al., 1966) correlations described. However, it is clear that a
rapid salivary clearance of harmful substances such as sucrose or acids is beneficial for oral
health (Dawes, 1996).
There are three main factors which determine oral clearance; firstly, oral sensory and motor
function and co-ordination which is directly affected by the number of natural teeth in the mouth
and the wearing of dentures. Secondly, the rate and efficiency of swallowing and thirdly, salivary
secretion rates.
Oral clearance has been investigated in a number of in vivo studies in elderly individuals.
The oral distribution of ingested sucrose was investigated in 10 subjects and it was found that the
concentration of sucrose in saliva in different regions of the mouth varied (MacPherson & Dawes,
1993). The lowest concentration of sucrose was found to be on lingual surfaces where
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submandibular saliva enters the mouth suggesting that a high salivary flow increases sucrose
clearance, reducing contact time with plaque and reducing the risk of dental caries.
Dawes (Dawes, 1983) used a mathematical model to show that oral clearance was affected
by unstimulated salivary flow rate and the volumes of saliva in the mouth immediately before and
after swallowing. In a later study in 1987 Dawes (Dawes, 1987) suggested that lower volumes of
saliva would result in faster clearance of sugar and a lower salivary flow rate would result in an
increased clearance time. The paper also discussed results from several studies which looked at
unstimulated flow rate and found that this ranged from 0.04mllmin to 0.39mllmin, and stimulated
flow rate, which ranged from 0.52rnl1min to 4.55rnl1min. Results from these studies did not show
any age-related change in flow rate, suggesting that the elderly have normal flow rates. However,
a survey of secretion rates of saliva in 629 adults found an age related decrease in saliva secretion,
but only in women, with females aged 64 to 74 years having the lowest unstimulated (0.2ml/min)
and stimulated (1.2rnl1min) salivary flow rates (Heintze et al., 1983). The authors suggested that
this may be due to post-menopausal changes in females (Heintze et al., 1983). This finding was
supported by Osterberg et al (1984), who reported a significantly lower unstimulated secretion of
saliva in women aged 70 years of age (Osterberg et al., 1984).
A study looking at glucose clearance in the elderly (Hase et al., 1987), compared the
clearance of glucose between hospitalised and non-hospitalised elderly. In total there were 54
persons, all aged over 75 years in the study, which showed all elderly had a slow salivary glucose
clearance, but this was more pronounced in the hospitalised elderly. This was thought to be due
to the reduced salivary flow rates found in the elderly, often due to consumption of xerogenic
medicines (see Section 3.4.7.4) (Osterberg et al., 1984), resulting in prolonged oral clearance
times. The authors also found a relationship between edentulousness and flow rate, with the
edentate having reduced flow rates, which could account for lower flow rates seen in some elderly.
Fermentable carbohydrates in liquids clear faster than solids (Edgar et al., 1975), with
carbohydrates from drinks, fresh fruit and vegetables being cleared quickly, compared with
carbohydrates in wheat grain and bread products, with the slowest clearance being from sticky
sweets, chewing gum and chocolate (Swenander, 1957). Clearance from plaque is dependent
upon the velocity of the salivary film, with a reduced salivary film flow rate resulting in reduced
clearance (Collins & Dawes, 1987). Also oral clearance is site specific with the slowest clearance
being from the maxillary anterior spaces, intermediate clearance occurring from the maxillary
37
Review of the literature
posterior region and the fastest clearance from the mandibular anterior spaces (Nevin & Walsh,
1951).
Individual factors may also affect the rate of oral clearance, with much variability between
individuals shown for salivary flow rate (Volker & Pinkerton, 1947). There have been
contradictory findings shown for the relationship between salivary flow rate and rate of sugar
clearance; with one study showing a positive correlation (Britse & Lagerlof, 1987) and another
showing no statistical difference (Swenander, 1957).
The literature on saliva and oral clearance has shown that the elderly generally have normal
salivary flow, however due to the large number of elderly being medically compromised and
potentially taking xerogenic medicines, they may have reduced salivary flow and a reduced rate of
clearance, which can increase the risk of dental caries for the dentate elderly.
A reduced rate of oral clearance has implications for foodstuffs and medicines that remain in
the oral cavity for longer periods of time. Examples of such medicines with prolonged oral
clearance would include liquid oral medicines, pastilles, lozenges, chewable, buccal and
sublingual tables. If, as some surveys have shown, the elderly have a reduced oral clearance of
sucrose, then any sucrose-containing medicines taken by this group of individuals, which due to
their dose form are retained in the mouth rather than immediately and completely swallowed, may
increase their risk of dental caries. Medicines with prolonged oral clearance will be discussed in
section 3.5.4.
3.4.7.4 Xerostomia
Absence of saliva is referred to as xerostomia which presents as a dryness of the mouth,
sometimes associated with a burning sensation.
Many prescription and over-the-counter drugs can cause a reduction in saliva production by
affecting the autonomic nervous systems and increasing sympathiomimetic tone leading to reduced
saliva production. These drugs include analgesics, anti-cholinergic and anti-spasmodic agents,
anti-diarrhoeals, anti-histamines, anti-hypertensives (Sreenby, 1996). The cholinergic nervous
system is responsible for regulating the internal environment of the body during periods of rest
and energy conservation, via' pathways of the autonomic nervous system. This system is to some
extent affected by the ageing process as a decrease in organ mass results in a decrease in the
number of receptors. Age-related changes in the cholinergic system may contribute to functional
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decline, with drugs that block the cholinergic system (anticholinergic drugs) producing further
negative effects (Feinberg, 1993).
A review of anticholinergic effects of medications in the elderly reported that xerostomia was
a common complaint (Peters, 1989). Lewis et al (Lewis et al., 1993) showed of the 4163 subjects
in their study, 56% were taking at least one type of medication that caused xerostomia.
Drugs with anticholinergic effects are used for a range of clinical disorders such as irritable
bowel syndrome (Colofac), urinary incontinence (hyoscine hydrobromide), motion sickness
(Stugeron) and Parkinson's disease (procyclidine). Some of these drugs with anticholinergic side
effects are listed in Table 3.3 (Feinberg, 1993).
A group of 40 dentate elderly subjects aged between 61 and 98 years from nursing homes
were divided into those taking medicines with anticholinergic effects and those not taking any
medication (Perrson et al., 1991). Of these 40 patients, two used no medications and 8 used no
medication with xerostomic effects. The remaining 30 patients all used medicines which may
cause xerostomic effects and there was significant decrease in the flow rate of stimulated whole
saliva in this group compared with the controls (O.94ml/min vs 1.52ml/min).
Table 3.3 Common drugs with anticholinergic effects (Feinberg, 1993)
Therapeutic group Example
Anti-parkinsonian Benzatropine, procyclidine
~cloplegics Atropine, cyclopentolate, homatropine
Antidepressants Amitriptyline, amoxapine, clomipramine, doxepin
Antihistamine Brompheniramine, clemastine, hydroxyzine
Antiemetic .(;yclizine, scopoloamine, meclozine
Antispasmodic Propantheline, dicycyclomine, oxybutynin
Antiarrllythmics Disopyramide, quinidine, procainamide
Antidiarrhoeals Diphenoxylate
Antipsvchotics Chlorpromazine, clozapine, haloperidol
Saliva secretion following therapy with other drugs known to cause xerostomia has been well
documented. Bertram et al (1979) examined 8 patients undergoing antidepressant therapy with
nortriptyline for 7 weeks, which included a 2 week blind placebo period (Bertram et aI., 1979).
They concluded that the antidepressant caused a reversible reduction in saliva secretion. Long-
term use of the antidepressant Maprotiline caused inhibition of salivary secretion rate, in a study
of 10 healthy volunteers (Momstad et al., 1986).
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The problem of xerostomia in the elderly appears to be extrinsic in aetiology, as most healthy
elderly have normal saliva secretion rates, although there is some evidence that menopausal
females may have a reduced rate of secretion. Osterberg et al (Osterberg et al., 1984) reported
that 30 per cent of women and 33 per cent of men had low unstimulated saliva secretion rates, and
that a reduction in the number of teeth resulted in low stimulated saliva secretion. They noted that
elderly people often complain of mouth dryness, however it was unclear whether this reduction in
saliva was due to age or was a result of other medical conditions or certain drug therapy, such as
the use of tricyclic antidepressants (Bertram et al., 1979). A dry mouth, whether drug-induced,
disease or age related, in combination with poor chewing function can lead to high levels of
periodontal disease and a high incidence of dental caries when associated with a high intake of
carbohydrate foods and medicines.
3.4.8 Attitudes to oral health in old age
Older people have difficulty in changing attitudes that have been forged over many years.
For many elderly, especially those aged over 75 years, dental care as a child would have been a
luxury and only sought due to reasons such as pain. In most cases a tooth would be removed
rather than saved (Ettinger, 1992).
A survey in Belfast investigated the attitudes to dental health of 81 adults aged 30 years and
over (Keogh & Linden, 1991). Adults from a higher socioeconomic class had better knowledge
and a more positive attitude to dental health, than those in a lower socioeconomic group.
A survey of attitudes in Hong Kong of398 middle aged (35-44 years) and 559 elderly (65-74
years) individuals was undertaken by Lo and Schwarz in 1991 (Lo & Schwarz, 1994) and of the
559 elderly in the study, 253 had not seen a dentist in the previous three years, and 80% said that
they felt they had no dental problems. The majority (59%) said they would contact a dentist if
they had toothache. This attitude was also found in a study by Steele et al (1996), who found in
their survey of three areas of England, involving 2280 subjects aged 60 years and over, that
between 19% and 28% were dental non-attenders (Steele et al., 1996). Reasons for not attending
included the belief that they did not need to attend (over 54% in all three areas), dislike or fear of
treatment (22% to 37% in the three areas) and the feeling that they 'couldn't be bothered' (12% to
25% in the three areas).
A survey of dentists attitudes towards the elderly was undertaken in 332 dental practices in
Washington, USA (Kiyak et al., 1982). The authors reported that in general dentists have an
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inaccurate perception of the elderly. The study also found that dentists who had been practicing
longer had better attitudes towards the elderly. The attitudes of dental students in clinical and
non-clinical years varied, with those in the clinical years having more positive attitudes than their
non-clinical colleagues (Devlin et al., 1994).
3.5 SUGARS AND MEDICINES WITH PROLONGED ORAL CLEARANCE
3.5.1 Introduction
It has been shown in previous studies that the elderly are prescribed large quantities of
medicines. This section will consider the impact of sugars in the diet and the implications of this
for those patients requiring long-term medication.
3.5.2 Sugars in the diet
3.5.2.1 Introduction
Sugar plays an important role in the western diet today, however its history can be traced
back thousands of years, with early sources of sugar reported to have come from sugar cane
which was thought to originate in Asia (Nevins, 1995). This was brought to the west via Africa
and onto Europe, where there was a great demand. In the 18th Century sugar beet rather than cane
Was introduced in Germany as a source of sugar, which was beneficial for western countries as
beet was able to thrive in more temperate climates, allowing European countries to reduce their
dependency on the tropical countries for sugar (Nevins, 1995).
Carbohydrates are a source of energy required by humans and animals for metabolism, and
they are found in certain food groups e.g. cereals, pasta and rice (Nevins, 1995). Sugar is a major
source of refined carbohydrates and is easily broken down by plaque bacteria to acid, which will
lower the plaque and salivary pH and predispose the tooth to dental caries (Thylstrup &
Fejerskov, 1986). The drop in the pH is dependent upon factors such as frequency of intake of
sugar, which is more important in terms of risk of dental caries than the amount of sugar ingested
(Holloway & Ryan, 1983).
3.5.2.2 Sugars and dental caries
Sugar as an aetiological factor in dental caries prevalence has been extensively researched
(Burt et al., 1988~ Catalanotto et al., 1979~ Rugg-Gunn & Edgar, 1984~ Woodward & Walker,
1994). This review will briefly look at some of the evidence.
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J Comparisons of skulls from ancient burial sites ill England with present day canes
prevalence have shown fewer cavities due to dental caries in ancient skulls (Holloway & Edgar,
1983). Dental caries only became recognised as a disease process around the 17th century, which
coincided with the establishment of the New World sugar industry. At this time the annual
consumption of sugar had risen from nil to approximately 10lb per head of the English population
per year (Holloway & Edgar, 1983).
More scientific evidence has come from reviews of the literature (Holloway & Drucker,
1983; Holloway & Edgar, 1983; Holloway & J.H.Shaw, 1983; Holloway & Moore, 1983;
Holloway & Ryan, 1983; Rugg-Gunn & Edgar, 1984). These researchers have looked at
evidence from world-wide epidemiological studies, war-time diet studies, human clinical trials,
laboratory experiments and animal studies. They also looked at studies of groups of people on
special diets, such as low sugar diets for diabetics and studies of people with high sugar diets (e.g.
workers in the confectionery industry). Their conclusions were that sugar is the most important
dietary item in caries aetiology, and as the availability of sugar increases in a country or
community, its concentration in foodstuffs increases. However, the frequency of sugar intake is
more important than the amount ingested overall. This has a number of implications in terms of
dental health education and the dental health messages for maintenance of a healthy mouth and
prevention of dental caries.
Many of the studies looking at sugars intake and dental health have been undertaken in
children and there is little published literature on the elderly. In a three year longitudinal study
(1982 to 1985) carried out in a group of school children aged 11 to 15 years from two American
communities in Quincy and Michigan (Burt et al., 1988), 499 children were interviewed and
received baseline and three-year dental examinations. Of these children, 22.2% were caries free at
the baseline examination. Comparison of the children whose sugar intake was low with those
Whose sugar intake was high showed that there was three-fold increase in the increment of
approximal caries in the low sugar intake group compared with the high sugar intake group. The
dmfs (decayed, missing and filled primary tooth surfaces) increment on approximal surfaces was
0.19 in the low sugar intake group compared with 0.65 in the high sugar intake group. In a
SUrvey of 328 12 year old English schoolchildren investigated in a cross sectional study in
Northumberland, a positive Correlation was found between sugar intake and caries experience
(Beighton et al., 1996). Woodward & Walker (1994) compared the DMFT (decayed, missing,
filled permanent teeth) scores for 12 year old children with the mean annual sugar consumption in
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the five years prior to the survey, in ninety countries (Woodward & Walker, 1994) and showed
that for all countries DMFT scores rose with sugar consumption.
3.5.3 Alternative sweeteners and dental health
The concerns regarding the cariogenic potential of sugars has led to the development and use
of sweeteners with low or no acidogenicity. Alternative sweeteners can be divided into two
groups: bulk sweeteners and intense sweeteners (Table 3.4). Six new sweeteners were added to
the list of those permitted for use in foods and drinks in the UK, in 1983, after new regulations
came into force in England and Wales (Ministry of Agriculture, Fisheries and Food 1983),
Northern Ireland (Department of Health and Social Services 1983) and Scotland (Scottish Home
and Health Department 1983). Prior to 1983, sorbitol and mannitol were the only bulk
sweetening agents permitted for use. The changes in regulations allowed xylitol, hydrogenated
glucose syrup, isomalt, maltitol and lactitol to be used.
There are four intense sweeteners currently available for use in the UK. Prior to 1983, only
saccharin was allowed, however changes to the regulations for artificial sweeteners introduced
three new intense sweetening agents; acesulfame potassium, aspartame and thaumatin.
Table 3.4 Bulk and intense artificial sweeteners permitted for use in the UK (Ministry of
Agriculture, Fisheries and Food 1983, Northern Ireland Department of Health and Social Services
1983 and Scottish Home and Health Department 1983)
Bulk Sweeteners Intense Sweeteners
Sorbitol Saccharin
Mannitol Acesulfame potassium
Xylitol Aspartame
Hydrogenated glucose syrup Thaumatin
Isomalt
Maltitol
Lactitol
3.5.3.1 Bulk sweeteners
Sorbitol has a relative sweetness of 0.5 compared with sucrose and has a negative heat of
dissolution, providing a cool taste. It is fermented slowly by oral bacteria, however studies have
shown that this is of little significance in terms of dental caries (Glass, 1983) and sorbitol also has
low acidogenicity.
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I Xylitol is an intermediate product of glucose metabolism in man and as with sorbitol it also
has a negative heat of dissolution causing and mouth-cooling effect. In vivo and in vitro studies
reviewed by Rugg-Gunn and Edgar (Rugg-Gunn & Edgar, 1985) have shown that xylitol is non-
cariogenic and may even promote remineralisation. In the Turku sugar studies (Scheinin &
Makinen, 1976; Scheinin et al., 1976) 125 subjects were divided into three groups; those
continuing to consume sucrose and two groups where sucrose in the diet was completely replaced
with xylitol or fructose. The results showed that the mean increment of decayed, missed and filled
tooth surfaces was 0 in the xylitol and fructose groups compared with 7.2 in the sucrose group.
The only hydrogenated glucose syrup to be licensed for use in foods and drinks is Lycasin.
Lycasin has a relative sweetness of 0.75 compared to sucrose and in vivo it is metabolised to
glucose and sorbitol. Lycasin was found to have lower acid producing potential than glucose,
with French Lycasin having a lower activity than the original Swedish Lycasin (Frostell &
Birkhed, 1978). A in vitro study looking at the acidity and demineralising actions of lozenges
containing sucrose, glucose or Lycasin, either on their own or in combination showed that the
fermentability of the Lycasin formulation by plaque bacteria was lower as was acid production
(Grenby, 1995).
3.5.3.2 Intense sweeteners
Intense sweeteners have no acidogenic properties, however they cannot directly be substituted
for sucrose as they lack the bulking properties. Saccharin which was discovered in 1879 and has
been used in foodstuffs for over 80 years (Rugg-Gunn, 1985). It is used extensively in diet soft
drinks as well as pharmaceuticals. Another common intense sweetener is aspartame which is 200
times more sweeter than sucrose, with a similar taste to sucrose. A relatively new sweetening
agent is acesulfame potassium which is 130 times sweeter that sucrose.
The intense group of sweeteners and their dental effects have not been studied as extensively
as the bulk sweeteners, however evidence from all studies show that they are non-cariogenic. A
study comparing sucrose and aspartame in six groups of 20 rats showed no caries in the rats that
Were fed aspartame, as well as a reduction in the number of carious lesions found in the rats fed
aspartame and sucrose, compared with rats fed sucrose alone (Das et al., 1997).
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315.4 The use of medicines with prolonged oral clearance
Liquid oral medicines (syrups, linctuses, elixirs), chewable tablets, pastilles, lozenges,
sublingual and buccal tablets all have a prolonged clearance from the oral cavity. These dose
forms are not swallowed directly but they are designed to be chewed, sucked or dissolved slowly
in the mouth. There are situations where it is advantageous to use medicines with prolonged oral
clearance instead of solid oral doses, for example where the patient has problems swallowing,
when such medicines are easier to administer and in the case of sublingual and buccal tablets,
when absorption of the drug occurs quickly through the oral mucosa. Liquid oral medications,
have a faster action compared with solid oral doses as the drug is immediately available for
absorption in the stomach. Pastilles and lozenges are more effective in alleviating upper
respiratory conditions such as cough and sore throat, having a direct soothing action during
dissolution in the mouth.
There has been little research regarding the use of medicines with prolonged oral clearance in
the UK and worldwide. The main area of research in this field has been on liquid oral medicines.
Maguire and Rugg-Gunn (1994) showed that in 1987,8.6% (581) of all drug preparations (6738)
dispensed in Great Britain were for liquid oral medicines (Maguire & Rugg-Gunn, 1994) and 43.9
million items (10.9% of all items) were prescribed for liquid oral medicines, in 1987. This
represented a volume of 10.3 million litres and a cost of £90.7 million. There was a similar
pattern of prescribing of liquid oral medicines in the Northern Region of England, with 2.7 million
prescription items and a volume of 0.7 million litres dispensed (Maguire & Rugg-Gunn, 1994).
The medicines used were from a large number of therapeutic areas such as Gastrointestinal,
Central Nervous System and Antibiotics, suggesting that liquid oral medicines as well as other
medicines with prolonged oral clearance were not restricted to specific therapeutic categories but
were available for use for a wide range of medical problems.
3.5.5 Sugars and medicines with prolonged oral clearance
3.5.5.1 Introduction
Many substances of medicinal value are associated with unpleasant bitter tastes which may
make compliance with their use difficult. To overcome this pharmaceutical manufacturers have
used low molecular weight carbohydrates to mask these tastes and make the medicine more
organoleptically acceptable.
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315.5.2 The use of sucrose
Sucrose is a colourless, odourless, white crystalline powder with a sweet taste (Royal
Pharmaceutical Society of Great Britain, 1988). It is a very soluble substance and is stable over a
pH range of 4-8. Sucrose is commonly used in the manufacture of pharmaceutical products,
especially liquid oral medicines, as well as other products with prolonged oral clearance. It is
effective at masking the bitter taste of some drugs as well as having a soothing effect on the
membranes of the throat (Billany, 1998). As well as providing sweetness, sucrose has many other
desirable properties, such as texture, bulk and stability, which also makes it ideal for the
manufacture of pharmaceuticals (Rugg-Gunn, 1985). It is a good bulking and suspending agent
in the manufacture of liquid oral medicines. Syrup BP is a commercial product containing
65%w/v sucrose. At this concentration it will retard the growth of micro-organisms, making it an
ideal preservative.
3.5.5.3 Sugar-containing medicines and dental caries
In 1953 James and Parfitt suggested syrup based iron tonics were a risk factor in dental
caries (James & Parfitt, 1953). Roberts and Roberts (1979) undertook a dental survey of 91
children, aged under six years of age (Roberts & Roberts, 1979). Forty four children were on
sugar containing liquid oral medicines were compared with 47 children, who acted as the control
group. The sweetening agent for all the medicines was sucrose. It was found that the children on
long-term sucrose-based medicines had significantly higher level of dental caries (mean def 5.6)
than the control group (mean def 1.3).
The dental health of school children aged 2 to 17 years taking only sugar-containing oral
medicines for one year or more was compared with their siblings and with other school children
(of similar age) taking only sugar-free liquid oral medicines for one year or more (Maguire et al.,
1996). Children taking long-term sugar-containing liquid oral medicines were found to have a
significantly higher level of dental caries than their siblings (p=O.046). There was no difference in
the prevalence of dental caries between the children on sugar-free medicines and those on sugar-
containing medicines. The authors suggested that this may have been due the sugars-free group
being on sugar-containing medicines for prolonged periods in the past.
A study of 158 preschool children in Reykjavik (Holbrook et al., 1989), showed that the 49
children on paediatric medicines (especially antibiotics and medicines for the treatment of asthma)
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had a higher prevalence of dental caries (dmft=3) compared with those not taking medicines
(dmft=2.1)(P<O.05). The mean dmft was 3.3 for all the children in the group.
The pH changes after consuming liquid oral medicines containing sucrose were assessed for
7 dental students (Rekola, 1989). The results showed that when the syrupy medicine was
sweetened with sucrose, the pH dropped from normal saliva pH to a low pH, predisposing the
patient to dental caries.
These studies that have been carried out on sugar-containing medicines and the prevalence of
dental caries in children have shown that long-term use of such medicines is a risk factor in the
aetiology of dental caries. In view of this there is some concern that liquid oral medicines as well
as other medicines with prolonged oral clearance, containing sucrose could adversely affect the
dental health of the elderly.
3.5.5.4 Formulation of medicines
The use of sugars in medicines formulation, in particular liquid paediatric medicines has been
comprehensively researched with many surveys linking dental caries in children with sugars-
containing medicines (Duxbury et al., 1988; Feigal & Jensen, 1982; James & Parfitt, 1953;
Roberts & Roberts, 1979). This has put pressure on pharmaceutical manufacturers of
remanufacture their products as sugars-free (Hobson, 1985; Hobson & Fuller, 1987).
The switch to sugars-free from sugars-containing is not a simple process as the sugar
provides the medicine with a number of properties which are difficult to replace with a sugars-free
sweetening agent. The sugar used in the formulation of a medicine also has preservation,
viscosity and bulking properties, and in the case of sucrose is cheaply available. To replace the
sugar the sugars-free sweetening agent would have to replace the properties of sucrose as
completely as possible.
The bulk sweeteners often have side effects such as flatulence and diarrhea. Their other
disadvantage is the relative cost, which is greater than sucrose. Intense sweeteners may also be
used in the formulation of sugars-free medicines however they lack the bulking and preservative
properties of sucrose and saccharin has a bitter aftertaste which can restrict its suitability for use.
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3!5.5.5 Sugar-free medicines with prolonged oral clearance
The well documented link between sugar-containing medicines and dental caries has led to
pharmaceutical manufacturers formulating medicines with alternative sweeteners. Currently the
industry have recognised this problem in children and responded by reformulating many paediatric
medicines as sugars-free, however they have failed to recognise the implications of the use of
sugars-containing medicines in adults and the elderly and many of these medicines remain as
sugars-containing products. There have been no studies on the use of medicines with prolonged
oral clearance in the elderly, so it has not been possible to assess the extent of the problem.
The availability of sugar-free medicines and the awareness of the dental risks of taking sugar-
containing medicines has led to more sugar-free products becoming available. In a two year
study involving pharmaceutical manufacturers of liquid oral medicines for which Syrup BP was
the recommended diluent (Jenkins et al., 1989), only 30% of pharmaceutical companies,
representing 34 from 115 products said that they would be able to suggest an alternative sugar-
free diluent to Syrup BP. At the time of the study in 1988, 23.3% of the manufacturers had
already reformulated one or more of their products and 34.4% were currently involved in a
reformulation process. However, the majority of the products that were being reformulated were
for paediatric medicines.
Journal articles have listed sugar-free medicines (Dangor & Veltman, 1986; Sadler &
Brandon, 1989) and other booklets have produced lists of medicines with their type and content of
SWeeteners (Bosso & Pearson, 1973; Greenwood, 1989; Jin & Naylor, 1984; Taylor, 1981).
Analysis of these publications has shown that the majority of sugars-free medicines with
prolonged oral clearance are for paediatric use and adult medication with prolonged oral clearance
tends generally to be sugars-containing.
The use of generic medicines has been previously highlighted as a potential problem in that
the specificity of the drug name used by the prescriber may influence whether a sugars-free or
sugars-containing medicine is dispensed (Maguire & Rugg-Gunn, 1994).
Work has also been undertaken with 'over the counter' medicines (Mackie et al., 1993).
DUring a one year period during which pharmacists in a test group were sent dental health
education leaflets, it was found that the mean number of sugar-containing liquid oral medicines
stocked by the test group pharmacists fell from 7.7 to 7.1 (p<0.05). However 70% of the
pharmacists still recommended sugar-containing medicines more than sugar-free. In a study
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evaluating a sugars-free medicines campaign in North East England, the authors concluded that
the campaign was most effective at changing prescribing habits of general medical practitioners
and had less of an impact on OTe medicines (Maguire et al., 1999).
In a study to determine the factors influencing general medical practitioners' decisions to
prescribe sugars-free medicines, 55% of general medical practitioners supported the principle of
sugars-free medicines prescribing, but only 30% felt their knowledge of sugars-free medicines was
up to date (Bradley & Kinirons, 1996). The main sources of information on sugars-free
medicines was from medical representatives and professional journals.
3.6 SUMMARY OF THE LITERATURE REVIEW
This literature review has focused on a number different areas which together affect the
health of the elderly. The main points for consideration are:
• The elderly population is increasing and they currently represent 16% of the population of
England (48.7 million).
• Research into ageing has highlighted the role of free radicals as well as the effects of the
environment such as diet and exposure to infection.
• Ageing is associated with a number of physiological changes which affect all the major
systems of the body and in tum affect the processes of drug absorption, distribution and
excretion.
• The elderly have higher a morbidity than younger members of the population, with 62% of
all elderly in 1994 in the UK reporting a medical problem
• As a result of ill-health, the elderly use more of healthcare resources than younger
members of the population. They were dispensed almost 50% of all drugs in England in
1994.
• Prescribing in the elderly is also high in other westernised countries such as the USA and
drugs for the cardiovascular, central nervous system and gastrointestinal medicines are
commonly used.
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• The concomitant use of many drugs is common in the elderly, which may result in adverse
drug reactions.
• Compliance with drugs in the elderly is poor and this has a number of implications
including ineffective treatment, possibly leading to hospitalisation and the cost of
medicines not being used.
• The dental health of the elderly is improving, with more elderly retaining their natural teeth
into old age.
• The elderly in general have poorer nutrition, and consume less fibrous food than younger
individuals, which may have health implications.
• Saliva is an important defence mechanism against dental disease and the oral clearance of
carbohydrates from the mouth is linked to dental caries.
• Oral clearance is affected by sensory and motor functions, the rate and efficiency of
swallowing and salivary secretion rate of stimulated and unstimulated saliva.
• A lack of saliva (xerostomia) will predispose patients to dental caries and although the
elderly have normal saliva secretion rates, the side-effects of their drug therapy may cause
dry mouth.
• Sugars such as sucrose have been implicated in the aetiology of dental caries and the
frequency, rather than the amount of sugar is important.
• Bulk and intense sweetening agents as alternatives to sugars are non-acidogenic or have
less acidogenic effects and are available for use in foods, drinks and medicines.
• There is an established link between medicines with prolonged oral clearance containing
sucrose and dental caries
• Sugars in liquid oral medicines (especially in paediatrics) have been extensively studied,
but there has been little research carried out into the use of other medicines with prolonged
oral clearance, and their use by other age groups.
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CHAPTER4
AIMS OF THE STUDY
4.1 INTRODUCTION
Most medical problems are managed by medication which may require short-term or long-
term use. This medication may be formulated as one with prolonged oral clearance, i.e. one that
lingers in the mouth after administration. Such medicines, if sugars-containing may be a threat to
dental health. Medicines with prolonged oral clearance may be obtained through numerous routes
of supply; by a prescription from a general medical practitioner, general dental practitioner or by
purchasing a OTe medicine, within the primary healthcare sector or from hospital pharmacy
services in the secondary healthcare sector. The methods to determine the prevalence and volume
of use of these medicines had to be designed specifically for this purpose.
4.2 MAIN AIM
To assess the prevalence of use of medicines (prescribed and 'over the counter') with
prolonged oral clearance used regularly (once daily or alternate day) and long-term (three months
or longer) by the elderly (aged sixty years and over).
4.3 SUBSIDIARY AIMS
4.1. To determine the age and gender profiles of elderly patients taking medicines with prolonged
oral clearance (prescribed and 'over the counter') regularly and long-term.
4.2. To determine the medical problems of the elderly patients taking medicines with prolonged
oral clearance regularly and long-term.
4.3. To determine the sugar content of medicines with prolonged oral clearance used regularly
and long-term by the elderly
4.4. To assess the volume of all medicines (prescribed and 'over the counter') with prolonged oral
clearance and those used long-term by the elderly, used in England, the Northern Region and
Newcastle, during a one year period.
4.5. To determine the effect ~f generic prescribing on the use of medicines with prolonged oral
clearance.
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The main and subsidiary aims relate to the whole study; aims specific to each survey will be
given at the beginning of the chapter corresponding to that survey.
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CHAPTERS
PRESCRIBED MEDICINES PREVALENCE SURVEY
5.1 INTRODUCTION
As a result of improving health and socioeconomic conditions, nationally and internationally
the number of elderly citizens is increasing. In 1997 the population of the UK was 59 million
individuals, of which 10.7 million (18%) were of a pensionable age, that is, aged 60 and over
(Office of Population Censuses and Surveys, 1998). The elderly population of the Northern
Region of England in 1995 was 0.62 million (21% of the overall Northern Region population),
which had increased from 0.44 million in 1979, when the elderly represented 14.2% of the
population. Appendix 5.1 show a map of the Northern Region and 1995 population data (Office
for National Statistics, 1995).
The dental health of the elderly has improved over recent decades - the proportion of all
adults in the UK with some or all of their own teeth increased from 21% in 1978 to 33% in 1988
(Todd & Lader, 1991). The proportion of adults aged 55 to 64 years with some natural teeth
increased from 36% in 1968 to 64% in 1988 (Todd & Lader, 1991). Over the same period the
Proportion of persons aged 65 to 74 years with some natural teeth increased from 21% to 44%,
and for those aged over 75 years from 12% to 20% (Todd & Lader, 1991).
Medical problems are common in the elderly (Diggory et al., 1991; Iliffe et al., 1991). In
1997, 49.3 % of all prescriptions dispensed in the general medical services were to patients over a
pensionable age, accounting for 247 million prescription items (Department of Health, 1998).
Most medical problems in the elderly are treated with oral medication, most commonly solid oral
doses, that is, tablets and capsules. This dose form is not always appropriate due to formulation
or compliance difficulties, and other oral dose forms such as liquids, syrups, chewable tablets,
pastilles, lozenges, sublingual and buccal tablets may be used. These other dose forms all have
prolonged clearance from the oral cavity however, there is no information on the use of these
medicines in the elderly and this was the purpose of the prevalence survey.
5.2 AIMS
5.2.1 Main aim
• To determine the prevalence of regular (daily or alternate day) and long-term (three months or
longer) use of prescribed oral medication with prolonged oral clearance in the elderly (60 years
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J and older), in five districts of the Northern Region (Newcastle, North Tyneside, South
Tyneside, Gateshead and Northumberland).
5.2.2 Subsidiary aims
• To determine the age and gender profile of elderly patients taking long-term prescribed oral
medication with prolonged oral clearance.
• To determine the medical problems for which prescribed oral medicines with prolonged oral
clearance are taken by the elderly.
• To determine the types of prescribed medicines with prolonged oral clearance used regularly
and long-term by the elderly.
• To determine the sugars content of prescribed medicines with prolonged oral clearance used
regularly and long-term by the elderly
5.3 METHODS
5.3.1 Introduction
The main aim of this study was to assess the prevalence of use, by elderly patients in the
Northern Region, of medicines with prolonged oral clearance. It was not practical to examine the
medication of all 0.62 million elderly persons in the Northern Region. Instead, it was decided to
select five representative districts in the Northern Region (Appendix 5.1) and within them choose
ten general medical practices from which the number of elderly patients taking medicines with
prolonged oral clearance regularly and long-term would be determined.
5.3.2 Sources of data
To assess the overall use of medication in the elderly would involve collecting data from a
number of sources. Preparation for this required all potential sources of data to be identified and
assessed to see if they could provide accurate information. In recent years the government has
required NHS services to be audited in a bid to improve patient care and reduce running costs and
as a result, most aspects of healthcare are carefully recorded. This record keeping has been
extended to provide useful information for both auditing and research purposes. This section
reviews the various types of data which were available and how the data source was selected for
the Prevalence Survey. Figure 5.1 shows the interactions between the patient and the providers of
54
Prescribed Medicines Prevalence Survey
primary health care; the general medical practice and the pharmacy, and the further interactions
with other organisations that may be potential sources of data.
5.3.2.1 The patient
The patient who requires healthcare has four mam options: to do nothing, to visit a
community pharmacy, to visit their general medical practitioner or go to hospital. The latter three
options may result in the provision of medication to relieve their symptoms or treat their condition,
making the patient a valuable source of research data for this and other surveys.
5.3.2.2 General medical practices
5.3.2.2.1 Computers in general practice
General medical practices in recent years have been encouraged by local health authorities to
use computers for the management of their patient records and other practice business. The main
types of computer software systems on the market currently are EMIS1, Meditee, Vamp' and
Genisyst", Although other medical computer systems are available, these four are the most
commonly used in practices in the Northern Region, as shown by surveying lists of computer
systems obtained from computer facilitators for general medical practices in five districts of the
Northern Region. EMIS and Meditel systems provide fast and accurate sorting, printing and
down-loading of demographic and medical information about the patients registered. EMIS uses a
series of databases to store patient demographic details, medical patient histories, medication
records and other notes. Access to medication records involves a number of key-strokes and is
time consuming however it allows searches to be undertaken by age, doctor, medication and other
variables.
In contrast, Meditel offers easier access to medication records than the EMIS system,
however it is a lot more difficult to use for searches as it requires the input of a complicated set of
instructions. Downloading information from the Meditel system is not an easy menu-driven
process and requires advanced knowledge about the software, unlike EMIS where searches are
easily saved onto floppy disk for further analysis.
1 Egerton Medical Information System
2 Meditel, AAH Meditel, Rigby Hall, Rigby Lane, Bromsgrove, B602EW Phone 01527 579414.
3 VAMP, Inpractice Systems, Delta Park, Smugglers Way, London, SWl8 lEG.4G .
emsyst, Aremissost, Theobald Business Centre, Knowl Piece, Wilbury Way, Hitchin, SG4 OIY.
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5.3.2.2.2 Patient medication records (PMRs)
General medical practices have traditionally kept detailed written records of all patient
consultations on cards stored in folders. With advances in computing and software availability,
many practices have started storing all medical information on computers. A recent survey in four
general medical practices in the Trent Region of England showed that in 1000 patient
consultations, 696 patients were issued an prescription. Only 87.2% of these prescriptions were
recorded on manual records compared with 100% in computer records (Pringle et al., 1995),
indicating that prescribing information obtained from general medical practice computer systems
can often provide a more accurate estimate of medicine use than manual records.
Storing information on computers has the additional advantage of allowing the general
medical practitioners quick access to a patient's medical history and facilitating a search for a
group of patients taking a specific medicine within certain set criteria; for example, all patients
within a specific age range can be identified. With these factors in mind, it was felt that it would
be most appropriate to undertake a survey of the prevalence of use of medicines by the elderly,
using computerised patient medication records.
5.3.3 The Sample
Mid-year population data showed that there were 0.62 million elderly individuals aged 60
years and over living in the Northern Region in 1995 (Office for National Statistics, 1995). After
discussions with two statisticians, it was decided that a cluster sampling technique would be the
best approach to data collection with each cluster comprising all the elderly patients aged sixty
years and over in a single general medical practice.
The survey was undertaken in five of the fourteen districts of the Northern Region of
England which collectively were representative of rural, inner city and urban areas. These
districts were Newcastle, North Tyneside, South Tyneside, Gateshead and Northumberland
(Appendix 5.1).
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J To ensure that the practices were representative of the whole population, it was decided that
only practices meeting the following inclusion criteria would be included in the survey:
• A large list size (5000 patients or greater)
• A good socioeconomic mix
• Computerised patient medication records (PMRs)
The Family Health Authority for each of the five districts was asked for a list of general
medical practices with computing facilities. From these lists, practices with comprehensive
computing facilities, (i.e. those using either EMIS, Genisyst, Meditel or VAMP) were highlighted.
Of these, ten general medical practices, two from each district, were chosen at random. If the
selected practice had a list size of less than 5000 then another was randomly selected. Once
selected, the practice was contacted by letter (Appendix 5.2) explaining the purpose of the survey
and asking for permission to use the patient medication records at the practice.
5.3.4 Ethical committee approval
The study involved access to confidential patient information, and required permission from
the ethical committees from the five districts. Applications for approval were sent to the five
district ethical committees and to the Newcastle and North Tyneside joint ethical committee in
June 1995. Once ethical committee approvals had been obtained, the senior partner in each of the
ten practices was contacted by a letter (Appendix 5.2) which outlined the aims of the study and
how the study would be carried out. The letter was followed up by a telephone call, when a
meeting was arranged with either the senior partner or a colleague and the practice manager to
discuss the survey further and arrange access to practice computer records, if the practice was
willing to participate in the survey.
5.3.5 Data collection and preparation
5.3.5.1 The database
A database was constructed using Microsoft (MS) Access to collect, store and collate all
data collected in this and related surveys (Chapters 6 and 7). A plan was made of all the types of
data that would be collected from the survey and from this, 'tables' were constructed in MS
Access. A table is a part of the overall database and each table held a number of fields which
Contained information. The database consisted of a series of these tables (Figure 5.2) linked
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together using common fields. The tables could be searched according to specific criteria,
individually or linked using 'queries'.
For the purposes of the Prevalence Survey, two tables were created to facilitate data
collection and subsequent analysis. The PATIENT DATA table (Figure 5.2) was designed to
hold demographic information about the patients in the survey. This table contained fields for the
following information:
• Patient code
• Practice
• Gender
• Date of birth
The PATIENT MEDICATION table (Figure 5.2) was created to hold the following data
from this survey:
• Patient code
• Medication problem code
• Drug code
• Dose
• Frequency of administration
• Date treatment started
• Date data collected
A DRUGS table (Figure 5.2) was designed to hold information on all medicines with
prolonged oral clearance. This table was derived from a database supplied by John Richardson
Computers plc.', which contained over 20,000 'prescription only' (POM) and 'over the counter'
(OTC) medicines and surgical items, and included all dose forms of medicines, including oral
medicines with and without prolonged clearance. By undertaking searches by dose form,
medicines with prolonged oral clearance were separated from all other preparations. The resulting
list was then checked against the British National Formulary (British Medical Association &
Royal Pharmaceutical Society, 1995) and Data Sheet Compendium (Association of British
Pharmaceutical Industry, 1995) to ensure that all medicines with prolonged oral clearance were
identified.
IJobn Richardson Computers, NDC, 57 Benedicts House, Brown Lane, Bamber Bridge, Preston, PRS 6ZB.
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For each preparation with prolonged oral clearance the following information was entered:
• BNF Section
• Unique medicine code to identify each individual preparation
• Dose form (e.g. liquid, solid or powder)
• Manufacturer
• How the medicine was prescribed (i.e. generic or proprietary name)
BNF Sections categorised the medicine in terms of its therapeutic area of use. Dose form
identified the nature of the medicine and its unit of measurement was recorded as follows:
• liquid oral medicines in millilitres
• solids with prolonged oral clearance (e.g. effervescent tablets) in number of tablets
• loose powders and oral gels in grams
• powders in sachets in number of sachets
In the UK, medicines are available as either generic or proprietary brands. Generic
preparations are often manufactured by many different pharmaceutical manufacturers to produce
many formulations of the same preparation. To account for these multiple formulations in the
analysis of the data from this survey, the table, GENERIC FORMULATIONS was created to
contain information on all the generic formulations of the generic medicines and was linked to the
DRUGS table.
5.3.5.2 Management of the data
Once the database was constructed, 'Data Entry Forms' were designed in MS Access which
provided an interface to allow the data to be entered into the relevant fields in the various tables.
The forms consisted of boxes into which the data were typed. The 'boxes' were programmed to
only accept certain types of data and maximise accuracy in data entry, for example, they were
programmed to accept a number only or a range of data such as a date of birth which would reject
any entry for patients under sixty.
The three tables in the database, described above and shown in Figure 5.2 were linked by
common fields in each table. For example the DRUGS table was linked to the PATIENT
MEDICATION table by the drug code and in tum the PATIENT MEDICATION table was
linked to the PATIENT DATA table by the patient code. The other tables shown in Figure 5.2
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are discussed in the relevant chapters. Data were also entered into these linked tables via the
forms. For example, the table which held demographic information about patients in the survey
was linked by a unique patient identifier code to a table into which information from a
questionnaire was entered.
5.3.5.3 Patient medication information
Patient medication data were collected in three phases for all ten practices, each phase being
completed for each of the ten practices before the next phase was started. Each practice was
visited at least once every two weeks during the period of data collection. The three phases of the
data collection are summarised in Table 5.1.
Table 5.1 Summary of data collection phases
Phase One Computer records of all elderly patients examined; those taking medicines
with prolonged oral clearance highlighted.
Phase Two Prescribing details of highlighted patients examined further; those taking
medicines with prolonged oral clearance regularly and long-term identified.
Phase Three Medication and prescribing details for identified patients entered into a
relational database
5.3.5.3.1 Phase One
For each practice an initial search was undertaken on the practice computer for all patients
aged sixty years and over, and details of name, gender, date of birth and patient registration
number within that practice (a unique identification number given to all patients registered on the
practice computer) collected on a printout.
Using patient registration numbers, the medication record for each of these patients was then
examined using the practice computer. Any patient currently taking a medicine with prolonged
oral clearance was highlighted and their medication details printed (Appendix 5.3).
1,3.5.3.2 Phase Two
In the second phase, the computer records for those patients taking medicines with prolonged
oral clearance were examined further. Each medication with prolonged oral clearance taken
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regularly (daily or alternate day) and long-term (3 months or longer at the time of the survey) by
the patient was identified and the start date, dose and schedule of prescribing recorded.
5.3.5.3.3 Phase Three
In the third phase, details of the patients identified as taking medicines with prolonged oral
clearance regularly and long-term were coded and entered into the PATIENT DATA table of the
database. Medication details for each individual patient were also coded and entered into the
linked PATIENT MEDICATION table (Figure 5.2).
5.3.5.4 Sugars content of medicines
Using the British National Formulary and ABP! Data Sheet Compendium (1995-96)
(Association of British Pharmaceutical Industry, 1995; British Medical Association & Royal
Pharmaceutical Society, 1995), information on the sugars content of each proprietary medication
with prolonged oral clearance was collected and entered into the DRUGS table of the database.
When these sources could not supply this information, the pharmaceutical manufacturers were
contacted. A preparation was considered to be sugars-free if it did not contain an acidogenic
sweetening agent. The British National Formulary advises that oral liquid preparations that do
not contain fructose, glucose or sucrose can be labelled as 'sugars-free' (British Medical
Association & Royal Pharmaceutical Society, 1997), and these guidelines were followed when the
medicines with prolonged oral clearance were classified according to their sugars content.
However, medicines containing milk sugars such as lactose, that are identified in the BNF as
being cariogenic but has low acidogenicity, were classified as sugars-containing.
All generic pharmaceutical manufacturers for each of the generic preparations were
approached for written information on the type and amount of sweetening agent for each medicine,
which was then entered into the GENERIC FORMULATIONS table of the database. Where
the pharmaceutical manufacturers did not respond they were contacted by telephone and verbally
asked for the information. Generic preparations which were available as both sugars-free and
sugars-containing formulations, were classified as variable.
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5.3.6 Validation
To maximise the accuracy of the data collection process, the records of 100 patients (20
patients from each of the five practices) were randomly chosen and checked for errors in
collection, coding and entry of data.
5.3.7 Population data
Regional and national demographic data for England, the Northern Region and the five
districts (Newcastle, North Tyneside, Gateshead, South Tyneside and Northumberland) were
collected using information from the Office of Population Censuses and Survey (OPCS 1996).
These mid-year data for 1995 included national, regional and local population sizes, by age and
gender (Office for National Statistics, 1995).
5.3.8 Data analysis
The data, once entered into the database tables was analysed using a series of queries. A
query is a question about data stored in tables. Once the data was entered into the database,
'queries' were designed and run to retrieve certain information, for example, all patients of a
specific age or all those taking a specific drug.
Once the query had been undertaken the results were viewed and printed in a number ways.
Results could be exported into a spreadsheet for further analysis or into a word processor. MS
Access also was used to produce and summarise reports, such as a list of medicines, sorted by
therapeutic category.
Statistical analysis was undertaken using a chi-squared test adjusted for age to look at
differences between age and gender of the patients taking medicines with prolonged oral clearance
regularly and long-term.
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5.{:aRESULTS
5.4.1 Contact with practices
The computing departments of each FHSA confirmed that all 199 practices in the five
districts were computerised. From this list of 199 practices, 125 (63%), were identified as
operating one of the four comprehensive computer systems (EMIS, Genisyst, Meditel and VAMP)
chosen to facilitate data collection. From these 125 practices, la (8%) were randomly selected to
provide ten clusters in which the survey was carried out.
Approval from the ethics committees in all five districts took 3 months to obtain and had
been granted by September 1995. The ten randomly selected practices were contacted by
November 1995, however three of these practices were unable to take part; two practices in
Newcastle were too busy to help and a third in Northumberland was already committed to another
research project. Therefore, three more practices were randomly sampled using the same process
of cluster sampling as discussed in section 5.3.3 and all three agreed to take part in the study.
5.4.2 Data collection and analysis
Data collection commenced in March 1996 and each of the ten practices were visited at least
once every two weeks, until November 1996. Three practices (practices 1, 5 and 6, in North
Tyneside, Gateshead and South Tyneside) had larger numbers of elderly patients and were visited
once a week. The manual examination of all computer records of all elderly patients (Phase 1)
was complete by June 1996 for all ten practices. The second phase in which patients taking
medicines with prolonged oral clearance regularly and long-term were identified and their
prescribing details, collected was started in July 1996 and completed by November 1996. Phase
3, where medication information was coded and entered into the database, was completed by
March 1997.
The validation exercise used a random sample of 100 patient records after Phase 3 and
checked these against the database and found that there were some minor errors such as wrongly
coded drugs and codes entered wrongly, however there were no data collection errors. This
exercise also highlighted minor problems with the structure of the database which is discussed in
section 5.5.3.
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5!4.3 The sample
The ten practices surveyed employed 48 full time equivalent (FTE) general medical
practitioners (GMPs), who provided medical services to a total of 92570 registered patients
(Table 5.2). Of these registered patients, 48.9% were male and 51.1% were female, with the
mean male:female ratio being 1:1.04, ranging from 1:l.23 in Practice 10 (Newcastle) to 1:0.93 in
Practice 3 (Newcastle).
The mean number of registered patients per practice was 9257 with a range from 4920 in
Practice 9 (Northumberland), to 14020 patients in Practice 1 (North Tyneside). The two
Northumberland practices had the smallest list sizes, the practices with the three largest list sizes
being in North Tyneside, South Tyneside and Gateshead. The mean number of patients per
general medical practitioner ranged from 1589 in Practice 9 (Northumberland), with three FTE
general medical practitioners to 2660 in Practice 7 (South Tyneside), also with three FTE general
medical practitioners. The mean number of patients per GMP for the ten practices was 1928
(SDev = 340.9).
Table 5.2 Practice profiles for tbe ten practices in tbe Prevalence Survey
Total no. FTEI
Practice District of patients Male Female GMPs Patients
registered No. % No. 0/0 No. IGP
1 North Tyneside 14020 6766 48.3 7254 51.7 6.5 2157
2 North Tyneside 7369 3495 47.4 3874 52.6 4.0 1842
3 Newcastle 9567 4966 51.9 4601 48.1 6.0 1594
4 Gateshead 9932 4866 49.0 5066 51.0 5.5 1806
5 Gateshead 11159 5657 50.7 5502 49.3 6.0 1860
6 South Tyneside 13654 6764 49.5 6890 50.5 6.0 2276
7 South Tvneside 7980 3947 49.5 4033 50.5 3.0 2660
8 Northumberland 6357 3062 48.2 3295 51.8 4.0 1589
9 Northumberland 4920 2356 47.9 2564 52.1 3.0 1640
10 Newcastle 7612 3409 44.8 4203 55.2 4.0 1903
Total - 92570 45288 48.9 47282 51.1 48.0 -
Mean - 9257.0 4528.8 - 4728.2 - 4.8 1928
SDev - 3003.7 1531.6 - 1491.0 - 1.3 340.9
lFuIl Time Equivalent
5.4.4 Elderly patients in the sample
Of the 92570 patients registered with the ten practices, 20371 (22%) were elderly patients
aged sixty years and over (Table 5.3). Of these elderly people, 8757 (42.9%) were male and
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11614 (57.1%) were female, with the male:female ratio being approximately 1:1.3, 13458 (66%)
were aged 60 to 74 years ('young' elderly), and 6919 (34%) aged 75 years and over ('old'
elderly). Of the elderly aged 60 to 74 years, 6467 (48%) were male and 6991 (52%) were female,
with male:female ratio of 1:1.1. The male:female ratio of elderly patients aged 75 years and over
was 1:2.0, with 2290 (33.1%) being male and 4623 (66.9%) female.
The number of elderly aged sixty years and over at each of the ten practices ranged from
1388 to 3051 patients, with a mean of2037 patients per practice. The mean number of males and
females aged sixty years and over was 876 (SDev = 235.7) and 1161.4 (SDev = 348.5)
respectively. Elderly patients as a proportion of the total number of patients registered in each
practice ranged from 17.5% in Practice 5 (Gateshead) to 28.2% in Practice 9 (Northumberland),
with a mean of 22%. The number of elderly patients per general medical practitioner ranged from
281 in Practice 3 (Gateshead) to 626 in Practice 7 (South Tyneside), with a mean of 424 patients
perGMP.
Table 5.3 Elderly profiles for each of the ten practices in the survey
Total Elderly Elderly No. elderly Elderly No.
Practice District elderly male female by age asa % Elderly
(No.) (No.) (No.) (years) of all per
(~60y) (~60y) (~60y) 60-74 ~75 patients GMP
1 N. Tyneside 3051 1248 1803 1964 1087 21.8 469
2 N. Tyneside 1681 691 990 1073 608 22.8 423
3 Newcastle 1689 923 766 1198 491 17.7 281
4 Gateshead 2298 945 1353 1513 785 23.1 418
5 Gateshead 1959 857 1102 1441 518 17.5 327
6 S. Tyneside 2976 1294 1682 2072 904 21.8 496
7 S. Tyneside 1879 808 1071 1318 561 23.5 626
8 Northumberland 1740 720 1020 1004 736 27.3 435
9 Northumberland 1388 604 784 791 597 28.2 463
10 Newcastle 1710 667 1043 1084 626 22.5 427
Total - 20371 8757 11614 13458 6913 - -
Mean - 2037.0 876.0 1161.4 1345.8 691.3 22.0 424
SDev - 565.0 235.7 348.5 413.2 188.5 - -
5.4.5 Comparison with regional and national data
As Table 5.4 shows, the total population of the ten practices (92570) represented 8.1% of the
1.14 million population of the live districts in which the study was undertaken, 3.2% of the 2.9
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million population in the Northern Region and 0.2% of the 48.9 million population in England in
1993 (Office for National Statistics, 1995).
The 20371 elderly patients registered at the ten practices aged sixty years and over
represented 22% of the total number of patients registered at these practices. Regional and
national data (Office for National Statistics, 1995) show that individuals aged sixty years and
over represented 21% of the population for both the Northern Region and England and the
male:female ratio for all 92570 patients registered in the ten practices was 1:l.04, which was
similar to the ratio for the Northern Region and England. Overall, the proportion of elderly males
and females in the ten practices was 43% and 57% respectively, which was similar to the
Northern Region and England (Table 5.4).
Table 5.4 Population data for England and the Northern Region (mid-year 1995) (Office
for National Statistics, 1995)
Population Elderly
All Ages ~60 years
Total Male Female Total Male Female
(xt03) (xt03) (xt03) (xt03) (xt03) (xt03)
Ten practices in the 92.6 45.3 47.3 20.4 8.8 1l.6
.£.Tevalencesurvey (49%) (51%) (22%)2 (43%) (57%)
5 districts in North- 1142.4 556.4 586.0 250.9 105.3 145.6
East England I (49%) (51%) (22%)2 (42%) (58%)
Northern Region 2923.2 1429.0 1494.2 617.8 262.1 355.1
(49%) (51%) (21%)2 (42%) (58%)
England 48903.4 24007.6 24895.8 1004l.0 4275.8 5765.2
(49%) (51%) (21%)2 (43%) (57%)
1Newcastle, North Tyneside, Gateshead, South Tyneside and Northumberland
2 % of the total population of all ages
5.4.6 Identification of medicines with prolonged oral clearance
5.4.6.1 Therapeutic classification
The DRUGS table of the database contained information on 613 medicines with prolonged
oral clearance. These 613 preparations were found in 11 of the 15 therapeutic sections identified
in the British National Formulary and as Table 5.5 shows, 65.9% (404 preparations) of these had
actions on the three BNF sections ofInfections (167 preparations), the Central Nervous System
(126 preparations) and the Gastrointestinal System (Ill preparations).
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Ofthe 167 medicines with prolonged oral clearance in the Infections section of the BNF, 144
(86 %) were antibiotics, 131 (78%) were formulated as liquid oral medicines and of these 115
(69%) were antibiotic liquid oral medicines. These medicines are mainly formulated for paediatric
use, although some are used by adults who have difficulty in swallowing solid dose forms. Of the
126 Central Nervous System medicines with prolonged oral clearance, 90 (71%) were liquid oral
medicines, with the three main therapeutic areas of use being minor analgesics (36 medicines),
anti-psychotics (27 medicines) and anti-epileptics (21 medicines).
Table 5.5 Preparations with prolonged oral clearance by BNF section and dose type.
BNF Section LOMs1 Solids Powders Sachets Total no.
with &Oral of preps
poe Gels
01 Gastrointestinal System 60 26 7 18 III
02 Cardiovascular System 15 10 0 5 30
03 Respiratory System 60 0 0 0 60
04 Central Nervous System 96 20 1 9 126
05 Infections 131 17 0 19 167
06 Endocrine System 0 1 0 2 3
07 Obstetrics and Gynaecology 3 2 0 0 5
08 Malignant Disease I 0 0 0 1
09 Nutrition and Blood 19 15 0 17 51
10 Musculoskeletal and Joint Disease 9 9 0 5 23
11 Eye 0 0 0 0 0
12 Ear, Nose and Oropharynx 13 16 6 1 36
Total 407 116 14 76 613
J.o/II} (66.4%) (18.9%) {2.3%} _(12.40/11) _(100.0%)
ILiquid oral medicines
5.4.6.2 Doseform
When analysed by dose form, 66% (407 preparations) of all medicines with prolonged oral
clearance were liquid oral medicines, with 19% (116 preparations) being solids. Loose powders
and oral gels and powders in sachets only accounted for 2% (14 preparations) and 13% (76
preparations) respectively ofa1l613 preparations with prolonged oral clearance.
5.4.7 Prevalence of the use of medicines with prolonged oral clearance
Of the 20371 elderly (aged ~60y) registered at the ten practices, 3777 (18.5%) patients were
taking medicines with prolonged oral clearance, both on a 'when required' basis and regularly. Of
these patients, 1752 (46.4%) were male and 2025 (53.6%) were female, showing a male:female
ratio of 1:1.2, compared with the male:female ratio of 1:1.33 for the elderly registered at the ten
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general medical practice in the survey. Of the 3777 patients, 61% (2304) were aged 60 to 74
years and 39% (1473) aged 75 years or older, compared with 66% and 34% respectively for all
elderly patients in the sample.
5.4.8 Prevalence of long-term and regular use of medicines with prolonged oral
clearance in the elderly
When long-term (>3 months) and regular (once daily or alternate day) use of medicines with
prolonged oral clearance was determined, of the 3777 patients taking medicines with prolonged
oral clearance, 2002 (53%) patients (~60 years) were taking at least one medicine with prolonged
clearance regularly and long-term. As Table 5.6 shows, this represented a mean prevalence of
9.8% of the 20371 elderly patients in the ten practices, with a range of prevalence from 5.9% in a
North Tyneside practice (Practice 2) to 13.3% in a Gateshead practice (Practice 5). For the 1070
patients aged 60 to 74 years the prevalence of long-term and regular use of medicines with
prolonged oral clearance was 7.9% and for the patients aged 75 years and over the prevalence was
13.5%.
Table 5.6 Elderly (aged ~60y) taking medicines with prolonged oral clearance regularly and
long-term by practice and district
No. Elderly patients taking medicines with poe
Practice District elderly long-term & re2Ular!y
registered Total % Male Female 60- ~75y
no. 74y
1 North Tyneside 3051 342 11.2 108 235 193 149
2 North Tyneside 1681 100 5.9 17 83 54 46
3 Newcastle 1689 188 11.1 61 127 109 79
4 Gateshead 2298 191 8.3 61 130 88 103
5 Gateshead 1959 261 13.3 95 165 169 92
6 South Tyneside 2976 294 9.9 108 186 158 136
7 South Tyneside 1879 137 7.3 49 88 77 60
8 Northumberland 1740 156 9.0 37 119 56 100
9 Northumberland 1388 150 10.8 51 99 75 75
10 Newcastle 1710 183 10.7 51 132 91 92
Total - 20371 2002 - 638 1364 1070 932
Mean - 2037.1 200.2 9.8 63.8 136.4 107.0 93.2
SDev - 565.0 75.8 - 30.5 47.2 49.2 31.5
5.4.8.1 Age and gender profiles
As Table 5.6 describes, of the 2002 patients taking medicines with prolonged oral clearance
regularly and long-term at the time of the survey, 1070 (54%) were aged 60 to 74 years and 932
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(46%) aged 75 years and over. When compared with the age distribution of the 3777 patients
taking medicines with prolonged oral clearance overall, the long-term medication group had a
larger proportion of individuals in the ~75y group. When the male and female ratio was
considered, 638 patients (32%) were male and 1364 (68%) were female; representing a
male:female ratio of 1:2.1, suggesting that patients taking medicines with prolonged oral clearance
regularly and long-term are also more likely to be female. Statistical analysis showed that females
aged ~75y were more likely to take medicines with prolonged oral clearance than other age and
gender groups (p<0.0001).
5.4.9 Medical problems of patients taking medicines with prolonged oral clearance
regularly and long-term
Analysis of the medical problems of patients taking medicines with prolonged oral clearance
regularly and long-term showed that the 2002 patients taking medicines with prolonged oral
clearance regularly and long-term reported 2956 medical problems, with a mean of 1.47 medical
problems per person, with a range of 1 to 8 (Table 5.7). Of the 2002 patients, 860 (43%) only
reported one medical problem. The major problems suffered by the elderly were cardiovascular
disease (37.7%) and musculoskeletal problems (23.7%). A full list of medical problems is shown
in Appendix 5.4.
Table 5.7 Medical problems by BNF (1995) Therapeutic
Section
BNF Therapeutic Section Number of %
patients
01 Gastrointestinal System 238 8.1
02 Cardiovascular System 1115 37.7
03 Respiratory System 268 9.1
04 Central Nervous System 192 6.5
05 Infections 7 0.2
06 Endocrine System 221 7.5
07 Obstetrics and Gynaecology 29 1.0
08 Malignant Disease 32 1.1
09 Nutrition and Blood 26 0.9
10Musculoskeletal and Joint Disease 700 23.7
11Eye 57 1.9
12Ear, Nose and Oropharynx 38 1.3
13 Skin 33 1.1
Total 29561 100.0
1
1142 patients reported more than one medical problem
(range 1 to 8)
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5~4.10 Medicines with prolonged oral clearance used by the elderly
5.4.10.1 Total number of medicines used by the elderly taking medicines with
prolonged oral clearance regularly and long-term
At the time of the survey, the 2002 elderly patients identified as taking medicines with
prolonged oral clearance regularly and long-term were taking a total of 11751 medicines of all
types, each of which represented a prescribing instance (PI). The medicines used were divided
into four medication categories shown in Table 5.8.
• oral medicines without prolonged oral clearance (e.g. solid oral doses such as tablets and
capsules)
• non-oral medicines (e.g, creams, injections, inhalers)
• medicines with prolonged oral clearance, used either on a 'when required' basis (e.g. minor
analgesics used for occasional pains) or used long-term and regularly
• medicines with prolonged oral clearance used regularly and long-term by the elderly
The most common medication category prescribed was for medicines formulated as solid oral
doses, with 53.5% of the 11751 prescribing instances being for either tablets or capsules. Non-
oral formulations accounted for 1831 (15.6%) of prescribing instances. Formulations with
prolonged oral clearance represented 30.9% (3625) of all the prescribing instances. Of these
7.1% (829) were for 'when required' use and 23.8% (2796) for regular and long-term use of 143
different preparations with prolonged oral clearance (Table 5.8). Overall there were 5.8
prescribing instances per head (range: 1-18), with medicines with prolonged oral clearance used
regularly and long-term accounting for 1.4 prescribing instances per head (range: 1-5).
Table 5.8 Number of Prescribing Instances (PIs) for 2002 elderly patients
taking medicines with prolonged oral clearance, by medication category
Medication category No. of
Prescribing
Instances %of No.
(Pis) total Plslbead
Oral medicines without poe (tablets or capsules) 6295 53.6 3.1
Non-oral medicines (creams, inhalers, injections) 1831 15.6 0.9
Medicines with poe used 'when required' 829 7.0 0.4
Medicines with poe used long-term 2796 23.8 l.4
Total 11751 100.0 5.8
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5:4.10.2 Medicines with prolonged oral clearance taken regularly and long-term by
the elderly
5.4.10.2.1 Number of preparations and prescribing instances by BNF therapeutic
sections
The 2796 prescribing instances for medicines with prolonged oral clearance taken regularly
and long-term at the time of the study were for 143 medicines.
As Table 5.9 shows, Gastrointestinal medicines accounted for 36% (52 preparations) of the
143 preparations but represented 53.4% (1494) of the 2796 prescribing instances.
Central Nervous System and Cardiovascular medicines were also commonly prescribed and
accounted for 31 (2l.7%) and 18 (12.6%) of the 143 preparations respectively. However these
two sections of the BNF accounted for 543 (19.4%) and 537 (19.2%) prescribing instances
respectively. Overall, these three BNF sections (Gastrointestinal System, Central Nervous
System and Cardiovascular System) accounted for 92% of the prescribing instances to the elderly,
whilst representing 70.7% of the preparations used regularly and long-term.
5.4.10.2.2 Number of preparations and prescribing instances by dose form
Of the 143 medicines used regularly and long-term by the elderly, 85 (59%) were liquid oral
medicines, 41 (29%) were solids with prolonged oral clearance, 4 (3%) loose powders and oral
gels, and 13 (9%) powders or granules packaged in sachets. Liquid oral medicines together with
solids with prolonged oral clearance accounted for 89% (2478) of the 2796 prescribing instances
(Table 5.9). Although accounting for fewer preparations, solids with prolonged oral clearance
accounted for more of the prescribing instances; 1251 (45%), compared with 1227 (44%) for
liquid oral medicines.
Of the 85 liquid oral medicine preparations, 62 (73%) were Gastrointestinal (31%), Central
Nervous System (24%) or Respiratory (19%) medicines, however of the 1227 prescribing
instances for these liquid oral medicines, 84% (1028) were for Gastrointestinal medicines, with
Central Nervous System and Respiratory medicines only accounting for 6.4% (79) and 5.5% (68)
of the prescribing instances. Closer examination of the 1028 prescribing instances for
Gastrointestinal medicines showed that 58% (596) were for antacids and 41% (417) for laxatives.
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I Of the 41 solid dose preparations with prolonged oral clearance, 37% (15 preparations) were
Gastrointestinal and 30% (9 preparations) Central Nervous System medicines. This distribution
by therapeutic section was very different when the 1251 prescribing instances for this dose form
were considered, with Cardiovascular and Central Nervous System medicines accounting for 41%
(516) and 37% (467) of the 1251 prescribing instances respectively. Only 13% of the prescribing
instances were for Gastrointestinal medicines.
Of the 516 prescribing instances for Cardiovascular medicines, 460 (89%) were for only one
preparation (aspirin 75mg effervescent tablets) and 406 (87%) of the 467 prescribing instances
for Central Nervous System medicines were for two different strengths of the analgesic co-
codamol effervescent tablets.
Solids with prolonged oral clearance can be split into distinct sub-dose forms; effervescent
and soluble tablets, chewable tablets, pastilles and lozenges and sublingual and buccal tablets.
Effervescent tablets contain a weak acid and base, which interact when added to water producing
the gas carbon dioxide, which causes the tablet to explode and disperse the drug in the solution.
There is usually excess acid in the formulation so that the resulting solution is acidic in nature and
more palatable. Of the 1251 prescribing instances for solid preparations with prolonged oral
clearance used regularly and long-term, 937 (75%) were for effervescent tablets.
5.4.10.3 Use of generic and proprietary medicines with prolonged oral clearance
5.4.10.3.1 Number of preparations. formulations and prescribing instances by
therapeutic section
The 143 medicines with prolonged oral clearance used regularly and long-term by the elderly
were classified according to whether they were available generically or as a proprietary brand.
Table 5.10 shows this distribution by therapeutic section. Of the 143 preparations, 101 (70.6%)
were proprietary preparations and 42 (29.4%) generic preparations. The 42 generic preparations
were produced by one or more different pharmaceutical manufacturer and accounted for a total of
144 generic formulations, manufactured by 27 companies.
Generic and proprietary preparations from the Gastrointestinal, Cardiovascular, Respiratory
and Central Nervous System. Sections of the BNF accounted for 83% of the 42 generic
preparations, 85% ofthe 144 generic formulations and 81% of the 101 proprietary preparations.
Generic medicines were found fairly evenly across all four sections of the BNF, with 16.7% in the
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Cardiovascular and Respiratory Sections, and 21% and 29% in the Gastrointestinal and Central
Nervous System Sections, whereas 43% of the 101 proprietary medicines were for
Gastrointestinal medicines.
Table 5.10 Number of generic and proprietary medicines with prolonged oral clearance
(pOC) used regularly and long-term in the elderly
Generic Medicines with POC Proprietary Medicines with
POC
BNF Preparations Formulations Prescribing Preparations Prescribing
Section' instances instances
No. % No. % No. % No. % No. %
01 9 21.4 30 20.8 448 30.9 43 42.6 1051 78.2
02 7 16.7 19 13.2 471 32.4 11 10.9 70 5.2
03 7 16.7 40 27.8 55 3.8 9 8.9 24 1.8
04 12 28.6 33 22.9 454 31.3 19 18.8 83 6.2
Others 7 16.7 22 15.3 24 l.7 19 18.8 116 8.6
Total 42 100.0 144 100.0 1452 100.0 101 100.0 1344 100.0
1 01 = Gastrointestinal System
03 = Respiratory System
02 = Cardiovascular System
04 = Central Nervous System
Of the 43 proprietary Gastrointestinal medicines, 19 (44%) were antacids and 12 (28%)
laxatives. The antacids were complex combinations of acid neutralising chemicals which act
locally in the stomach to reduce excess acidity. Although many have been on the UK market for a
number years and no longer have patents, generic companies have not produced direct equivalents.
Due to the large number of active ingredients in each preparation general medical practitioners
and other prescribers tend to use the simpler proprietary name when prescribing these medicines.
Of the 42 generic preparations with prolonged oral clearance, the 7 respiratory medicines had
the highest number generic formulations associated with them. These 40 formulations were
mainly three medicines; salbutamol syrup, pholcodeine linctus and simple linctus.
As Table 5.10 shows, the 42 generic preparations accounted for 1452 (52%) of the 2796
prescribing instances for medicines with prolonged oral clearance used regularly and long-term at
the time of the study, with proprietary medicines accounting for 1344 (48%) prescribing
instances. Prescribing instances (PIs) for Cardiovascular (471 PIs), Central Nervous System
(454 PIs) and Gastrointestinal (448 PIs) medicines accounted for 94% of all 1452 prescribing
instances for generics with prolonged oral clearance (Table 5.10). The distribution of proprietary
medicines with prolonged oral clearance was considerably different, with 1051 (78%) of the 1344
prescribing instances being for Gastrointestinal medicines.
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Of the 471 prescribing instances for generic Cardiovascular medicines, 460 (98%) were for
aspirin 75mg effervescent tablets. The 454 prescribing instances for generic Central Nervous
System medicines were mainly analgesics (423 (93%) prescribing instances) and of the 448
generic Gastrointestinal medicines, 404 (90%) were laxatives, of which lactulose liquid accounted
for 350 prescribing instances. Of the 1051 prescribing instances for proprietary Gastrointestinal
medicines, 706 (67%) were antacids and 321 (31%) laxatives.
5.4.10.3.2 Dose form
As Table 5.11 describes, of the 42 generic preparations used regularly and long-term by the
elderly in the survey, 31 (73.8%) were liquid oral medicines accounting for 542 prescribing
instances (37% of the total of 1452 prescribing instances for generic preparations), and 10 were
solids with prolonged oral clearance representing 909 prescribing instances (63% of the total). In
contrast, of the 101 proprietary preparations 54 (54%) were liquid oral medicines which
accounted for 685 prescribing instances (50% of the 1344 prescribing instances for proprietary
preparations), and 31 (31%) were solids with prolonged oral clearance accounting for 342
prescribing instances (26% of the 1344 prescribing instances). Of the 1344 prescribing instances,
298 (22%) were for proprietary medicines formulated in sachets as powders or granules (Table
5.11).
Table 5.11 Numbers of preparations and prescribing instances for generic and proprietary
medicines with prolonged oral clearance used regularly and long-term, by dose type
Generic Pr«!prietary Total
No of No. of No of No. of No of No. of
preps PIs preps PIs _l!rel!_s PIs
Liquid oral medicines 31 542 54 685 85 1227
Solids with prolonged oral clearance 10 909 31 342 41 1251
Powders and Oral Gels 0 0 4 19 4 19
Sachets 1 1 12 298 13 299
Total 42 1452 101 1344 143 2796
5.4.10.4 Top ten medicines with prolonged oral clearance used by the elderly
Of the 143 preparations with prolonged oral clearance taken regularly and long-term by the
elderly, the ten most commonly prescribed, representing 75.7% (2116) of the 2796 prescribing
instances are shown in Table 5.12. Seven of these top 10 preparations were Gastrointestinal
medicines, with two Central Nervous System and one a Cardiovascular medicine. Of the 7
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dastrointestinal preparations which accounted for 1257 (45%) prescribing instances, 4
preparations were antacids, accounting for 603 prescribing instances and 3 preparations were
laxatives, accounting for 654 prescribing instances.
As Table 5.12 shows the most commonly used preparation (long-term and regularly) with
prolonged oral clearance in the elderly was aspirin 75mg effervescent tablets. This preparation
was prescribed 460 times in the 2002 elderly patients identified as taking medicines with
prolonged oral clearance regularly and long-term at the time of the survey and represented 16.5%
of the total of 2796 prescribing instances.
The ten medicines in Table 5.12, are shown by their generic names. Of these, 4 were
available as both generic and proprietary formulations, however all four were prescribed
generically in all prescribing instances. The remaining six preparations were only available as
proprietary brands although one (lspaghula Husk) was prescribed by generic name in 33% of the
255 instances of long-term prescribing.
5.4.11 Duration of use oflong-term medicines with prolonged oral clearance
When the duration of use by patients for medicines with prolonged oral clearance was
determined, it was found that 48% of all prescribing instances were from three months to two
years, with 27% of the prescribing instances being for medicines prescribed for one to two years.
Overall, 78.6% of the prescribing instances were for medicines with prolonged oral clearance used
for one year or longer (Table 5.13).
Prescribing of Gastrointestinal medicines was found in all periods of use; the greatest number
of prescribing instances being for medicines prescribed for 1 to 2 years at the time of the survey
(Table 5.13). Cardiovascular medicines were mainly prescribed for a period of 3 months to 2
years at the time of the study, accounting for 62.3% of the prescribing instances. Central Nervous
System medicines were prescribed predominantly in two time periods; 1 to 2 years (26.1 %) and
over 5 years (19.7%).
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Table 5.12 Number of prescribing instances (PIs) for the top 10 medicines with prolonged
oral clearance used long-term in the elderly by generic (G) and proprietary (P) name
Avail- %
BNF No. ability generically
Preparation Sectien' of PIs 0/0 as prescribed
of total GorP
Aspirin 75mg dispersible tablets CVS 460 16.5 G&P lOO
Sodium alginate 250mg/ sodium GIT 423 15.1 P 0
bicarbonate 133.5mg/ calcium
carbonate 80mg 15rnlliquid
Co-codamol 500mg/ Smg CNS 363 13.0 G&P lOO
effervescent tablets
Lactulose liquid GIT 350 12.5 G&P 100
Ispaghula husk 3.5g sachets GIT 255 9.1 P 33
Alginic acid 200mg/ aluminium GIT 64 2.3 P 0
hydroxide 80mg/ magnesium
trisilicate 40mg/ sodium
bicarbonate 70mgl chewable tablets
Alginic acid 500mg/ aluminium GIT 62 2.2 P 0
hydroxide 100mg/ magnesium
trisilicate 25mg/ sodium
bicarbonate 170mg I chewable
tablets
Aluminium hydroxide 420mg/ GIT 54 1.9 P 0
activated dimethicone 135mg/light
magnesium oxide 70mg 15ml
suspension
Co-danthramer suspension GIT 49 1.S G&P 100
Co-codamoI500mg/30mg CNS 36 1.3 P 0
effervescent tablets
Other POC medicines used long- - 680 24.3 - -
term and regularly
Total - 2796 100.0 - -
1BNF Section: GIT = Gastrointestinal System (BNF Section 1)
CVS = Cardiovascular System (BNF Section 2)
CNS = Central Nervous System (BNF Section 3)
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Table 5.13 Duration of time over which medicines with prolonged oral clearance were prescribed
Duration Total Prescribing Instances
of use no. % Section 011 Section 021 Section 031 Section 041 Other'
of PIs No. % No. of 0/0 No. 0/0 No. % No. %
of PIs Pis of PIs of PIs of PIs
< 1 year 582 20.8 287 19.1 160 29.6 16 20.3 78 14.5 41 29.3
~1 to <2 y 752 26.9 377 25.2 177 32.7 19 24.1 140 26.1 39 27.9
~2 to <3 y 352 12.6 216 14.4 53 9.8 4 5.1 59 11.0 20 14.3
~3 to <4 Y 433 15.5 251 16.7 68 12.6 6 7.6 90 16.8 18 12.9
~4 to <5 y 289 10.3 166 11.1 38 7.0 14 17.7 62 ll.s 9 6.4
~ 5 years 376 13.4 196 13.l 43 7.9 20 25.3 106 19.7 11 7.9
No Info. 12 0.4 6 0.4 2 0.4 0 0.0 2 0.4 2 1.4
Total 2796 100.0 1499 100.0 541 100.0 79 100.0 537 100.0 140 100.0
101 = Gastrointestinal
03 = Respiratory System
2 Other BNF Sections
02 = Cardiovascular
04 = Central Nervous System
5.4.12 Frequency of administration of medicines with prolonged oral clearance
used regularly and long-term
The frequency of administration of the 143 medicines with prolonged oral clearance used
regularly and long-term was classified into four categories: once daily (including morning and
night), twice daily, three times a day and four times a day (Table 5.14). A large proportion (67%)
of the prescribing instances were for dosing frequencies of 'four times a day' (36.9%) or 'once
daily' (30.1 %), where 'once daily' included single instances of morning and night use (Table
5.14).
When the frequency of administration was analysed by dose form, liquid oral medicines used
'four times a day' accounted for 519 (42%) of the 1227 prescribing instances and 'twice daily'
use accounting for 305 (25%) prescribing instances (Table 5.14). Medicines used 'four times' a
day were generally antacids and the those used 'twice daily' were laxatives (Table 5.15). In
contrast, medicines formulated as solids with prolonged oral clearance were used 'once daily' as
well as 'four times a day'. The solid medicines with prolonged oral clearance used 'once daily'
were mainly Cardiovascular medicines (414 prescribing instances), with those used 'four times a
day' being effervescent analgesics (Central Nervous System) and antacid chewable tablets
(Gastrointestinal Section). Medicines used at night accounted for 212 prescribing instances, of
which 194 (92%) were liquid, oral medicines and 158 (75%) of these were Gastrointestinal
medicines (Table 5.15). Of the 299 prescribing instances for sachets, 231 were for medicines
prescribed 'twice daily', and these were all Gastrointestinal medicines (laxatives).
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I
Night time use of medicines with prolonged oral clearance is important in terms of dental
health as salivary flow is reduced at night and this increases the time taken for the medicine to
clear from the oral cavity. Of the 212 prescribing instances for night time use, 194 (92%) were
liquid oral medicines and of these 15S (SI %) prescribing instances were for Gastrointestinal
medicines, the majority (147 prescribing instances) being laxatives.
When the dosing frequencies for the top 10 medicines with prolonged oral clearance used
regularly and long-term by the elderly were analysed (Table 5.16), it was clear that the majority of
the prescribing instances were for the standard dose frequency recommended by the manufacturer,
however there was a range of prescribing at other doses. For example, lactulose liquid is
recommended to be used 'twice daily', however the survey recorded its use over all dosing
frequencies. Similarly, ispaghula husk has a recommended dose frequency of 'twice daily', but in
the survey it was used at all other dose frequencies recorded.
5.4.13 Prescription only medicines (POM) versus 'over the counter' (OTC)
medicines prescribed regularly and long-term
Many medicines which are prescribed can also be bought 'over the counter' from community
pharmacies. Of the 143 preparations with prolonged oral clearance used regularly and long-term
in the elderly, SI (57%) were 'prescription only medicines' (POM), the other 62 (43%) being
'over the counter' (OTC) medicines, of which 29 (47%) were available as 'pharmacy only', that
is, only available from a pharmacist, and the remaining 33 (53%) were 'general sales list' (GSL)
medicines, available from all retail outlets.
Over SO% of both the POM and OTC medicines were from the four BNF Sections of
Gastrointestinal, Cardiovascular, Respiratory and Central Nervous System, with 17 (21%) POM
preparations being Cardiovascular and Central Nervous System medicines accounting for 27
(33%) preparations, and 5S% ofOTC medicines being Gastrointestinal (36 preparations).
Only two of the top ten medicines with prolonged oral clearance and used long-term and
regularly by the elderly were POM medicines. These were the laxative, co-danthramer suspension
and the minor analgesic, co-codamol 500mg/30mg effervescent tablets. The other eight
preparations were OTC medici~es; four 'general sales list' and four 'pharmacy only'.
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Of the 2796 prescribing instances for the 143 preparations with prolonged oral clearance
only 400 (14.3%) were for POM medicines. The remaining 2404 (85.7%) prescribing instances
were for medicines which could be prescribed on a NHS prescription, but may also be bought
from a pharmacy as a 'pharmacy only' (P) medicine (1314 prescribing instances) or from any
retail outlet as 'general sales list' (GSL) medicine (1082 prescribing instances).
5.4.14 Sugar content of medicines with prolonged oral clearance used regularly
and long-term by the elderly
5.4.14.1 Number of preparations that were sugars-free and sugars-containing
The quality of current information from the literature on which preparations were sugars-free
and sugars-containing was variable and in most cases the type of sweetening agent was not given.
Therefore, after the initial search of sources of literature for sugars content of medicines with
prolonged oral clearance, (Association of British Pharmaceutical Industry, 1995; British Medical
Association & Royal Pharmaceutical Society, 1995), it was decided to seek information on the
sugars content of all preparations directly from the manufacturers of these medicines.
The information received varied in quality, from those manufacturers that gave the type and
quantity of sweetening agent in each medicine to those who just supplied information as to
whether it was sugars-free or sugars-containing. The manufacturers of proprietary preparations
were more responsive in that the majority of companies posted or faxed information after the first
request. In contrast, of the 27 manufacturers of the 144 generic formulations, only 6 responded
after the first written request, the remainder were contacted by letter and fax, but even then only a
further 5 responded. The remaining 16 companies were then contacted by telephone for the
information, and all responded. The quality of information was poorer from the generic
manufacturers compared with the proprietary preparations, in that for 78 of the 144 formulations
the sweetening agent were not given, with the only information offered being whether the
formulation was sugars-free or sugars-containing.
Using this information from the pharmaceutical manufacturers, the preparations were
classified as sugars-free or sugars-containing. Generic medicines that were manufactured both as
sugars-free and sugars-containing formulations were classified as variable.
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5.4 .14 .l.1 Proprietary medicines
As Table 5.17 describes, 52.5% (53 preparations) of the 101 proprietary preparations with
prolonged oral clearance used regularly and long-term by the elderly were sugars-free, 39 (38.6%)
were sugars-containing and no information could be obtained for the remaining nine preparations.
Fifty-four of the 101 proprietary preparations were liquid oral medicines and of these 32
(59.3%) were sugars-free and 18 (33.3%) sugars-containing (Table 5.17). Of the 31 solid
proprietary preparations with prolonged oral clearance only 12 (38.7%) were sugars-free.
Seventeen solid preparations (54.8%) were sugars-containing and no information was obtained for
the remaining two. Of the 12 sugars-free solids with prolonged oral clearance, 7 were
effervescent tablets, the remainder being chewable tablets. Of the 17 sugars-containing
preparations, 13 were chewable or buccal and sublingual tablets.
Table 5.17 Number of proprietary sugars-free and sugars-containing preparations with prolonged oral
clearance by dose form
Liquid oral Solids with Powders! oral Powders in
medicines prolonged oral gels sachets Total
clearance
No. of % No. of % No. of % No. of 0/0 No. of %
preps preps _l!re_ps preps pr§!s
Sugars-free 32 59.3 12 38.7 1 25.0 8 66.7 53 52.5
Sugars- 18 33.3 17 54.8 3 75.0 1 8.3 39 38.6
containing
No 4 7.4 2 6.5 0 0.0 3 25.0 9 8.9
Information
Total 54 100.0 31 100.0 4 100.0 12 100.0 101 100.0
5.4.14.l.2 Generic medicines
Of the 42 generic preparations used regularly and long-term by the elderly, 14 (33.3%) were
sugars-free and 23 (54.8%) were sugars-containing (Table 5.18), with no information available
for 1 (2.4%) preparation. The remaining 4 (9.5%) generic preparations with prolonged oral
clearance were available as both sugars-free and sugars-containing and were classified as
variable.
Thirty-one (73.8%) of the -generic preparations were liquid oral medicines and of these 10
(32.3%) were sugars-free, 18 (58.1 %) sugars-containing, with 3 liquid oral medicines available as
both sugars-free and sugars-containing and classed as variable. Of the 10 solid preparations with
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prolonged oral clearance 4 (40%) were sugars-free, 4 (40%) sugars-containing, 1 (10%) variable
and for 1 (10%) no information was available.
Of the 10 sugars-free liquid oral medicines, 4 were Gastrointestinal preparations, mainly
laxatives and 3 were Cardiovascular medicines. Of the 18 sugars-containing liquid oral
medicines, 8 were Central Nervous System preparations.
Table 5.18 Number of generic sugars-free and sugars-containing medicines with prolonged oral
clearance by dose form
Liquid oral Solids with Powders/ Powders in
medicines prolonged oral oral gels sachets Total
clearance
No. of % No. of % No. of 0/0 No. of 0/0 No. of %
preps preps preps preps preps
Sugars-free 10 32.3 4 40.0 0 - 0 0.0 14 33.3
Sugars- 18 58.1 4 40.0 0 - 1 100.0 23 54.8
containing
Variable 3 9.7 1 10.0 0 - 0 0.0 4 9.5
No 0 0.0 1 10.0 0 - 0 0.0 1 2.4
information
Total 31 100.0 10 100.0 0 0 1 100.0 42 100.0
5.4.14.2 Number of prescribing instances for sugars-free and sugars-containing
medicines with prolonged oral clearance
Overall, when the 2796 prescribing instances for medicines with prolonged oral clearance
used regularly and long-term by the elderly were analysed according to sugar content, 1986 (71%)
were sugars-free, 715 (25.6%) were sugars-containing, 41 (1.5%) were variable and there was no
information for 54 (1.9%) prescribing instances (Table 5.19). Of the 1452 prescribing instances
for generic preparations 947 (65.2%) were sugars-free and 461 (31.7%) were sugars-containing,
with 41 (2.8%) being for generic preparations where the sugar content was variable (Table 5.19).
Of the 1344 prescribing instances for proprietary medicines, 1039 (77.3%) were sugars-free
and 254 (18.9%) were sugars-containing, with no information available for 51 (3.8%) prescribing
instances (Table 5.19).
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Table 5.19 Number of prescribing instances for sugars-free and sugars-containing
medicines with prolonged oral clearance used regularly and long-term in the elderly
Generic Proprietary Total
No. of 0/0 No. of % No. of 0/0
Pis PIs PIs
Sugars-free 947 65.2 1039 77.3 1986 7l.0
Sugars-containing 461 3l.7 254 18.9 715 25.6
Variable 41 2.8 0 0.0 41 1.5
No information 3 0.2 51 3.8 54 l.9
Total 1452 100.0 1344 100.0 2796 100.0
5.4.14.2.1 Proprietary medicines
As Table 5.19 shows, there were 1344 prescribing instances for proprietary preparations
with prolonged oral clearance of which 1039 (77.3%) were sugars-free and 254 (18.9%) sugars-
containing. Proprietary liquid oral medicines accounted for 685 (51%) of the total of 1344
prescribing instances for proprietary medicines (Table 5.20) and of these 625 (9l.2%) were
sugars-free. Of the 342 prescribing instances for solid proprietary preparations, 149 (43.6%)
were for sugars-free preparations and 52.6% were sugars-containing. Of the 298 prescribing
instances for powders and granules in sachets, 263 (88.3%) were sugars-free (Table 5.20).
Of the 625 prescribing instances for sugars-free proprietary liquid oral medicines, 569 (91%)
were for Gastrointestinal medicines of which antacids accounted for 561 prescribing instances.
Of the 159 prescribing instances for sugars-free proprietary solids with prolonged oral clearance
99% were accounted for within the three BNF Sections of Gastrointestinal (45%), Nutrition and
Blood (28%) and Central Nervous System (26%), with 92 (62%) of the 159 prescribing instances
being for chewable tablets and 57 (38%) for effervescent tablets. Of the 180 prescribing instances
for proprietary sugars-containing preparations, 89% (161) were from the Gastrointestinal (41%),
Cardiovascular (31%) or Nutrition and Blood (17%) Sections of the BNF, 93 (53%) being for
chewable tablets and 59 (33%) for buccal or sublingual tablets.
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Table 5.20 Number of prescribing instances (PIs) for proprietary medicines with prolonged oral
clearance by dose form
Liquid oral Solids with Powders & Powders in
medicines prolonged oral oral gels sachets Total
clearance
No. % No. % No. 0/0 No. 0/0 No. %
of of of of of PIs
PIs PIs PIs PIs
Sugars-free 625 91.2 149 43.6 2 10.5 263 88.3 1039 77.3
Sugars- 52 7.6 180 52.6 17 89.5 5 1.7 254 18.9
containing
Variable 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
No Information 8 1.2 13 3.8 0 0.0 30 10.1 51 3.8
Total 685 100.0 342 100.0 19 100.0 298 100.0 1344 100.0
5.4.14.2.2 Generic medicines
In contrast to proprietary medicines, liquid oral medicines only accounted for 37% (542) of
the 1452 prescribing instances for all generic medicines (Table 5.21) and of these 437 (80.6%)
were sugars-containing, 90 (16.6%) sugars-free, with 15 (2.8%) prescribing instances being for
variable preparations. Solid preparations with prolonged oral clearance accounted for 62% of the
prescribing instances, of which 94.3% were sugars-free, 2.5% (23) sugars-containing and 2.9%
(26) variable (Table 5.21).
Table 5.21 Number of prescribing instances (PIs) for generic medicines with prolonged oral
clearance by dose form
Liquid oral Solids with Powders & Powders in
medicines prolonged oral oral gels sachets Total
clearance
No. % No. 0/0 No. % No. % No. of 0/0
of PIs of PIs of PIs of PIs PIs
S\!gars-free 90 16.6 857 94.3 0 - 0 0.0 947 65.2
Sugars- 437 80.6 23 2.5 0 - 1 100.0 461 31.7
containing
Variable 15 2.8 26 2.9 0 - 0 0.0 41 2.8
No 0 0.0 3 0.3 0 - 0 0.0 3 0.2
infonnation
Total 542 100.0 909 100.0 0 - 1 100.0 1452 100.0
Of the 437 prescribing instances for sugars-containing generic liquid oral medicines, 359
(82%) were for Gastrointestinal medicines, of which 350 (98%) were for the laxative lactulose.
Of the 857 prescribing instances for sugars-free generic solids with prolonged oral clearance, 460
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(54%) were for the Cardiovascular medicine, aspirin 75mg effervescent tablets and 397 (46%) for
Central Nervous System medicines, of which 363 (91%) were for the analgesic, co-codamol
effervescent tablets.
5.4.14.3 Types of sweetening agents used in sugars-free and sugars-containing
medicines with prolonged oral clearance
Each manufacturer of the 144 generic formulations and 101 proprietary formulations was
contacted separately. All information on whether the formulation was sugars-free or sugars-
containing was obtained for all of the 144 generic preparations, however it was not possible to
obtain information on the type of sweetening agents used in 78 formulations. In contrast,
manufacturers of all but 9 proprietary preparations provided detailed information on the types of
sweetening agents in their preparations.
The 245 preparations (101 proprietary and 144 generic) contained 18 different sweetening
agents either singly or in combination. Seven of these were classified as sugars-containing, the
remaining 11 were classed as sugars-free.
5.4.14.3.1 Proprietary Preparations
For proprietary preparations, information was obtained for 92 of the 101 preparations. Of
these 92 preparations 53 (58%) were sugars-free and 39 (40%) were sugars-containing (Table
5.22).
Of the 53 sugars-free preparations, eight preparations contained no sweetening agent, 28
contained saccharin (singly in 14 preparations and in combination with other sugars in 14
preparations). Saccharin was also found in three sugars-containing preparations.
Of the 39 sugars-containing preparations the most common sugar was sucrose which was
either the sole sugar (23 preparations) or in combination with other sweetening agents (6
preparations) .
5.4.14.3.2 Generic preparations
For the 42 generic medicines there were 144 different formulations, manufactured by 27
pharmaceutical companies (Table 5.23). Information on whether the product was sugars-free or
sugars-containing was obtained for all but 1 of the 144 formulations, however the manufacturers
of 78 formulations (33 sugars-free, 44 sugars-containing and 1 for which no information was
87
Prescribed Medicines Prevalence Survey
available) declined to provide information on the type of sweetener used in the formulation. From
the remaining 66 formulations, 36 contained sugars-free sweetening agents and 30 sugars-
containing sweetening. Four formulations contained no sweetening agents and were classed as
sugars-free.
Of the 36 sugars-free formulations for which information was obtained, saccharin was the
most common sweetening agent, being used in 18 formulations as the only sweetening agent and in
7 preparations in combination with other sweeteners. The majority of saccharin containing
formulations (16 formulations) were solid doses with prolonged oral clearance.
Of the 30 sugars-containing generic formulations for which information was obtained, 25
(83%) were liquid oral medicines, 4 formulations were solids with prolonged oral clearance and
one was a sachet. Sucrose was the main sweetening agent found in sugars-containing generic
formulations accounting for 19 formulations, with 16 containing only sucrose and 3 formulations
using sucrose in combination with other sugars.
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Table 5.22 Sweetening agents found in 101 proprietary preparations with prolonged oral clearance
Proprietary Medicines
Liquids Solid Powderl Sachets Total
2els
Suzars-free
No Sugar 3 2 1 2 8
Saccharin 10 4 0 0 14
Aspartame 0 2 0 5 7
Sorbitol 6 0 0 0 6
Xylitol 0 0 0 1 1
Saccharin + Sorbitol 6 1 0 0 7
Saccharin + Mannitol 0 1 0 0 1
Saccharin + Cyclamate 0 I 0 0 1
Sorbitol + Lycasin + Aspartame 0 1 0 0 1
Glycerol + Sorbitol 1 0 0 0 1
Saccharin + Glycerol 2 0 0 0 2
Saccharin + Sorbitol + Glycerol 3 0 0 0 3
Sorbitol + Saccharin + Glycerol + 1 0 0 0 1
Lycasin
Total 32 12 1 8 53
Sut!ars-containin2
Sucrose 14 5 3 1 23
Lactose 1 7 0 0 8
Sucrose + Saccharin 0 1 0 0 1
Sucrose + Glucose + Sorbitol 1 0 0 0 1
Sucrose + Sorbitol + Saccharin 2 0 0 0 2
Sucrose + Glucose + Dextrose 0 1 0 0 1
Mannitol + Saccharin + Lactose 0 1 0 0 1
Sucrose + Sorbitol+ Lycasin + 0 1 0 0 1
Aspartame
Lactose + Sorbitol + Saccharin + 0 1 0 0 1
Aspartame
Total 18 17 3 1 39
Overall Total
Sugars-free 32 12 I 8 53
Sugars-containing 18 17 3 1 39
No information 4 2 0 3 9
Total 54 31 4 12 101
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Table 5.23 Sweetening agents found in 144 generic formulations with prolonged oral
clearance
Generic Medicines
Liquids Solid Powder! Sachets Total
gels
Suzars-free
No Sugar 4 0 0 0 4
Saccharin 4 14 0 0 18
Sorbitol 3 0 0 0 3
Lycasin 3 0 0 0 3
Saccharin + Sorbitol 5 2 0 0 7
Sorbitol + Lycasin 1 0 0 0 1
Total 20 16 0 0 36
Suzars-eeatainms
Sucrose 14 1 0 1 16
Lactose 0 1 0 0 1
Lactulose 7 0 0 0 7
Sucrose + Sorbitol 1 0 0 0 1
Sucrose + Lactose 0 1 0 0 1
Sucrose + Lactose + Starch 0 1 0 0 1
Lactose + Lactulose + Galactose 2 0 0 0 2
Fructose + Tagatose + Galactose + 1 0 0 0 1
Lactose + Epifructose
Total 25 4 0 1 30
Overall Total
Sugars-free 20 16 0 0 36
S1!8ars-containing 25 4 0 1 30
No information 49 29 0 0 78
Total 94 49 0 1 144
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5.5 DISCUSSION
5.5.1 The sample
To estimate the prevalence of use of medicines with prolonged oral clearance prescribed and
taken regularly and long-term by the elderly (aged sixty years and over) the sample had to be
representative of the total elderly population. In general, the larger the practice list size, the better
the socioeconomic mix of subjects would be, however, the location of a practice would also
determine its population and therefore it was important that a representative sample of all
socioeconomic classes was included in the survey. With this in mind, practices from five districts
representing urban (North Tyneside and South Tyneside), inner city (Newcastle and Gateshead)
and rural (Northumberland) settings were included in the sampling frame. In general, the North
East of England is more deprived than other areas in England; unemployment in the North East
was 9.8% in 1997 compared with the 6.9% for the whole of England (Office for National
Statistics, 1998) and studies have shown that social deprivation is linked to morbidity. In view of
this some caution is needed in extrapolating the results of this study in the Northern Region,
nationally.
Other criteria for inclusion in the study for the medical practices included a large list size and
the use of computerised patient medication record systems. It was important that these computer
systems allowed easy searching of records and provided clear information on repeat prescribing.
During the planning of this study advice was taken on the feasibility of using general practice
computing systems for undertaking a prevalence survey and a number of computer systems were
considered. The ease of printing information and conducting of searches using different variables
was discussed and it became apparent that two systems: EMIS and MEDITEL offered these
facilities. Of the ten practices that were finally included in the survey, nine used the EMIS system
and one used MEDITEL. Both systems allowed easy searching and printing of patient records
and offered on-screen information about current repeat prescribing along with information on start
dates for each medication, which was vital for easy and accurate data collection. In addition, both
systems allowed the connection of an additional external printer to the terminal, to output patient
medication data, which was important as it did not interfere with the running of the medical
practices and the printing of prescriptions by practice staff. The technical help lines which both
systems offered were used initially to gain information on the use of the computer where practice
staff could not help and provided data on practice demographics at the time of the study.
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The 1° general medical practices were selected at random, using a cluster sampling process,
from a list of all practices that had comprehensive computing facilities. All practices had list sizes
of approximately 5,000 and over and complied with the inclusion criteria. Three practices of the
10 initially selected were unable to help; one was already involved in another research project and
the other two were too busy. With changes in primary health care, the role of the general medical
practitioner in recent years has evolved to include more management and audit work as well as
clinical duties. The practices that agreed to help were highly organised and employed practice and
fund-holding managers. These practices also were highly computerised, using the practice
computer for not only for patient records but also for general practice management and audit. It
may be that due to the highly organised structure of these practices that their prescribing may vary
from smaller and less structured practices and place a selection bias in this study; for example, all
these practices had adopted practice formularies, devised with the help of health authority and
community pharmacists, to optimise cost-effective prescribing. The use of a practice formulary
may lead to some variation in prescribing compared with those practices that don't use one,
however in the Northern Region, the district health authority, in a bid to cut prescribing costs, has
introduced practice formularies in the majority of general medical practices. The use of
formularies tends to result in the prescribing of a narrower range of drugs both overall and for
particular medical problems and increased use of cheaper generic formulations (Consumers
Association, 1997).
The aim of a cross-sectional study of this design was to estimate prevalence at a single point
in time: ideally one day in which all the elderly patients registered with the 1° practices taking
medicines with prolonged oral clearance regularly and long-term would be identified. This
however was unrealistic since there were 20371 elderly patients registered at the ten practices. It
was estimated during the planning of the study that data collection would take approximately 12
months for all ten practices but the majority of the elderly tend to take the same medication over
long periods of time. In this survey 78.8% of the prescribing instances for medicines with
prolonged oral clearance used regularly and long-term were being prescribed for over a year with
prevalence of use remaining fairly constant over relatively long periods of time and it was felt that
this time span for data collection was acceptable. The fact that the data were collected over 12
months also helped to eliminate.any seasonal variations in prescribing. The manual aspect of the
data collection was main reason for this long time span and this discussed further in Section 5.5.3.
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The 20371 elderly patients in the sample represented 22% of the total population of the
practices, which was very similar to the proportion of elderly in the five districts of the study
(22%), the Northern Region (21%) and England (21%). Also the proportion of male (43%) and
female (57%) elderly patients in the sample was similar to the proportion of elderly males and
females in the five districts (42% and 58% respectively), the Northern Region (42% and 58%
respectively) and England (43% and 57% respectively) (Office for National Statistics, 1995).
This was also true of age distribution and showed that the sample was suitably representative and
any extrapolation on a local and regional level could be made with reasonable confidence.
5.5.2 The data collection process
During the period of data collection each of the ten practices were visited at least once every
two weeks and all ten practices were at the same stage throughout the data collection process. An
alternative way to collect the data would have been to collect the data from one practice at a time,
reducing the time taken to collect the data from each practice. However the data would then have
been collected at different times during the year, and seasonal variations in prescribing would
influence the results. On balance, collection of information from the ten practices using the
methodology chosen was felt to have been the most appropriate method.
The data collection process was very time-consuming; in Phase 2 the records of over 20000
patients had to be examined manually on the computer screen, to extract demographic and medical
data which then had to be coded and entered into a database. This process could have been
facilitated by downloading the data straight from a practice computer to a disk and then importing
these data into a database, however this would have involved copying large amounts of data
(approximately 4 Megabytes) onto computer disks. At the time of the survey computer disks
capable of holding large amounts of data (> 1.4 Megabytes) were not commercially available and
this did prolong the time taken to complete this part of the survey. Although this method would
provide a more accurate point prevalence survey than the method used in this study, the
technology was not available at the time.
5.5.3 Accuracy of the data
As all the data in the Prevalence Survey were taken directly from practice computer systems,
the accuracy of the data relied on how accurate the general medical practice computer records
were. It has been demonstrated that prescribing information is very accurate in general medical
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practice, with one survey showing 100% of all consultations where a prescription was issued
being logged onto the computer (Pringle et al., 1995).
With the large amounts of data which had to be manually collected, coded and entered into
the database it was important to ensure that all data collection and coding was accurate. Data
entry into the database was controlled by programming the fields to only accept certain types of
data. For example, when entering the date of birth of a patient, the field was programmed to
accept a series of 8 digits only, for example in the form 01011997. In addition the database
would reject any month over 12 and it would not allow entry of a date of birth for a patient aged
under sixty years of age. A 5% random sample of the data from the 2002 patients taking
medicines with prolonged oral clearance regularly and long-term was randomly taken from five of
the ten practices and checked for collection, coding and entry errors. No errors were discovered
due to collection, coding and entry of the data, however the validation exercise did highlight
problems with the construction of the database. To analyse data from different tables, there had
to be similar fields in the tables and the data in these fields had to match, for example the medicine
code had to be the same for the tables holding information on patients medicines (PATIENT
MEDICATION) and medicines information (DRUGS). In practice this information was entered
separately for each table, however during the course of the study it became apparent that this
process could have been automated by the database.
The process of collecting and entering data manually is no longer necessary as advances in
computing technology have allowed computers to be connected directly to practice computers and
allowed information to be down-loaded directly into a database. The whole process, which took
over a year for this survey could be done in much less time in any future work of this nature.
Further advances in the use of information technology in general medical practice, include the
release of the PRODIGY project in 1998 (Purves, 1998). This system provides the general
medical practitioner with a software program helping him decide which drugs to prescribe, based
on evidence of efficacy and cost The Royal Pharmaceutical Society is also setting up a working
party looking at the use of computer technology in primary care with view to standardise all
general medical practice and pharmacy systems. This will allow interchange of data between
pharmacies, general medical practices and the Prescription Pricing Authority, perhaps even
eliminating the paper based prescription form. The implications of this technology for future
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studies of this nature, i.e. prevalence surveys are that the data may be directly downloaded from
computer systems, eliminating the time-consuming process of data collection and entry.
5.5.4 The estimate of prevalence of use of medicines with prolonged oral clearance
used regularly and long-term in the elderly
The survey of 92570 patient records in ten practices identified 20371 elderly patients of
whom 3777 (18.5%) were taking at least one medicine with prolonged oral clearance. Of these
elderly patients 9.8% (2002) of all elderly patients sampled were taking medicines with prolonged
oral clearance regularly (daily or alternate day) and long-term (>3 months). This prevalence rate
varied between the practices, from 5.3% of the elderly population of a North Tyneside practice
compared with 13.3% of a South Tyneside practice and regular and long-term use of similar
practices, for example, two urban practices from North Tyneside also varied dramatically (5.9%
and 11.2%) in the prevalence rate. These results would suggest that the prevalence of use of
medicines with prolonged oral clearance regularly and long-term by the elderly is not dependent on
the area (i.e. rural, inner city or urban) or the district, as two different areas such as rural
Northumberland and urban South Tyneside had similar rates. It is more likely that medical and
other factors such as age influence the prescribing of medicines with prolonged oral clearance.
The 10 practices surveyed provided a representative sample of the five districts in the
Northern Region of England in terms of the male:female ratio as well as the proportion of elderly
individuals. Extrapolation of the prevalence rates of7.9% in the 60y to 74y group and 13.5% in
the 75y and over group to the five districts with an elderly population of 0.25 million (Office for
National Statistics, 1995) would mean that 24588 elderly in these five districts (19821 aged 60y
to 74y, 33872 aged ~75y) may be taking medicines with prolonged oral clearance regularly and
long-term. Further extrapolation to the whole of the Northern Region with an elderly population
of 0.62 million in 1995 (Office for National Statistics, 1995) would mean that 60544 elderly
(48806 aged 60y to 74y, 83403 aged ~75y) may be taking medicines with prolonged oral
clearance regularly and long-term. In view of the socioeconomic differences between the Northern
Region and the rest of the country and the impact of these differences on health, the extrapolation
for England should be treated with some caution, however, with an elderly population of 10
million in England (Office for National Statistics, 1995), over 2 million elderly (790000 aged 60y
to 74y, 1.35 million aged ~75y) may be potentially taking medicines with prolonged oral
clearance regularly and long-term. Since there are sugars-containing medicines with prolonged
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oral clearance and the elderly are retaining their natural teeth, then these elderly are at risk from
these medicines in terms of dental health.
5.5.5 Age and gender profiles of the elderly taking medicines with prolonged oral
clearance regularly and long-term
Of the total population of all ages in all ten practices in the survey (92,570 patients), 5l.1 %
were female, with 57% aged 60 years and over being female, reflecting demographic trends in
England which show that females have greater life expectancy (Office for National Statistics,
1998). This proportion was very similar to that found in the Northern Region and England where
the elderly females (aged 60 years and over) represented 58% of all elderly patients (Table5.4).
However, the results of the Prevalence Survey showed that of the 2002 elderly patients on regular
long-term medication with prolonged oral clearance, 68.l % were female (60y to 74y - 63%
female, ~75y - 74% female). In the population identified there were more female than male
elderly patients and the proportion of elderly male to females was consistent throughout the five
districts, the Northern Region and England. The patients on long-term medicines with prolonged
oral clearance were more likely to be female (p<0.0001) and as the patients aged, the proportion
of females increased; 74% of the patients aged ~75y being female. This is important in terms of
targeting population groups for health education, with regard to medicine use.
5.5.6 Medical problems of patients
All 2002 patients identified in the Prevalence Survey suffered from at least one medical
problem, with a range of 1 to 8 medicines with prolonged oral clearance used regularly and long-
term. The major medical problems of patients taking medicines with prolonged oral clearance
were cardiovascular (38%) and musculoskeletal (24%), with most cardiovascular problems being
hypertension and angina, and the main musculoskeletal problem being arthritis. Prescribing data
for all medicines dispensed to elderly patients (those exempt from prescription charges) in 1994
show that 27.6% of all 184.2 million prescriptions dispensed were for cardiovascular medicines
(Prescription Pricing Authority, 1995), which was lower than the prevalence of the disease in the
study population. This could be due to a higher rate of cardiovascular disease in the North; 40.7
males and 27.2 females per 1000 patients of all ages in 1996 was diagnosed with Coronary Heart
Disease (Office of Health Economics, 1997). One of the risk factors for cardiovascular disease is
hypertension and in a study of 1948 patients from 13 general medical practices in England,
looking at cardiovascular risk factors, 53.3% were on treatment for raised blood pressure
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(Poulter et al., 1996). The authors also reported that all risk factors for cardiovascular disease
were higher in the Northern practices.
5.5.7 Types of medicines with prolonged oral clearance used regularly and long-
term by the elderly
5.5. 7.1 Preparations
The 2002 patients identified as taking at least one medicine with prolonged oral clearance
were taking 11,751 medicines in total (mean = 5.9 medicines per person, range = 1 to 18). Of
these instances of prescribing, 53.5% (6295) were for oral medicines without prolonged oral
clearance (i.e. solid oral doses). In the UK the solid oral dose is the most common dosage form as
it is convenient for the patients in that it is easy to administer a specific dose without taste
problems and is not bulky to store. It is also cheaper than liquids to produce because it is stable
and does not have the high storage and transport costs incurred by bulky liquid oral medicines,
making it a popular choice. However the patients taking medicines with prolonged oral clearance
regularly and long-term were also taking other medicines in the form of tablets and capsules. This
would indicate that either the formulation of the medicine with prolonged oral clearance was
contributing to the therapeutic effect, that medicines with prolonged oral clearance taken regularly
and long-term were not available as a solid oral dose or that the prescriber (for some reason)
preferred to prescribe medicines with prolonged oral clearance. Prescribers may choose to use
medicines with prolonged oral clearance for reasons such as swallowing difficulties, in a bid to
improve compliance. Medicine factors could be a faster onset of action by prolonged oral
clearance medicines and less local side effects.
There is no evidence in the literature to suggest that prescribers prefer medicines with
prolonged oral clearance to solid dose forms and it is more likely that the medicine with prolonged
oral clearance was being used for either its local effect in the oral cavity (such as lozenges or
cough syrups) or in the stomach, such as antacids or laxatives. This is confirmed by the results of
the Prevalence Survey, which have shown that of the 143 medicines used regularly and long-term
by the elderly, 36.3% (52 medicines) were from the Gastrointestinal Section of the BNF and 23 of
these were antacids. Antacids are normally alkaline substances which neutralise the acid
produced in the stomach and alleviate the symptoms of excess acid such as indigestion. Antacids
are more effective as liquids or chewable tablets, since a large volume is required to produce an
antacid effect, and this could not be achieved by solid oral doses such as capsules and tablets.
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The liquid or chewable tablet dose forms have a faster action as there is a greater surface area of
drug to have the neutralising effect required in the stomach.
Laxatives were the other main medicines used in the gastrointestinal section; there were 17
preparations with prolonged oral clearance in this therapeutic sub-section, used regularly and
long-term by the elderly. The smooth muscle of the bowel becomes less efficient with age and this
problem is compounded by the large number of medicines used in the elderly, many of which can
cause chronic constipation (e.g. anticholinergic medicines). The bowel function is further
compromised by the poor diet of the elderly, who consume less fibre than younger members of the
population (Finch et al., 1998). The laxatives commonly used were ispaghula husk, a bulk-
forming powder which is reconstituted with water prior to use, and lactulose, a liquid laxative
which is mainly composed of the disaccharide lactulose and other sugars which produce an
osmotic effect drawing water into the gut to soften the faeces. Both these types of laxatives rely
on dose form for effect and are not available as solid oral doses.
Central nervous system medicines with prolonged oral clearance were also commonly used
regularly and long-term by the elderly. Most of these were anti-psychotics, minor analgesics and
anti-depressants in liquid oral form, since anti-psychotics and antidepressants are often tailored to
the individual patient and require the dose to be changed, often by small increments. By using a
liquid preparation the prescriber can accurately administer the correct dose and also change this if
required by altering the volume. The majority of minor analgesics identified as being used
regularly and long-term by the elderly in this study were co-codamol effervescent tablets taken on
a regular basis to control pain in chronic arthritic conditions. The physical size of the solid oral
dose tablet is fairly large making it difficult for frail elderly individuals to swallow the tablets.
Effervescent tablets offer an easier dose form, being dissolved in water before oral administration
which will also increase the surface area of the drug, providing a faster reaction. Effervescent
tablets work on the basis of a acid base reaction when placed in contact with water which causes
the tablet to explode and disperses the drug in the water. There is usually an excess of weak acid
resulting in an acidic solution which as well as producing a palatable solution, may also have
dental health implications as this solution may cause dental erosion on contact with teeth. This is
an area of increasing concern, previously highlighted in children (Nunn et al., 1996), where the
main cases appear to be the increasing consumption of carbonated drinks, many of which are
acidic or liberate acid on contact with teeth. Although there is little literature on the use of solid
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doses with prolonged oral clearance and dental erosion, recent studies have reported dental erosion
associated with chewable tablets (Giunta, 1983; Sullivan & Kramer, 1983).
One group of medicines with prolonged oral clearance used regularly and long-term by the
elderly was respiratory system medicines (16%) which were mainly syrups and linctuses to
alleviate cough. Cardiovascular preparations with prolonged oral clearance accounted for 12.6%
of the preparations used regularly and long-term and most of these were diuretics such as
frusemide, and the four different strengths of the anti-angina preparation glyceryl trinitrate in a
buccal formulation. In both cases other more commonly used dose forms are available, such as
frusemide oral tablets and isosorbide mononitrate (a nitrate similar to glyceryl trinitrate),
suggesting that the reason for giving a prolonged oral clearance medicine was for the patient
reasons. The patient may have problems swallowing solid oral doses and in a bid to improve
compliance the doctor may have prescribed a liquid oral medicine, as compliance is a problem in
the elderly (Salzman, 1995), where poor compliance was estimated to be as much as 40% to 75%.
Compliance with medication tends to decrease in the elderly as they generally take more medicines
than younger members of the population. The Royal Pharmaceutical Society of Great Britain has
recently launched an initiative ('From compliance to concordance') to assess the reasons for poor
compliance and to look at ways of improving it (Royal Pharmaceutical Society of Great Britain,
1997).
5.5. 7. 2 Prescribing instances
The number of prescribing instances for medicines used, rather than the number of
preparations gave a more accurate indication of what medicines were commonly being used by the
elderly. The results showed that 75.7% of all prescribing instances for medicines with prolonged
oral clearance used regularly and long-term were for only ten preparations. Analysis by BNF
Section showed that 53.4% of prescribing instances were for Gastrointestinal medicines and 87%
of these were for ten preparations. This illustrates the narrow range of these medicines for the
elderly. The elderly do suffer from gastric problems and ageing is associated with a decline in
gastric secretions, especially acid secretions, with secretory volumes as low as 50% in some
elderly patients, compared with younger individuals (Geokas & Haverback, 1969). This often
leads to gastritis increasing with age, with a reduction the number of chief and parietal cells in the
mucosa (Lamy, 1991), resulting in an ageing stomach which is vulnerable to insult from
exogenous substances, especially drugs, and in particular, non-steroidal anti-inflammatory and
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corticosteroid drugs. This would explain why the elderly are commonly prescribed antacids which
have optimal efficacy when formulated as chewable tablets or liquid oral medicines.
Of the 541 prescribing instances for the Cardiovascular Section, 506 (75%) were for one
medicine: aspirin 75mg effervescent tablets, used as prophylaxis against blood clotting. There has
been an increase in the use of oral aspirin in patients who are at risk from cardiovascular disease,
with one study showing that 9.5% of men used aspirin daily for coronary heart disease prevention
(McCallum et al., 1997). The overall number of prescribing instances for aspirin may not
accurately reflect its use as this medicine may be bought from pharmacies due to its low cost and
patients may prefer to purchase this rather than have it prescribed.
The Central Nervous System represented the third most prescribed area of regularly and
long-term use of medicines with prolonged oral clearance. Two differing strengths of the minor
analgesic co-codamol effervescent tablets represented 86% of all 537 prescribing instances for
Central Nervous System medicines, again showing that prescribing was centered round a small
range of medicines. The dose form used reflected the benefit gained from using aspirin in this
effervescent form, allowing a greater surface area of the stomach to contact the drug preventing
high concentrations of the drug coming into contact with the stomach lining, which may cause
ulceration. This is a particular problem with aspirin, however there is no pharmacological reason
for using co-codamol effervescent tablets as they do not cause local irritation from high
concentrations in the stomach. The decision to choose this dose form may relate to swallowing
difficulties or patient preference.
5.5.7.3 Doseform
Of the 143 medicines with prolonged oral clearance, used regularly and long-term in the
elderly, liquid oral medicines were the most commonly used dose form and accounted for 85
preparations. Liquid oral medicines are the traditional alternative dose form to solid doses. This
is especially true in children, however oral liquids also have an important role in the elderly where
swallowing problems and general ill health may prevent them from using solid oral doses. Other
newer dose forms with prolonged oral clearance include solids such as chewable, effervescent,
buccal and sublingual tablets and lozenges and pastilles, all of which are retained for prolonged
periods in the mouth. They are less bulky and more stable than liquid oral medicines, with a
longer shelf life and offer a convenient method of administration. The other two dose forms which
only accounted for 17 preparations were sachets and loose powders and oral gels. Loose powders
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are rarely used as they do not offer an accurate means of measuring doses and in this study their
use was restricted to laxatives. Powders and granules in sachets are becoming more common as
they have the advantage of being dispersed to be administered as an oral liquid but unlike liquid
oral medicines they are not bulky to transport. However they are expensive alternatives.
Of the 41 solid preparations with prolonged oral clearance, 67% were Gastrointestinal or
Central Nervous System medicines, although only 13% of the prescribing instances were for
Gastrointestinal medicines, with 79% being for Cardiovascular and Central Nervous System
medicines. Aspirin 75mg effervescent tablets accounted for 99% of the prescribing instances for
solid Cardiovascular medicines with prolonged oral clearance and co-codamol effervescent tablets
for 89% of the prescribing instances for solid Central Nervous System medicines with prolonged
oral clearance. Unlike dose forms such as inhalers and injection devices there is no literature on
the use of solid doses with prolonged oral clearance and the analysis in this study could not be
compared with any published data.
Although there was a wide range of preparations with prolonged oral clearance used in the
Prevalence Survey, the majority of prescribing for these medicines to the elderly was across a
narrow range of preparations in a few therapeutic areas.
5.5.8 Frequency of administration of medicines with prolonged oral clearance
Each pharmaceutical preparation has a recommended dose and dosing frequency, which is
found in the drug data sheet (Association of British Pharmaceutical Industry, 1995). The
frequency at which a medicine is prescribed is at the discretion of the prescriber, and most follow
the prescribing guidelines set out in the British National Formulary and data-sheets, set following
the result of stringent testing by manufacturers. However this survey showed a variation in the
frequency at which a medicine was administered. Although most of the prescribing instances were
for the standard frequency, there was a variation especially with the laxatives lactulose and
ispaghula husk. For many drugs a range of dose frequencies is not a cause for concern, however a
pharmacist must ensure that a prescribed dose is safe as well as effective and it would seem that
there is a need for a closer working relationship between the general medical practitioner and the
pharmacist, to ensure rational prescribing.
Antacids generally have no standard dosing regime and instead are administered on a 'when
required' basis. However the antacids used regularly and long-term in the elderly were nearly all
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prescribed for administration four times a day, highlighting the high level of use of gastrointestinal
medicines in the elderly. Many of the conditions causing gastric problems such as excess acidity
and chronic constipation may be due to poor health education by the professionals and
improvements in diet and fluid intake may reduce the need for these medicines. Laxatives and
antacids are also often used as an adjunct to treatment where the where another drug such as a
laxative is prescribed to supplement the medication schedule, if the original prescribed medicine is
causes constipation, rather than review and change the original medication. Although no
medicines in this survey were used in a manner that would cause harm to the elderly patient, this
was not an ideal situation and perhaps the introduction of practice protocols on the use of
laxatives may reduce the level of such prescribing.
5.5.9 Generic and proprietary with prolonged oral clearance
The importance of generic prescribing in government efforts to reduce the national drugs bill,
which was over £1.3 billion in 1994 in England (Prescription Pricing Authority, 1995), was
highlighted as far back as 1982 with the publication of the Greenfield report to the secretary of
state for health and social security on the findings of an informal working group on effective
prescribing (Greenfield, 1982). The respective proportions of medicines prescribed generically
and dispensed generically currently are 60.3% and 48.9%, respectively and rising (Department of
Health, 1998). The current rate of generic prescribing in the Northern Region is 67% and locally
in Newcastle it is even higher, at 71% (Department of Health, 1998). With pressure on practices
to reduce prescribing costs, the level of generic prescribing will continue to increase.
In this survey, generic medicines with prolonged oral clearance prescribed to the elderly on a
regularly and long-term basis accounted for 144 different formulations manufactured by 27
pharmaceutical companies. Those elderly on repeat medication prescribed generically could
receive one of a number of formulations which may change each time a repeat prescription is
issued depending on which pharmacy the patient attended. Pharmacies tend to stock the generic
which is the cheapest available and this may change regularly depending on promotions and
special offers from the pharmaceutical companies and pharmaceutical wholesalers, so that
patients attending the same pharmacy may even receive different formulations on different
occasions. Regardless of which generic formulation the pharmacist chooses to dispense, a set
price decided by the government and referred in the Drug Tariff (Department of Health, 1995) is
paid to the pharmacist. For proprietary preparations the prescribed brand would be the same each
time it is dispensed, since this is a requirement of the 1968 Medicines Act (HMSO, 1969). The
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increase in generic prescribing poses problems for the elderly as they are a vulnerable group of the
population who become easily confused. Changes in packs, colour of medicine and taste may
cause them concern and this could lead to a reduction in compliance, which is already a problem
in the elderly (Salzman, 1995).
Of the top ten medicines with prolonged oral clearance used regularly and long-term by the
elderly, six preparations were only available as proprietary preparations and 4 preparations were
available as both generic and proprietary brands from a number of manufacturers. For the latter
four preparations the final preparation received by the patient would depend on where the
prescription was dispensed. Even when there is no generic equivalent available, general medical
practitioners are encouraged to prescribe generically in anticipation of a generic becoming
available. This has led to more and more medicines being dispensed with their chemical name,
which may also have implications for prescribing in the elderly, with confusion over medicines
names leading to poorer compliance. During a changeover period from proprietary to generic
prescribing the patient may mistakenly use both, believing they are different medicines although
there is no evidence in the literature to suggest that currently this is a significant problem.
5.5.10 Prescription only and 'over the counter' (OTC) medicines
The Prescribed Medicines Prevalence Survey looked at whether the prescribed medicines
with prolonged oral clearance were available as prescription only medicine (POM) or if they could
be purchased 'over the counter (OTC) from a pharmacy. Of the 143 preparations, 43% could be
purchased OTC, however 85.7% of the 2796 prescribing instances were for medicines available
for purchase over the counter (OTC). That medicines with prolonged oral clearance used
regularly and long-term by the elderly could be bought without prescription and that many elderly
may be buying these medicines reinforced the need for a prevalence survey of OTC medicines use
by the elderly to provide an overall view of medicine use in the elderly. This aspect is covered
later in the Over the Counter Medicines Survey (Chapter 6).
5.5.11 Duration of use of medicines with prolonged oral clearance used
Of all 2796 prescribing instances, in the 2002 elderly patients identified as taking medicines
with prolonged oral clearance regularly and long-term, 78.8% were for medicines with prolonged
oral clearance were used for one year or more. Their use appeared to be stable over long periods,
which could be cause for concern in the case of laxatives and antacids which may be being used
long-term unnecessarily. Computer generated repeat prescriptions were used by all practices in
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the survey. Although efficient in terms of time saved compared with manually written
prescriptions this system does have a number of disadvantages, including the difficulty in
checking and reviewing each prescription, to monitor repeat prescribing. Many medicines such as
antacids and laxatives may be initially prescribed short term but once on the practice computer
there may be a tendency for regular repetition. Repeat prescribing monitoring is encouraged and
software for computers can highlight repeats for patients who have not seen their doctor for a
number of weeks to enable a review appointment to be made with the patient.
5.5.12 Sugar content of medicines with prolonged oral clearance taken regularly
and long-term by the elderly
Medicines with prolonged oral clearance linger in the mouth after administration, and they
are in contact with teeth much longer than other medicines such as tablets and capsules. A review
a number of studies, mostly with children, have shown that sugars-containing liquid oral
medicines taken regularly and long-term increased the risk of dental caries (Feigal & Jensen,
1982; Kenny & Somaya, 1989; Roberts, 1988; Roberts & Roberts, 1979). Although many of
these sugars-containing medicines are also available sugars-free, the specificity of prescribing
determines the sugar content since both sugars-free and sugars-containing preparations now exist.
In the Prevalence Survey, information from pharmaceutical manufacturers of the 143
preparations was used to classify each preparation used as sugars-free or sugars-containing. In
general, information from the manufacturers of proprietary medicines was obtained promptly and
was detailed. In contrast, the response from the 27 pharmaceutical companies that manufactured
the 144 generic formulations was very poor. The poor response from the generic manufacturers is
regrettable as health professionals will rely increasingly on information from generic companies as
prescribing moves from to proprietary to generic. This information will need to be accurate and
comprehensive to ensure that patients receive the most appropriate medication for which the
prescriber and pharmacist has all the necessary therapeutic data readily available. This should
include information on sugars content.
Overall, there were more sugars-free than sugars-containing proprietary preparations and the
number of prescribing instances for sugars-free preparations medicines were three times that for
sugars-containing medicines. Analysis by dose type showed that proprietary liquid oral medicines
prescribed to the elderly were more likely to be sugars-free (59.3% of preparations and 9l.2% of
the prescribing instances) than sugars-containing, whereas solid doses with prolonged oral
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clearance were more likely to be sugars-containing, (54.8% of preparations, 52.6% of prescribing
instances) .
In contrast, the generic medicines showed a very different distribution in terms of sugars
content. Of the 42 generic preparations used, 54.8% were sugars-containing and only 33.3%
sugars-free. Although, overall the majority of the prescribing instances for generic medicines
were for sugars-free medicines, the majority of the prescribing instances for liquid oral medicines
were sugars-containing (80.6%) and majority of prescribing instances for solid doses were sugars-
free (94.3%).
Both in terms of number of preparations and number of prescribing instances, sugars-free
medicines were more commonly used regularly and long-term, however, the Prevalence Survey
showed that generic liquid oral medicines were an area for concern due to the large proportion
which were sugars-containing. There has been considerable work done in the field of liquid oral
medicines and children's dental health (Hobson, 1985; Mackie & Bentley, 1994; Maguire &
Rugg-Gunn, 1994; Maguire & Rugg-Gunn, 1994). As a result many manufacturers have
reformulated paediatric liquid oral medicines as sugars-free formulations. This has occurred
mainly with proprietary formulations and with OTC preparations (Maguire & Rugg-Gunn, 1994).
It would appear that there is a need for generics to be targeted, particularly the liquid oral
medicines, and the advances made with paediatric formulation changes to sugars-free alternatives
should progress into adult formulations.
Another area of some concern was solid doses with prolonged oral clearance that were
chewable tablets as these were more likely to be sugars-containing, however they were mainly
available as proprietary brands. The survey has identified that chewable tablets are used long-
term and may be sugars-containing, and it is important manufacturers are aware of this in view of
recommendations made by Hobson and Fuller (1987) that "the pharmaceutical industry should
provide a greater range of sugars-free preparations, particularly those which are commonly used
by children on a long-term basis" (Hobson, 1985). In a progress report, two years later, Hobson
1987 (Hobson & Fuller, 1987) reported that The Industrial Pharmacists Group Committee of the
Royal Pharmaceutical Society had said that sugar was being removed from medicines gradually,
however this was a costly process. Over ten years later, this survey has shown that sugar is still
being used in medicines with prolonged oral clearance, although paediatric liquid oral medicines
were generally sugars-free. The pharmaceutical manufacturers must be aware of the risk of dental
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caries in adults and the elderly and be informed of the medicines with prolonged oral clearance
that are used regularly and long-term.
Of the 39 sugars-containing proprietary preparations and 30 sugars-containing genenc
formulations, sucrose was found in 74% of the preparations and 63% of the formulations. The
main sweetening agent in sugars-free medicines was the non-acidogenic intense sweetener
saccharin found in 29 of the proprietary preparations and 25 generic formulations, and commonly
used in the formulation of effervescent tablets. It was difficult to obtain an accurate overview of
the types of sweetening agent in generic medicines due to the lack of information available.
This survey used information from general medical practices on the use of medicines with
prolonged oral clearance used regularly and long-term in the elderly. The practices could not
provide information on medicines that were not prescribed, i.e. purchased from community
pharmacies or other retail outlets. In order to assess overall use of medicines with prolonged oral
clearance used in the elderly, another survey, looking at the use of 'over the counter' (OTC)
medicines use in the elderly was undertaken (Chapter 6).
5.6 CONCLUSIONS
The main findings from this survey of assessing the prevalence of use of prescribed
medicines with prolonged oral clearance are summarised below.
• The prevalence of use of medicines with prolonged oral clearance, used regularly and long-
term, in ten pratices in the Northern Region was 9.8% (2002 elderly patients).
• Of these 2002 patients, 32% were male and 54% were aged 60 to 74 years, with females
aged ::?75years more likely to take medicines with prolonged oral clearance regularly and
long-term (P<O. 0001).
• The main medical problems for patients taking medicines with prolonged oral clearance
regularly and long-term were cardiovascular (37.7%) and musculoskeletal (23.7%).
• The 2002 patients were taking 143 medicines with prolonged oral clearance regularly and
long-term, 2796 times. .
• Of these 2976 prescribing instances, 54% were for gastrointestinal medicines and 44% and
45% were liquid oral medicines and solids with prolonged oral clearance respectively.
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• Generic formulations accounted for 42 preparations, 144 formulations and 52% of the
prescribing instances .
• In terms of sugar-content, 39 (39%) of the 101 proprietary and 23 (55%) of the 42 generic
were sugars-containing.
• Of the prescribing instances for proprietary liquid oral medicines, 8% were sugars-
containing compared with 81% of the prescribing instances for generic liquid oral
medicines.
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APPENDIX 5.1
Map showing the five districts in the Northern Region, in which the study was
undertaken.
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APPENDIX 5.2
Letter to general medical practices
11 September, 1995.
«GP»
«ADDRESS»
«PHONE»
Dear «GP»,
I write to ask for your help in a research project, currently being undertaken in the Dental School at the
University of Newcastle upon Tyne.
The local effects of sugared medicines with prolonged oral clearance, e.g. pastilles, syrups, liquids, lozenges,
buccal and sublingual tablets, upon dental health have been recognised for a number of years by the medical
and dental professions. Increasing numbers of individuals in the community are retaining their natural teeth
into old age - however, the number of elderly individuals taking such medication is unknown. I am currently
canying out a survey in order to determine this, together with Wasim Baqir (pharmacist and Research Student)
and Dr Anne Maguire (Clinical Lecturer).
We would like to carry out a prevalence survey which would consist of a General Medical Practice Survey of ten
practices (randomly sampled from the five Districts of Newcastle, North Tyneside, South Tyneside, Gateshead
and Northumberland) which would aim to search practice computer records of all patients over the age of 60
years, to identify the numbers and medication regime of those patients on regular (daily or alternate day) long-
term (3 months or longer) medication with prolonged oral clearance. The study has been approved by the
Research Ethics Committees of the five Districts.
We have taken advice from the Department of Medical Statistics and Dr Ian Purves in the Department of
Primary Health Care with regard to the sampling of practices with comprehensive computing facilities, and I
understand that your practice would be a good candidate for sampling since I believe that you have a flourishing
practice with a broad age and socio-economic mix of patients in your care.
The survey has been registered with the Data Protection Registrar of the University of Newcastle upon Tyne,
and information collected would be treated with the strictest confidence, and individual patients would only be
identified by a code and not their name, under the terms of the Data Protection Act 1984. I enclose a copy of
the information sheet which would be used to collect patient information.
We would like to collect data in a manner that would cause minimal disruption to the day to day running of the
practice and I am writing to you in the first instance so that you might have a chance to discuss this matter with
your partners. Then perhaps it would be possible for Mr Baqir to meet with you or one of your colleagues to
discuss the matter further? If this is acceptable, Mr Baqir will contact your secretary within the next two weeks
to arrange a convenient appointment to see you.
With many thanks.
Yours sincerely,
Professor Andrew 1. Rugg-Gunn
Professor of Preventive Dentistry
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Example of a patient medication record from a general medical practice
computer record
No:1234 Mrs A. Smith
12/03/28 (Age 70)
123 Any Road, Anytown, A12 12A
19/04/98
Current (Acute) Prescribing Issued
Amoxycillin 250mg caps tds 15/12/97
Repeat Prescribing Start Last
Lactulose Liquid bd 13/05/93 4/04/98
Frusemide 40mg tabs od 19/08/96 4/04/98
Senna Syrup 7.5mgl5m1 nocte 24/11/97 4/04/98
Gaviscon Liquid qds 12/09/96 4/04/98
Paracetamol 500mg tabs qdspm 09/01/94 9/03/98
Atenolol 50mg tabs od 22/09/96 4104198
APPENDIX 5.4
Medical problems of patients taking medicines with prolonged oral clearance
regularly and long-term
III
APPENDIX 5.4 (continued)
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Over the Counter (OTC) Medicines Prevalence Survey
CHAPTER6
OVER THE COUNTER (OTC) MEDICINES PREVALENCE
SURVEY
6.1 INTRODUCTION
'Over the counter' (OTC) medication is available from community pharmacies for purchase
for a large number of minor medical conditions. However, it was unclear how many of these
medicines have a prolonged oral clearance, what proportion contain sucrose, and which medicines
are taken regularly and long-term by the elderly. The information from the practices in the
Prescribed Medicines Prevalence Survey did not contain details of medication that an elderly
patient may have bought from community pharmacies. Therefore it was necessary to investigate
this aspect of medication use further and this was undertaken using a survey of OTe medicines
use in a sub-sample of the elderly surveyed in the Prescribed Medicines Prevalence Survey.
6.2 AIMS
6.2.1 Main aim
• To determine the prevalence of use of OTe medicines with prolonged oral clearance used
regularly (daily or alternate day) and long-term (for three months or longer) in the elderly.
6.2.2 Subsidiary aims
• To assess the age and gender profiles of patients taking OTe medicines with prolonged
oral clearance regularly and long-term.
• To identify the medical problems for which OTe medicines with prolonged oral clearance
are used regularly and long-term by the elderly.
• To assess the sugar content of OTe medicines used by the elderly, regularly and long-
term.
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6.3 METHODS
6.3.1 Ethical committee approval
Once Ethical Committee approval in the five districts used in the Prescribed Medicines
Prevalence Survey (Newcastle, Northumberland, North Tyneside, South Tyneside and Gateshead)
had been given, preparation for the OTC Medicines Survey commenced.
6.3.2 Pilot study
Information on over the counter (OTC) medicines used by the elderly was required for this
survey. However, as OTC medicine use information is not recorded for patients registered in
general medical practices, other data collection methods were needed to provide a source of
information on OTC medicine use.
Collecting data directly from pharmacies was considered and ten pharmacies were randomly
chosen from the Newcastle area for a pilot study. For a period of 4 weeks pharmacists and
pharmacy staff were asked to note every sale of an OTC medicine with prolonged oral clearance
and determine the age of the person purchasing the product. This project relied entirely on the
participants enthusiasm and them remembering to note each sale. The initial results showed that
this form of data collection would not produce accurate results as feedback from the pharmacies
showed that many purchases were not recorded and many staff admitted later to 'guessing' the
number of purchases. Another drawback was the difficulty in determining the age of the patient
for whom an OTC medicine was being purchased, requiring the pharmacist or pharmacy staff to
explain the aims of the study when making an inquiry about age.
An alternative approach to a survey of OTC medicines use was to collect data directly from
an elderly population already identified in the Prescribed Medicines Prevalence Survey. This was
considered to be the most appropriate way to collect these data and was the method used.
6.3.3 The sample
After consultation with statisticians it was decided that a sub-sample of the patients aged 60
years and over from the ten general medical practices selected in the Prescribed Medicines
Prevalence Survey, would be used.
Ten general medical practitioners were selected at random from a list of all 48 general
medical practitioners at the ten practices surveyed previously in the Prescribed Medicines
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Prevalence Survey and contacted by a letter (Appendix 6.l) which explained details of the survey
and requested access to a list of their registered patients aged 60 years and over.
Once permission had been given, a computer search was undertaken for all patients aged 60
years and over registered to each randomly chosen practitioner, and fifty percent of these patients
were randomly selected, to form the sample. The name and address, date of birth, gender and
patient identification code for each patient was obtained from the practice computer, and saved to
a floppy computer disk as a text file.
Before this information could be used the text file had to be modified. Using a text editor,
'commas' were placed in the text so that the database recognised where one field stopped and
another started. For example placing the 'comma' between the first name and surname allowed
the database to enter these data into separate fields. This modified text file was imported into the
SUBSAMPLE PATIENT DATA table of the relational database described below (6.3.4).
6.3.4 The database
A database of all 'over the counter' (OTC) medicines with prolonged oral clearance was
constructed using the OTC Directory 1994/1995 (Proprietary Association for Great Britain,
1995) to identify all OTC medicines with prolonged oral clearance on the market in 1995. This
database was incorporated into the main study database as a table called OTC (Chapter 5, Figure
5.1). Each OTC medicine identified was given an individual code and the following information
was obtained and entered into the database:
• BNF Section
• Dose form (e.g. liquids, solids etc.)
• Manufacturer
• Active ingredients
• Pack sizes
• The type and amount of sweetening agent used in the medicine
Another table, SUBSAMPLE PATIENT DATA (Chapter 5, Figure 5.1) was designed and
created to hold demographic information and contained the following fields:
• Patients name and postal address
• Date of birth
• Gender
• Practice number
• Patient identification code (PIC)
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The patient identification code was a unique number to identify each patient in the database.
It was formed by prefixing each patients 'patient medication record' (PMR) number with a
practice code, identifying the practice at which the patient was registered.
6.3.5 Postal Questionnaire
A questionnaire (Appendix 6.2) was designed with advice from the Centre for Health
Services Research (University of Newcastle upon Tyne). Close attention was paid to the
questionnaire's construction and the accompanying letter (Appendix 6.3) to ensure clarity and
avoid confusion. The letter provided details of the study, requested participation in the study and
was signed by the researcher's head of department and the patient's general medical practitioner.
This questionnaire was piloted with 196 persons aged 60 years and over randomly sampled
from a practice in Corbridge, Northumberland. Each questionnaire was sent along with an
evaluation form asking the patients for their comments about the layout, ease of reading and any
possible ambiguities in the questionnaire.
From the 196 questionnaires distributed, 120 (61%) were returned. All questionnaires were
accurately completed indicating that the individual had understood the questions and did not find
the questionnaire confusing or difficult. From these results and the evaluation forms returned it
was clear that the format of the questionnaire was appropriate and it was decided that a postal
questionnaire would be the method of choice for collecting data from the elderly for this survey.
The questionnaire consisted of two parts (Appendix 6.2). The first section asked the patient
to note their current medical problems, number of natural teeth, how often they bought medicines
from a pharmacy, the type of medicine they preferred to buy and whether they asked for sugar-
free medicines. The second section asked patients to list all their current medication, both
prescribed and bought 'over the counter' (OTC) and include details of the start date and frequency
of administration of each medicine listed. A commercial printing company was used to print
3,000 copies of the questionnaire for distribution.
6.3.6 Mailing schedule
The SUBSAMPLE PA1JENT DATA table of the database, created from the modified text
files from the general medical practices, was used to produce mailing labels with each patient's
name and address for questionnaire distribution. For each patient a corresponding self-addressed
label for the return of the questionnaire was printed. This self-addressed label also held a patient
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identity number which was used to identify the original questionnaire upon its return and protect
patient confidentiality, since the questionnaire itself did not carry any form of patient
identification.
Just prior to postal distribution an inquiry was made to each participating practice to ensure
that none of the patients had de-registered or died. If this was the case then this was noted in the
database. The questionnaires were posted by district, with the sampled patients from the same
district being posted together. The initial mailing of the questionnaires was made in four batches,
followed by two reminders for all non-respondents.
Once returned, the patient's identity code on the self-addressed label was transferred to the
completed questionnaire and a 'Returned Questionnaire' field in the main patient database was
completed for each patient. After a two week interval to allow patients to return the
questionnaires, using the 'Returned Questionnaire' field of the database, non-respondents were
identified and were sent two reminders, approximately two weeks apart.
6.3.7 Data entry and analysis
A table called QUESTIONNAIRE DATA was created to hold information from the
returned questionnaires using the following fields:
• Medical condition
• Medicine code
• Start date
• Frequency of use
• OTC medicine (Yes or No)
All information collected from the returned questionnaire was coded to prior to entry into the
QUESTINNAIRE DATA table of the database. Each medical problem identified was allocated
a code using a specially designed coding frame (Appendix 6.4). The medical condition code was
derived from the relevant British National Formulary (BNF) Section together with a unique
number for each condition. For example, 'angina' was allocated the code 02.04, where the '02'
was the BNF Section (cardiovascular system) and '04' was the unique code for this condition.
Each medicine used was coded according to whether it was, firstly, a medicine with prolonged oral
clearance, and then whether it was a prescribed or purchased OTC medicine. Each coded
medicine was then entered into the database along with the date when it was started and the
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frequency of administration. The coding frames used were based on the OTC table of the
database (Section 6.3.4) allowing links to be established between this table and the
QUESTIONNAIRE DATA table, for data analysis.
Queries were run to link information from the SUBSAMPLE PATIENT DATA,
QUESTIONNAIRE DATA and OTC tables of the database, to determine the prevalence of use
of OTe medicines with prolonged oral clearance and identify the types of OTe medicines used
and the medical problems for which these medicines were commonly used.
6.4 RESULTS
6.4.1 The sample size and response rate
The ten general medical practitioners randomly selected were from eight of the ten practices
used in the Prescribed Medicines Prevalence Survey. One of the sampled general medical
practitioners who agreed to help had to be withdrawn from the survey and another practitioner
sampled in his place as it was difficult to download the names and addresses of his sampled
patients onto floppy disks using the practice computer system (MEDITEL). The sub-sample
survey of OTe medicines use was started in July 1997. Mailing to the patients was staggered due
to the large number of questionnaires involved. Preparation and mailing for each practice took
three weeks, with all questionnaires being posted by mid-September and the last returned
questionnaire received by mid-December 1997. A total of 2322 questionnaires were sent out to
the patients of the ten practitioners and the response to the survey is shown in Table 6.1.
Overall, of the 2322 questionnaires sent out, 1661 (71.5%) responses were received, however
after the initial posting only 1029 (44.3%) questionnaires had been returned (Table 6.1). The first
reminder resulted in a further 308 questionnaires being returned, increasing the response rate to
57.6%. The final reminder took the response rate to 71.5%.
The responses from 129 (7.8%) of the 1661 respondents could not be used in the survey. Of
these 42 (2.5%) were unopened questionnaires returned as the patient no longer lived at the
address, 55 (3.3%) were returned questionnaires where the patient had refused to take part in the
study, 22 (1.3%) gave medical reasons for not completing the questionnaire, and despite efforts to
eliminate this problem, questionnaires were sent to 10 (0.7%) patients who had died. The number
of questionnaires which could be used in the survey was 1532, giving an overall response rate of
66%.
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A telephone number was provided on the covering letter to enable patients to request further
information about the questionnaire and the aims of the study and 141 patients made use of this
service, after which 131 took part in the study.
The response from patients at individual practices varied from 58.8% of the 102 sampled
from Practice 5 in Gateshead to 81.2% of the 138 sampled from Practice 10 in Newcastle.
6.4.2 Age and gender profiles of respondents
As Table 6.2 describes, of the 1532 patients who completed the questionnaire, 656 (42.8%)
were male and 876 (57.2%) were female, 1039 (67.8%) were aged 60 to 74 years and 493
(32.2%) were aged 75 years and over. This compares well with the 2322 patients in the sample,
of which 42.5% (987) were male, 57.5% (1335) female, 65.2% (1513) were aged 60 to 74 years
and 34.8% (809) aged 75 years and over.
When compared with the elderly population at the ten practices (Table 5.3, Chapter 5) there
were similar proportions of elderly males and females in the ten practices (43% and 57%
respectively) and the sample of respondents (42.8% and 57.2% respectively). The proportion of
young (60 to 74 years) and old (75 years and over) elderly at the ten practices was 66.1% and
33.9% respectively, which compared well with the respondents in this survey (67.8% and 32.2%)
respectively.
Of the 1513 patients aged 60 to 74 years, 1039 responded (68.7%) compared with 493
responses from the 809 patients aged 75 years and over (60.9%). Of the 719 males aged 60 to 74
years sent a questionnaire, 67.6% (486) responded, compared with 59.4% of males aged 75 years
and over (170 responses from 286 questionnaires). The response from females aged 60 to 74
years was 69.6% (553 responses from 794 questionnaires) compared with only 59.7% (323
responses from 541 questionnaires) from females aged 75 years and over. In summary, the
response suggested that 'young elderly' females were more likely to respond than the other
groups.
6.4.3 Number of natural teeth
Of the 1532 respondents, 45.6% were dentate, (13.9% with ~12, 31.7% with >12 natural
teeth), 52.2% were edentate and 2.2% gave no information (Table 6.3).
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When all ages were considered together, of the 656 male respondents, 41% (269) were
edentate and 56.3% (369) had some or all natural teeth and of the 876 females who responded,
60.6% (530) were edentate and 37.6% (330) were dentate (Table 6.3).
Table 6.3 Number of edentate and dentate elderly in the OTC
Medicines Survey by gender
No. of Male Female Total
natural teeth No. % No. % No. %
0 269 41.0 530 60.6 799 52.2
~12 112 17.1 102 11.6 214 13.9
>12 257 39.2 228 26.0 485 31.7
No information 18 2.7 16 1.8 34 2.2
Total 656 100.0 876 100.0 1532 100.0
When analysed by age, the 60 to 74 year old group contained more dentate (53.5%) than
edentate individuals (44.7%). Conversely, in the ~75 year old group there were fewer dentate
respondents (29%) than edentate (68%) (Table 6.4). Of the 556 dentate respondents aged 60 to
74 years, 38.8% had more than 12 natural teeth, compared with 16.6% of the ~75 year old
dentate respondents.
Table 6.4 Number of edentate and dentate elderly in
the OTC Medicines Survey by age
No. of 60-74y ~75y
natural teeth No. % No. %
0 464 44.7 335 68.0
1 to 12 153 14.7 61 12.4
>12 403 38.8 82 16.6
No information 19 1.8 15 3.0
Total 1039 100.0 493 100.0
6.4.4 Medical problems
The questionnaire also collected information on the current medical problems of the
respondents (Table 6.5). In total, of the 1532 respondents, 1308 (85%) suffered from 2095
medical problems with a mean of 1.36 medical problems per patient (range = 0 to 8). The
majority of medical problems suffered by the elderly respondents were cardiovascular (36.5%)
and musculoskeletal (23.6%) in nature, with most cardiovascular problems being hypertension
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and angina, and the main musculoskeletal problem being arthritis (Table 6.5 and Appendix 6.4).
Appendix 6.4 provides a full distribution of all medical problems reported in the survey.
Table 6.5 Medical problems suffered by 1532 elderly patients in tbe
OTC Medicines Survey
BNF Section Number of 0/0
Patients
01 - Gastrointestinal System 170 8.1
02 - Cardiovascular System 764 36.5
03 - Respiratory System 183 8.7
04 - Central Nervous System 133 6.3
05 - Infections 4 0.2
06 - Endocrine System 171 8.2
07 - Obstetrics, Gynaecology and Urinary Tract 20 1.0
08 - Malignant Disease 24 1.1
09 - Nutrition and Blood 23 1.1
10 - Musculoskeletal and Joint Disorders 495 23.6
11 - Eye 42 2.0
12 - Ear, Nose and Oropharynx 27 1.3
13 - Skin 39 1.9
Total 20951 100.0
1224 patients bad no medical problems and 1308 suffered from more
tban one medical problem
6.4.5 Prevalence of use of OTC medicines
Of the 1532 respondents, 13% were currently taking OTe medicines and overall there were
258 instances of use for a total of 88 OTe preparations. This included OTe medicines with and
without prolonged oral clearance.
The number of instances of use of OTe medicines with prolonged oral clearance was 88,
with 44 OTe medicines taken by 79 patients. These OTe medicines with prolonged oral
clearance were taken on a 'when required' basis as well as those taken long-term (Table 6.6).
Over 58% of these OTe preparations were for gastrointestinal and respiratory medicines.
Only 13 OTe medicines with prolonged oral clearance were taken regularly and long-term by
17 patients representing a prevalence rate of 1.1%. Of these patients, 53% were male, 47%
female, 77% aged 60 to 74 years.
Although the prevalence rate of 1.1% was low, when extrapolated for the elderly population
of the five districts and the Northern Region of England, which was 0.25 million and 0.62 million
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respectively, in 1995 (Office for National Statistics, 1995), approximately 2760 and 6796 elderly
persons over the age of 60 years might be expected to be taking OTC medicines with prolonged
oral clearance regularly and long-term, in the five districts and the Northern Region, respectively.
Of the 17 patients identified as taking OTC medicines with prolonged oral clearance
regularly and long-term, only three reported a medical problem: with each reporting one problem -
angina, migraine or diabetes.
6.4.6 OTC medicines with prolonged oral clearance used by the elderly
Table 6.6 shows the number of OTC medicines and instances of use for all OTC medicines
with prolonged oral clearance and OTC medicines with prolonged oral clearance used regularly
and long-term by the elderly, by BNF Section.
The main areas of use of all OTC medicines with prolonged oral clearance used by the
elderly were the Respiratory System, Gastrointestinal System, Central Nervous System and
Nutrition and Blood, which together accounted for 84% of the 44 OTC medicines, respectively
(Table 6.6). In terms of instances of use, 63.6% were for OTC medicines in Gastrointestinal
(29.5%) and Respiratory Sections (34.1%) of the BNF.
Of the 13 OTC medicines with prolonged oral clearance used regularly and long-term, 8
(61.6%) were Gastrointestinal (30.8%) or Nutrition and Blood (30.8%) medicines (Table 6.6). In
terms of instances of regular and long-term use, Nutrition and Blood accounted for 29.4% and the
Gastrointestinal System, 23.5% of the total.
Table 6.7 shows the OTC medicines with prolonged oral clearance used regularly and long-
term by the elderly in this survey. Of the four Nutrition and Blood preparations, 3 were cod liver
oil preparations and one was a health tonic (Metatone). Three of the four Gastrointestinal
preparations were antacids and one a laxative. Of the 13 OTC medicines, 7 were liquid oral
medicines and 6 were solid doses with prolonged oral clearance (5 tablets, I lozenge).
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Table 6.6 Number of preparations and instances of use for all OTC medicines with
prolonged oral clearance and those used regularly and long-term.
BNF Section All OTC medicines with OTC medicines with POC
POC used regularly and long-
term
Preparations Instances of Preparations Instances of
use use
No. 0/0 No. % No. 0/0 No. %
01 - Gastrointestinal System 12 27.3 26 29.5 4 30.8 4 23.5
02 - Cardiovascular System 1 2.3 4 4.5 1 7.7 2 11.8
03 - ResQ_irato_ryS_ystem 13 29.5 30 34.1 1 7.7 2 11.8
04 - Central Nervous System 7 15.9 12 13.6 2 15.4 3 17.6
05 - Infections 0 0.0 0 0.0 0 0.0 0 0.0
06 - Endocrine System 0 0.0 0 0.0 0 0.0 0 0.0
07 - Obstetrics, Gynaecology 0 0.0 0 0.0 0 0.0 0 0.0
and Urinary Tract
08 - Malignant Disease 0 0.0 0 0.0 0 0.0 0 0.0
09 - Nutrition and Blood 5 11.4 8 9.1 4 30.8 5 29.4
10 - Musculoskeletal and Joint 0 0.0 0 0.0 0 0.0 0 0.0
Disorders
11 - Eye 0 0.0 0 0.0 0 0.0 0 0.0
12 - Ear, Nose and Oropharynx 6 13.6 8 9.1 1 7.7 1 5.9
Total 44 100.0 881 100.0 13 100.0 172 100.0
Itaken by 79 patients
2taken by 17 patients
Table 6.7 Number of instances of use for the 13 OTC preparations with POC used regularly and
long-term in the elderly
BNF Section Medicine Instances % Sugars-
of use free?
09 - Nutrition and Blood Seven Seas cod liver oil 2 11.8 Yes
09 - Nutrition and Blood Seven Seas cod liver oil lemon 1 5.9 Yes
09 - Nutrition and Blood Sanatogen cod liver oil 1 5.9 Yes
09 - Nutrition and Blood Metatone Liquid 1 5.9 No
01 - Gastrointestinal System Regulose Solution 1 5.9 No
01 - Gastrointestinal System Setlers Tablets 1 5.9 No
01 - Gastrointestinal System Mil-par liquid 1 5.9 Yes
01 - Gastrointestinal System Bisodol Antacid tablets 1 5.9 No
04 - Central Nervous System Aspro Clear eff. Tablets 2 11.8 Yes
04 - Central Nervous System Solpadeine Eff Tablets 1 5.9 Yes
03 - Respiratory System Covonia Cough Mixture 2 11.8 No
02 - Cardiovascular System Beecham Aspirin tablets 2 11.8 Yes
12 - Ear, Nose and Oropharynx Merocet Lozenges 1 5.9 No
Total 17 100.0 -
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6.4.7 Duration of use of OTe medicines with prolonged oral clearance used
regularly and long-term
Of the 17 instances of regular and long-term use, 8 were for medicines taken for two years or
longer at the time of the survey, 3 for medicines taken for 1 to 2 years and 2 for medicines taken
for 3 months to 1 year (Table 6.8). For the remainder no information was given on duration of
use.
The 8 instances of medicines used for 2 years and longer were for 6 OTC medicine
preparations, four of which were Nutrition and Blood preparations, the remaining two being a
minor analgesic (AsproClear effervescent tablets) and aspirin 75mg effervescent tablets used in
the prevention of cardiovascular disease (Table 6.8).
Of the three patients taking OTC medicines with prolonged oral clearance regularly and long-
term who reported a medical problem, the patient with diabetes had been taking an antacid for 1 to
2 years at the time of the study, the patient with angina had been taking aspirin 75mg effervescent
tablets for 1 to 2 years and the patient with migraine had been taking a cough suppressant for over
2 years.
Table 6.8 Duration of use of tbe 13 OTC medicines witb prolonged oral clearance
used regularly and long-term by tbe 17 elderly patients identified in the OTC
Medicines Survey
Number of instances of use
OTC Medicine 3 montbs 1 to 2 > 2years No
to 1 years years information
Seven Seas cod liver oil 0 0 1 1
Seven Seas cod liver oil lemon 0 0 1 0
Sanatogen cod liver oil 0 0 1 0
Metatone Liquid 0 0 1 0
Regulose Solution 0 1 0 0
Setlers Tablets 0 0 0 1
Mil-par liquid 1 0 0 0
Bisodol Antacid tablets 0 1 0 0
Aspro Clear eff. Tablets 0 0 2 0
Solpadeine Eff Tablets 0 0 0 1
Covonia Cough Mixture 0 1 0 1
Beecham Aspirin tablets 0 0 2 0
Merocet Lozenges 1 0 0 0
Total 2 3 8 4
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6.4.8 The sweetening agents used in OTC medicines with prolonged oral clearance
used regularly and long-term by the elderly
Seven of the thirteen O'I'C medicines with prolonged oral clearance used regularly and long-
term by the elderly contained sweetening agents with no acidogenic properties and were classified
as sugars-free (Table 6.7); the remainder were sugars-containing.
Of the sugars-containing O'TC medicines, sucrose was the most common sweetening agent,
being found in five of the six preparations (Table 6.9). Of the 7 sugars-free O'TC medicines, 4
contained no sweetening agents and the intense sweetening agent, saccharin was found in the other
three preparations, in one preparation in combination with the bulk sweetening agent, sorbitol.
Table 6.9 Type of sweetening agents in OTC medicines with prolonged
oral clearance used regularly and long-term in the elderly
Sweetening agent Liquids Solids with Total
POC preps
Suzar-centainina
Sucrose 1 1 2
Sucrose and glucose I I 2
Sucrose and saccharin 0 I I
Lactose + galactose +Iactulose 1 0 1
Sub-total 3 3 6
SU_2_ar-free
No sugar 4 0 4
Saccharin 0 2 2
Saccharin and sorbitol 0 1 1
Sub-total 4 3 7
Total 7 6 13
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6.5 DISCUSSION
Data obtained from the Prescribed Medicines Prevalence Survey (Chapter 5) provided
information on the use of prescribed medicines with prolonged oral clearance used regularly and
long-term by the elderly. However as the medical practices did not record information on
medicines which a patient may have purchased from community pharmacies it was unclear
whether OTC medicines formed a large part of regularly and long-term medication use in the
elderly. There is evidence to suggest that OTe medicine use is increasing overall (Baines &
Whynes, 1997; Batty et al., 1997; Bradley & Blenkinsopp, 1996), and government is encouraging
patients to visit the pharmacist before seeking advice of a general medical practitioner (Baines &
Whynes, 1997). Therefore it was important that a prevalence survey of OTC medicine use was
conducted to enable an overall estimate of prevalence of use of medicines with prolonged oral
clearance to be made in terms of both prescribed and OTC medicines.
6.5.1 The data collection process
As there is no national or local data on OTC medicine purchase by elderly patients,
information on the use of OTC medicines with prolonged oral clearance in the elderly could only
be obtained from either the pharmacy that sold the medication or by asking the patient directly.
International Medical Statistics (IMS), a data management company, collect quantity and cost
data for orders of OTC medicines to pharmacies but this is not patient related. After pre-study
information gathering with pharmacists in Newcastle it was clear that OTC sales data in the
elderly could not be collected accurately from a pharmacy without causing administrative and
operational problems. It was decided that the most efficient and accurate way to estimate the
prevalence of use of OTC medicines with prolonged oral clearance would be by collecting data
from patients.
The use of a patient questionnaire has inherent problems in relying on the patient to provide
information on medicine use. The reliability of this information will vary between patients and be
affected by a number of factors such as health, literacy, understanding of their health and
willingness to help. For instance, they may feel that a certain medication is not important enough
to be included because they bought it from a supermarket, or may not offer other information on
frequency and length of use .if they have forgotten. However information from the pilot study
indicated that a patient completed questionnaire could provide sufficient information to enable an
estimate of prevalence of use of OTC medicines and it was decided that this method of data
collection would be the most appropriate. However, the medical problems question was
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commonly not completed by patients and it was difficult to know whether this was because they
had no medical problems or because they had refused to answer the question. In retrospect this
aspect of the questionnaire could have been worded more accurately to allow patients to record if
they had no medical problems.
6.5.2 The sample
This study was undertaken immediately after the Prescribed Medicines Prevalence Survey
had been carried out and where a good working relationship with general medical practices
involved had developed. It was decided that the use of a sub-sample of the patients used in the
Prescribed Medicines Prevalence Survey where the use of prescribed medicines had been
determined, would be appropriate and useful. The collection of name and addresses from practice
computers was relatively straight forward since the practices all allowed full access to computers
for transfer of data files to floppy disks. This allowed the names and addresses to be imported
directly into a database to produce names and addresses after modification of the text file using a
text editor.
Of the two types of computing systems used, the MEDITEL system proved to be
problematic. Several attempts were made to download the names and addresses of the patients to
a floppy disk and after a number of trips to the practice and many telephone calls to MEDITEL it
became necessary withdraw the general medical practitioner from the study and randomly select
another doctor.
The name and address data were collected three to four days pnor to sending the
questionnaire out to reduce the chances of sending a questionnaire to a deceased patient. In
addition, the practice was phoned on the day of the mailing to check that none of the sampled
patients had died, however from the 2322 questionnaires posted ten were to patients who had died.
This was regrettable but had occurred because notification to the general medical practice had not
been made by the local Family Health Services Authority.
6.5.3 The response rate
To maximise the response rate the covering letter was signed by the patients doctor as well as
the researcher's head of department. In the letter the patient was reassured about confidentiality
and told that their care in the practice would not be affected if they refused take part in the study.
A telephone number on the cover letter allowed patients to phone for advice on filling the
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questionnaire, which was used by 141 respondents. The telephone calls were mainly from people
with no medical problems and no medication, who were not clear as to whether they should
complete and return the form. As well as reassuring the patient that this questionnaire did not
directly affect their medical treatment, it was also possible to advice the patient verbally on how to
complete the form and improve the quality of information received. It was felt that the telephone
help line was useful.
The overall response rate was 71.5% (1661 respondents) after two reminders which
compared favourably with other epidemiological studies involving the use of questionnaires in an
elderly population (Table 6.10). The response rate may have been increased by telephoning the
patient or actually visiting the patient at home and helping them with the questionnaire, however
with large number of questionnaires involved, this was not felt to be practical.
Table 6.10 Response rates in questionnaire studies in older adults
Authors Type of study Reference Response
Rate (o/«»_
Trenkwalder C. et a/ Door to door survey of patients aged Archives of Neurology. 82.5
65 years and over 52 (10):1017-22,1995
Noro A. and Aro S. Health-related quality of life among Quality of Life 83.0
the least dependent institutional Research. 5 (3):355-
elderly compared with the non- 66, 1996
institutional elderly population.
Calder S.l. et a/ A subjective health indicator for Journal of Bone & 67.4
follow-up. A randomised trial after Joint Surgery - British
treatment of displaced intracapsular Volume. 77 (3):494-6,
hip fractures. 1995
O'Keefe E.A. et a/ Bowel disorders impair functional Journals of 75.0
status and quality of life in the Gerontology. Series A,
elderly: a population-based study. Biological Sciences&
Medical Sciences. 50
(4):MI84-9,1995
Of the 1532 questionnaires included in the OTC Medicines Survey, 51.2% were from
females and 67.8% from patients aged 60 to 74 years. This was similar to the age and gender
profiles of the elderly patients of the 10 general medical practices where 51.1 % were female and
66.1% were aged 60 to 74 years (see Chapter 5) suggesting that patients responding were
representative of the practices where they were registered.
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6.5.4 The prevalence rate
The survey identified 79 patients taking OTe medicines with prolonged oral clearance. Of
these, only 17 were taking these medicines regularly and long-term, representing a prevalence rate
of 1.1% of the 1532 patients who returned the questionnaire. Extrapolation of this prevalence rate
would mean that as many as 6796 patients in the Northern Region (mid-1995 population of 0.62
million (Office for National Statistics, 1995) may potentially be taking OTe medicines with
prolonged oral clearance regularly and long-term. In comparison with prescribed medicines this
was a significantly lower prevalence of long-term use, however, with 45.6% the patients who
responded having some or all of their natural teeth (53.5% of respondents aged 60 to 74 years and
29% of respondents "z'75 years), the long-term use of these OTe medicines, if sugars-containing,
could pose a threat to their dental health.
6.5.5 Medical problems
The medical problems of the 1532 respondents were mainly cardiovascular (36.5%) and
musculoskeletal (23.6%) which were very similar to the medical problems identified in patients in
the Prescribed Medicines Prevalence Survey taking prescribed medicines with prolonged oral
clearance regularly and long-term. Prescribing data for all medicines dispensed to elderly patients
(those exempt from prescription charges) in 1994 showed that 27.6% of all 184.2 million
prescriptions dispensed were for cardiovascular medicines (Prescription Pricing Authority, 1995),
which was lower than the prevalence of the disease in the study population (36.5%). This could
be due to a higher rate of cardiovascular disease in the North; 40.7 males and 27.2 females per
1000 patients of all ages in 1996 were diagnosed with coronary heart disease (Office of Health
Economics, 1997).
A survey looking at 1409 elderly patients in Nottingham, England reported that 30.4% were
taking cardiovascular medicines (Rumble & Morgan, 1994), however the use of musculoskeletal
medicines (9.3%) is lower than the prevalence of the disease in the practice population (23.6%).
6.5.6 Types of OTC medicines used regularly and long-term
The 17 patients taking OTe medicines with prolonged oral clearance regularly and long-term
were taking 13 different preparations 17 times overall. These 13 preparations were mainly
Gastrointestinal (4 preparations) and Nutrition and Blood (4 preparations) medicines.
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The pharmacists role is to decide whether the medical complaint of an individual purchasing
a medicine over the counter is minor and treat it appropriately or whether to refer the patient to his
doctor or a hospital. Over the counter medicines are generally used to treat minor ailments and
are indicated for short term use. Pharmacists are trained to discourage patients from using them
regularly and long-term. However this survey showed that some OTC medicines are purchased
and used long-term. Other OTC medicines are indicated for long-term use and these include
vitamin supplements and mineral replacement products such as cod liver oil.
Aspirin has traditionally been used as a analgesic for minor aches and pains, however, more
recently its association with Reyes Syndrome has stopped its use in children. Aspirin 75mg
dispersible tablets are now the mainstay of prophylactic treatment for cardiovascular disease. A
review of aspirin use in cardiovascular concluded that aspirin therapy was associated with a
reduction in risk of subsequent myocardial infarction (MI) in patients with pre-existing
cardiovascular disease (Hennekens, 1997). This review also reported that there is clear reduction
of risk of MI when used in primary prevention. McCallum et al concluded from their study of
5751 British men aged 57 to 73 years, in 1992, that despite the strong evidence for the benefits of
aspirin in cardiovascular disease, many patients were not receiving aspirin (McCallum et al.,
1997). However the study may have underestimated aspirin use as many patients may be buying
it OTC. This was shown in a study of six general medical practices in Eating, Hammersmith and
Houslow where patients with MI were surveyed using a questionnaire. Regular aspirin was used
by 80% of the sample, of which 22% was OTC aspirin (Hoper & Pierce, 1998). It may be that the
patients general medical practitioner is aware of them buying this medicine OTC and they are
being monitored, however there is some anecdotal evidence to suggest that some patients may buy
this medicines as a result of reading about its health benefits in the national press.
Five of the 13 OTC medicines used regularly and long-term by the elderly were Nutrition and
Blood and Cardiovascular System preparations, and were appropriate for long-term use. These
were three cod liver oil preparations, a health tonic and dispersible aspirin 75mg. However, 8 of
the 13 OTC medicines used long-term were not indicated for long-term use. These were antacids,
laxatives, cough medicines and pain killers which should be used on a 'when required' basis. This
was of some concern since the use of OTC preparations may mask more serious conditions which
present as dyspepsia, constipation, cough and general pain. For example, long-term dyspepsia
may be a symptom of a gastric ulcer, which if not treated may become perforated and life
threatening.
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6.5.7 Duration of use
Of the 17 instances of use of OTC medicines with prolonged oral clearance used regularly
and long-term, 8 were for medicines used for two years or longer. All these were medicines that
were appropriate for long-term use as discussed above. Medicines not generally indicated for
long-term use (antacids and cough preparations) were being used for periods of between 3 months
and 2 years. Currently, the pharmacist and pharmacy staff can only monitor regular use of these
medicines if the patients buys them from the same pharmacy and this may not be the case as the
patient can purchase from any pharmacy of their choice. Even when a pharmacist has highlighted
a potential problem of overuse, determined patients will only go to another pharmacy if they are
refused a sale. Improving patient knowledge about the dangers of OTC medicines is required to
ensure that these medicines are used appropriately and the introduction of patient records of OTC
medicines, perhaps linked to existing pharmacy systems would highlight those at risk.
6.5.8 Sweetener content of OTC medicines used regularly and long-term
There were almost equal numbers of sugar-containing (6 preparations) and sugar-free (7
preparations) preparations. Of the six sugar-containing preparations, three were liquid oral
medicines and three were solids. These sugars-containing medicines with prolonged oral
clearance will increase the risk of dental caries if they are being used regularly and long-term in
patients with natural teeth, many of whom may have salivary flow compromised by other
medications (Bertram et al., 1979; Mornstad et al., 1986; Perrson et al., 1991) or age associated
morbidity (Gandara et al., 1985). Patients should be encouraged to use sugars-free alternatives or
change to another similar product if a direct equivalent is not available. The pharmacist is ideally
placed to advise patients to purchase sugars-free OTC medicines where available, however there
may be lack of understanding of the dangers of sugars-containing medicines used regularly and
long-term and there is a need to ensure that pharmacists are educated about this issue. In an
evaluation of a sugars-free medicines campaign in the North East of England it is reported that
greatest impact of the event was with prescribed medicines with the effect on OTC medicines
being less (Maguire et al., 1999).
6.5.9 Supply of OTC medicines
Currently over the counter medicines can be bought without the general medical practitioner
knowing and if a GSL product is bought from a non-pharmacy retail outlet then there will be no
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involvement from a healthcare professional. This survey has shown that, although only a small
number of patients were involved, OTe medicines were being used regularly.
The role of the pharmacist is to regulate the safe supply of all medicines and it is their job to
ensure that patients buying OTe medicines are using them effectively and safely. However this
survey has shown that OTe medicines not intended for long-term use are being used regularly and
long-term. Pharmacy monitoring of OTe medicines purchases is difficult: without computing
technology the patient would have to buy all their medicines from one pharmacy and the same
pharmacist should be on duty. Pharmacies are increasingly opening for longer periods which
involves a large turnover of pharmacists on duty. In addition patients visit city and town centre
pharmacies as a 'one off' when they are 'passing by'. Pharmacy computer systems are now well
developed for dispensing and keeping records of prescribed medicines, and although most new
systems will allow recording of OTe sales this is rarely done, since there are obstacles to
recording these data. The OTe medicine buyer may not have a record necessitating the creation
of a new record as well as entering the sale which would be time-consuming and may cause
delays. However, the advantage of such a system include the retention of records of the sale to
allow a check to be made against any future medicines for interactions and possible interactions
with prescribed medicines. With further advances in computing, future innovations in information
technology may allow easy entry of OTe purchases using a bar code or a PMR system linked to
the cash register.
6.6 CONCLUSIONS
The main findings from this survey of OTe medicines with prolonged oral clearance used
regularly and long-term by the elderly are summarised as follows:
• Of the 2322 elderly persons (~60 years), 1532 (66%) returned a questionnaire and
were included in the survey.
• Of the 1532 respondents, 42.8% were male and 67.8% were aged 60 to 74 years .
• 45.6% of the respondents were dentate.
• The prevalence of'use of OTe medicines with prolonged oral clearance used regularly
and long-term was 1.1% (17 patients).
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• Only three of these 17 patients reported a medical problem.
• The 17 patients were taking 13 OTC medicines with prolonged oral clearance regularly
and long-term, 17 times.
• Of the 13 medicines, 7 were sugars-free and 6 sugars-containing accounting for 10 and
7 instances of use, respectively.
• Sucrose was the most common sweetening agent, found in 5 of the 6 sugars-containing
OTC medicines, with saccharin being the most common sweetening agent for sugars-
free medicines.
137
APPENDIX 6.1
Letter to general medical practitioners
14 March, 1997
Dear Dr
RE: USE OF MEDICINES WITH PROLONGED ORAL CLEARANCE IN THE
ELDERLY
Wasim Baqir (Pharmacist and Research Student), under the supervision of Dr Anne Maguire, has
been, over the last year, collecting data from your practice as part of a survey to assess the
prevalence of the use of prescribed medicines with prolonged oral clearance in the elderly.
This survey is now complete and Wasim is now ready to start the final phase of the project. A
sample of patients will be surveyed using a postal questionnaire, to collect information regarding
the use of 'over the counter medicines' (OTC) with prolonged oral clearance. The project has
received approval from the Local Ethics Committee of your district.
A random sample of 10 out of 47 general medical practitioners surveyed in the prevalence survey
has selected you for the sub-sample survey if you are agreeable. I write to ask if you would
consider allowing us to survey a sample of your elderly patients using the enclosed questionnaire.
The questionnaire has been designed with the help of the Centre for Health Services Research
(University of Newcastle upon Tyne) and has been piloted in one practice already.
If you are happy for this survey to take place we would like to ask you to sign a covering letter
(enclosed) with myself as a co-signatory. We feel this would reassure these patients and minimise
any concerns they might have. The responses from the patients would remain confidential, with
no reference being made to individual responses.
If you would kindly agree to help, Wasim would be happy to contact yourself and arrange a time
for a short meeting to discuss the project further.
Please do not hesitate to contact me or Wasim (0191 222 7017), if you require any further
information.
Yours sincerely
Professor Rugg-Gunn
Professor of Preventive Dentistry
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APPENDIX 6.2
Questionnaire sent to patients in OTC Medicines Prevalence Survey
For Official Use
School of Dentistry
UNIVERSITY OF
NEWCASTLE UPON TYNE
CONFIDENTIAL
USE OF MEDICINES QUESTIONNAIRE
Please answer the questions on page 1 and then complete the table on
page 2 (continuing on page 3 if necessary).
The information you give us will be treated with the strictest confidence.
Thank you for taking part in this study. Please return the completed
qUestionnaire in the enclosed 'freepost' envelope (no stamp required) to
Wasim Baqir, Medicine Use Survey, Child Dental Health, FREEPOST
NEA902, Newcastle upon Tyne, NE2 IBR.
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APPENDIX 6.2 (continued)
Questionnaire sent to patients in OTC Medicines Prevalence Survey
USE OF MEDICINES QUESTIONNAIRE
Please answer the following questions:
1. What Medical Conditions do you have (e.g. angina, diabetes, etc.)?
List all current medical problems
2. How many natural teeth do you have?
Please tick one box
None D Up to 12 D More than 12 D
3. How often do you buy medicines from a pharmacy?
Please tick one box
Hardly ever D
At least once a month D
At least once a week D
Every two to three days D
4. Which type of medicines do you prefer to buy from pharmacies?
Please tick one box
Tablets and capsules D
Liquids (e.g. syrups) D
Either (no preference) D
Depends on what the medicine is for D
5. When buying a liquid medicine do you ask for a sugar-free version?
Please tick one box '
Yes D
No D
Sometimes D
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APPENDIX 6.3
Cover letter to patient
Dear SirlMadam,
A SURVEY OF MEDICINE USE
Professor Andrew Rugg-Gunn and Dr Anne Maguire of The Dental
School, University of Newcastle Upon Tyne would like your assistance in
a research project they are carrrying out. They are interested in looking at
the use of medicines in older adults. This medical practice is one of a
number of practices they have chosen in this region.
I hope that you will agree to help in this survey but we emphasise that the
choice of whether to take part is entirely yours and will not affect your
care in this practice in any way.
If you are willing to help, I would be grateful if you or someone on your
behalf could fill in the short questionnaire enclosed. On it please list all
the medication you are currently taking. This includes any medicines
bought from a pharmacy. Please then return it in the enclosed freepost
envelope (no stamp required).
If you have any queries or require help in completing the questionnaire,
then please do not hesitate to contact Wasim Baqir (Pharmacist and
Research Student) on 0191 222 7017.
With many thanks for your help in this project.
Yours faithfully,
Dr
Health Centre Name
Professor AJ. Rugg-Gunn
Professor of Preventive Dentistry
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CHAPTER 7
OVERALL CONSUMPTION OF MEDICINES WITH PROLONGED
ORAL CLEARANCE
7.1 INTRODUCTION
In the UK, dispensing of the majority of medicines used by the population is carried out by
pharmacists. Pharmacy practice occurs mainly within the three areas of hospital, community and
industrial pharmacy with most dispensing of medicines in the general medical services being by NHS
contracted community pharmacists for prescriptions prescribed by general medical practitioners.
General dental practitioners as prescribers and 'over the counter' (OTC) medicines sold by
pharmacists account for a smaller volume of use, although as a result of recent changes in primary
health care, both financial and organisational, and the changing role of community pharmacy, more
emphasis has been placed on the role of pharmacists as the first port of call for healthcare and advice
(McElnay & Dickinson, 1994; Moore & Johnson, 1993). This, together with the increasing range of
'over the counter' (OTC) medicines available as more 'prescription only medicines' (POMs) become
'pharmacy' (P) medicines, has increased the use of such medicines. OTC medicines are classified as
pharmacy only (P) medicines or general sales list (GSL) medicines. P medicines are only available
from pharmacies and must be sold under the supervision of a qualified pharmacist, whereas GSL
medicines may be sold from any retail outlet, such as a supermarket or petrol station. Medicines
used by the hospital service are dispensed by hospital pharmacy departments and there is normally
little use ofOTC medicines in hospitals. Unlike prescribed medicines dispensed within primary health
care services in the community, hospital medicine usage is not collated at a national, regional or local
level, but information on medicines dispensed is collected by some hospitals for audit purposes.
However medicine ordering information is available and this was used to estimate the quantity of
medicines with prolonged oral clearance dispensed through hospital pharmacies.
To assess the overall consumption of medicines with prolonged oral clearance, quantity data for
these prescribed and OTC medicines used in the primary health care and hospital services were
required. These data were collected using three surveys: A Prescription Analysis Survey, a Hospital
Drug Ordering Survey and an 'Over the Counter' (OTC) Medicines Survey.
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7.2 PRESCRIPTION ANALYSIS SURVEY
7.2.1 Introduction
At the end of each month community pharmacists in England and Wales send all dispensed
prescription scripts to the Prescription Pricing Authority (PPA), a special health authority based in
Newcastle upon Tyne. The PPA is responsible for reimbursing the pharmacist the cost of the
medicines as well as other professional fees based on the information from each prescription form
entered into a computer database at the PPA. Raw prescribing data are also collated to analyse
national, regional and local dispensing.
7.2.2 Aims
• To determine the number of prescription items and the quantities of all medicines with
prolonged oral clearance and those used regularly and long-term by the elderly, dispensed
from prescriptions issued in primary health services, during a one year period (1994) in
England, the Northern Region and one district within the Northern Region (Newcastle) .
• To determine the sugars content of prescription items and quantities for medicines with
prolonged oral clearance used regularly and long-term by the elderly, dispensed during a one
year period (1994) in the Northern Region of England.
• To determine the proportion of generically prescribed medicines with prolonged oral
clearance dispensed during a one year period (1994) in the Northern Region of England.
7.2.3 Methods
7.2.3.1 Sources of data
The PPA produce two types of reports, published by Her Majesty's Stationary Office (London):
Prescribing Analysis and Cost (PACT) reports, which provide prescribing data by the area in which
the prescription was prescribed and Prescription Cost Analysis (PCA) reports which provide
dispensing information by the area where the prescription was dispensed.
PACT and PCA data provide information on the number of prescription items and quantities of
medicines dispensed as well as their net ingredient cost before dispensing fees are added. These data
offer an accurate breakdown of dispensing, being compiled from all prescriptions dispensed, from a
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general practitioner level to a national level. However the two types for prescribing data vary in that
PCA data are based on the health authority in which the prescription was dispensed and give the total
number of prescription items and quantity for each preparation dispensed, whereas PACT data are
based on the health authority where the prescription was prescribed and give the number of
prescription items dispensed by quantity prescribed for each preparation. PCA data are only
available at a regional and national level, whereas PACT data are available at general medical
practitioner, practice, district, regional and national level.
7.2. 3. 2 The database
As Figure 5.2 in Chapter 5 describes a number of different tables were used to construct the
database that was used in all five surveys in the study. The DRUGS table was the main database
table and held information on all 613 medicines with prolonged oral clearance that were identified
from a database of all medical and surgical products supplied by John Richardson Computers pic. In
the case of generic medicines, where there could be one or more manufacturer, this field in the
DRUGS table, was allocated the code 999 which identified the medicine as a generic medicine. The
DRUGS table was linked to two other tables: PATIENT MEDICATION and CONSUMPTION
DATA which held data collected from the Prescribed Medicines Prevalence Survey (Chapter 5) and
Prescription Analysis Survey, respectively. As described in Chapter 5, using the Generics
Supplement 1995 (Chemist and Druggist, 1995), the GENERIC FORMULATIONS table was
created to hold information for each generic formulation and this was also linked to the DRUGS
table.
In addition a field in the DRUGS table of the database recorded whether the 613 medicines with
prolonged oral clearance were sugars-free or sugars-containing and collected information on the type
of sweetening agent used in their formulation. A similar set of fields in the GENERIC
FORMULA TIONS table recorded the sugar content and type of sweetening agent used in the
generic formulations.
7.2.3.3 Retrieval of dispensing data
The Prescription Pricing Authority was contacted by letter and permission obtained to retrieve
PACT and PCA data for Newcastle, the Northern Region and England for a one year period (1994).
The pharmaceutical advisor for Newcastle was also informed about the study. Since the PACT and
PCA data required were also held at the Northern Region Health Authority Regional Drug
147
Overall Consumption of Medicines with Prolonged Oral Clearance
Information Unit, Newcastle upon Tyne, permission was sought, in writing, from the unit for access
to these data.
Data from the Prescription Analysis Survey were entered into the CONSUMPTION DATA
table of the database (Figure 5.1, Chapter 5). A field was used to record dose form and identified the
medicine as a:
• liquid oral medicine
• solid dose with prolonged oral clearance (e.g. effervescent or chewable tablets)
• oral gel, loose powder or granule for reconstitution with a liquid (usually water)
• powder or granules packaged in a sachet for reconstitution with a liquid (usually water)
It was necessary to separate the medicines by dose types as they all had different units of
measurement. Quantities for liquid oral medicines were measured in litres, solid doses with
prolonged oral clearance as single units as were sachets containing powders or granules. Quantities
for loose powders, granules and oral gels were both measured in grams. The number of prescription
items and quantities dispensed were determined for:
• all medicines with prolonged oral clearance (613 medicines)
• prescribed medicines with prolonged oral clearance used regularly and long-term by the
elderly identified in the Prescribed Medicines Prevalence Survey (143 medicines)
7.2.3.4 Data entry
Prescribing Cost Analysis (PCA) dispensing data for England for a one year period (1994) were
examined manually and the number of prescription items and quantity dispensed for each medicine
with prolonged oral clearance was retrieved and entered into the relevant fields of the
CONSUMPTION DATA table of the database. For the Northern Region and Newcastle, PACT
prescribing data for a one year period (1994) were manually examined and individual quantities for
each quantity prescribed were added to give a total quantity prescribed for each medicine before
entering into the CONSUMPTION DATA table of the database.
7. 2. 3. 5 Data analysis
After entering all the data into the CONSUMPTION DATA table of the database, analysis was
undertaken to assess the number of prescription items and quantities prescribed and dispensed for all
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medicines with prolonged oral clearance and medicines with prolonged oral clearance taken regularly
and long-term by the elderly. A closer analysis was made of the use of medicines with prolonged oral
clearance in the Northern Region by generic prescribing and sugar content.
PACT data provided information on all generic prescribing, including those medicines where no
generic equivalent was available. The numbers of prescription items and quantities for generically
prescribed medicines where there was no generic available were added to the numbers of prescription
items and quantities for the proprietary preparation that was dispensed.
A link was established between the MEDICATION DATA table in the Prescribed Medicines
Prevalence Survey and the CONSUMPTION DATA table which held information on number of
prescription items and volume of medicines used in this survey. Using these linked tables the number
of prescription items and quantities of medicines prescribed and dispensed for preparations used long-
term and regularly by the elderly in the Prescribed Medicines Prevalence Survey was calculated for
England, the Northern Region and Newcastle.
7.2.4 Results and Discussion
7.2. 4.1 Data retrieval and sources of data
The data, although produced by the Prescription Pricing Authority (PPA) were held at the
Regional Drug Information Unit in Newcastle who kindly allowed access to the unit for data
retrieval. Access to the unit was initially restricted to two afternoons per week, but later increased to
every afternoon. The retrieval of PCA data for England began in June 1996, and was completed by
August 1996. Collection of PACT data for Newcastle was started December 1996 and completed in
February 1997, with information from the Northern Region PACT data commencing in April 1997
and being complete two months later in June 1997.
To assess the overall use of medicines with prolonged oral clearance the most accurate data
available were PCA and PACT as these data were based on 100% of all dispensed prescriptions.
However, these data only record what was prescribed and subsequently dispensed to the patient and
an estimate of what may have been consumed. Poor compliance is a common problem (Royal
Pharmaceutical Society of Great Britain, 1997), especially in the elderly (Salzman, 1995), and had to
be considered when analysing the data. The two forms of data used, PCA and PACT, varied slightly
in that PCA was a record of what was dispensed and PACT recorded what was prescribed. In
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reality there is little difference between these two sources, however the use of PCA for England
reduced the time spent calculating total quantities for individual medicines.
PCA data already contained information on quantities dispensed allowing dispensing
information to be entered directly into the database. However, PCA data were not available for the
Northern Region or Newcastle and for these areas PACT data had to be used. Although the
difference between data from the two reports related only to the area where the prescription was
prescribed (PACT) compared to the area where dispensed (PCA), the collection of PACT data was
time consuming as it involved entering information into a spreadsheet to calculate the total quantities
for each preparation, followed by entry of this information into the CONSUMPTION DATA table
of the database.
Data entry forms were created in MS Access to facilitate data entry and were linked to the
CONSUMPTION DATA table of the database. The forms were programmed to accept only
numeric values and to reject any wrong numbers (e.g. more than one decimal point or negative
numbers). This helped eliminate errors from the data entry process and allowed a number of entries
to be rejected during the data entry process, for example, entering two values in the same field.
Since this study, the PPA have released a new version of PACT data called ePACT (electronic
PACT), which is a modified version of current electronic systems (PACTLINE, HAEPACT and
EXEPACT) and will eventually replace these and the paper based data. The PPA are currently
introducing this service into all general medical practices (PPA Web Site: http://www.ppa.org.ukJ).
The impact of this is that any future prescribing analysis studies of this nature could be simplified,
allowing data to be downloaded straight into a database for analysis.
7.2.4.2 Number of different preparations dispensed (Table 7.1 and Appendix 7.1)
The database of all medicines with prolonged oral clearance identified 613 preparations (Table
7.1). From Table 7.1 it can be seen that overall, medicines with prolonged oral clearance covered a
wide range of BNF Sections. However, of the 613 preparations, 404 preparations (65.9%) had
actions on only three BNF Sections: Infections (27.2%, 167 preparations), the Central Nervous
System (20.6%, 126 preparations) and the Gastrointestinal System (18.1 %, III preparations).
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Of these 613 preparations with prolonged oral clearance, 93.3% (572) were dispensed in
England, and 84.6% (522) prescribed in the Northern Region and 63.6% (390) in Newcastle, in
1994 (Table 7.1). The proportion of medicines with prolonged oral clearance prescribed in the
Northern Region compared with all medicines with prolonged oral clearance available varied from
79.6% (Infections) to 100%. In Newcastle the range was wider, 11% (Ear, Nose and
Oropharynx) to 100% (Table 7.1).
The lower numbers of medicines used in Newcastle compared to the Northern Region and
nationally was mainly due to the lower number of general medical practitioners involved with a
smaller prescribing range. It may also have been due to prescribing initiatives aimed at cutting
drug costs and the use of local drug formularies. General medical practitioners from similar local,
medical and educational backgrounds, in Newcastle, compared with the Northern Region and
nationally, would also contribute to the smaller range of medicines prescribed locally. Medicine
use between the BNF Sections for all three areas was fairly consistent apart from the Ear, Nose
and Oropharynx Section, where only 11.1% of the 36 preparations with prolonged oral clearance
available were used in Newcastle compared with 86.1% in both England and the Northern Region.
This may also have been due local formularies limiting the number of medicines to choose from,
although a number of medicines with prolonged oral clearance in this section are antiseptic
lozenges and oral sprays, which general medical practitioners may be encouraged not to prescribe
as well as advice from the BNF states that "there is no convincing evidence that antiseptic
lozenges and sprays have a beneficial action and they sometimes irritate and cause sore tongue
and sore lips. Some of these preparations contain local anaesthetics which relieve pain but may
cause sensitisation." (British Medical Association & Royal Pharmaceutical Society, 1997). The
143 medicines with prolonged oral clearance that were used regularly and long-term by the elderly
in ten general medical practices in five districts of the North East of England are discussed in
detail in Section 5.4.10 of Chapter 5.
7.2.4.3 Number o/prescription items dispensed in England, the Northern Region and
Newcastle
7.2.4.3.1 For all medicines with and without prolonged oral clearance
In England, during 19?4, 457 million prescription items were dispensed for all medicines
with and without prolonged oral clearance (Table 7.2). For the Northern Region and Newcastle,
the total number of prescription items prescribed during 1994 were 32 million and 2.97 million,
representing 7% and 0.7% of the total for England respectively. There was slight variation in
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prescribing within the BNF Sections for these three areas with the proportion of prescription items
for the Central Nervous System being higher in Newcastle (22.2%) and the Northern Region
(20.6%) than England (18%). The higher use of these medicines could be due to patients visiting
their general medical practitioners rather than buying minor analgesics from pharmacies. In the
Northern Region (including Newcastle) there are more lower income households (especially
elderly householders) than the national average. There are higher levels of long-term unemployed
person the north compared with the rest of the country (Office for National Statistics, 1998),who
are entitled to free prescriptions and who may see a general medical practitioner for minor
ailments rather than purchase an over the counter treatment from their pharmacist.
Table 7.2 Number of prescription items (millions) dispensed for all medicines in England, the
Northern Region and Newcastle in 1994 by BNF Section (Source of data: PACT, Prescription
Pricing Authority, 1995)
BNF Section Prescription items
EnS!land Northern Region Newcastle
No. %of No. %of No. %of
(millions) total (millions) total (millions) total
01 Gastrointestinal System 37.5 8.2 2.8 8.6 0.27 9.1
02 Cardiovascular System 82.2 18.0 6.0 18.4 0.57 19.2
03 Respiratory System 46.0 10.1 3.1 9.5 0.31 10.4
04 Central Nervous System 82.2 18.0 6.7 20.6 0.66 22.2
05 Infections 48.9 10.7 3.3 10.1 0.32 10.8
06 Endocrine System 26.5 5.8 1.7 5.2 0.16 5.4
07 Obstetrics and Gynaecology 11.7 2.6 0.8 2.5 0.07 2.4
08 Malignant Disease 2.3 0.5 0.2 0.6 0.01 0.3
09 Nutrition and Blood 14.0 3.1 0.8 2.5 0.08 2.7
10 Musculoskeletal and Joint Disease 25.5 5.6 1.8 5.5 0.14 4.7
11 Eye 11.3 2.5 0.7 2.1 0.06 2.0
12 Ear, Nose and Oropharynx 8.8 1.9 0.5 1.5 0.05 1.7
Others 60.1 13.2 4.2 12.9 0.27 9.1
Totals 457.0 100.0 32.6 100.0 2.97 100.0
7.2.4.3.2 For medicines with prolonged oral clearance (Table 7.3 and Appendix 7.1)
As Table 7.3 shows, in England in 1994, 61.4 million prescription items were dispensed for
medicines with prolonged oral clearance which represented 13% of the total number of
prescriptions items dispensed for all medicines. Of these prescriptions, 65% were from three BNF
Sections: Gastrointestinal System (27.2%), Infections (21.4%) and Central Nervous System
(16.7%), and represented similar proportions to the number of preparations in these Sections.
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Of the 37.5 million items dispensed in England for all gastrointestinal medicines (Table 7.2),
44.5% (16.7 million prescription items) were for medicines with prolonged oral clearance (Table
7.3). Prolonged oral clearance medicines represented a smaller percentage of the number of
prescription items by therapeutic section for Infections, Nutrition and Blood and the Central
Nervous System, with 27% (13.2 million), 17.8% (2.5 million) and 12.4% (10.2 million) being for
medicines with prolonged oral clearance, respectively. Overall, gastrointestinal medicines were
more likely to have a prolonged oral clearance from the oral cavity, since most gastrointestinal
medicines act locally to achieve their effect, for example, antacids interact with acid in the
stomach to neutralise it and a liquid oral medicine provides a larger surface area available for
interaction with the stomach acid. Of the 16.7 million prescriptions items dispensed for
gastrointestinal medicines, 8.1 million (48.5%) were for antacids and 7.9 million (47.3%) for
laxatives.
The medicines with prolonged oral clearance for infections accounted for 13.2 million
prescriptions items of which 12 million (91%) were for antibiotics, and of the 10.2 million
prescriptions items dispensed for central nervous system medicines (Section 04), 8.1 million
(79%) were for minor analgesics.
In the Northern Region, 4.5 million prescription items were prescribed for medicines with
prolonged oral clearance (Table 7.3) which represented 14% of all prescription items prescribed in
the Northern Region in 1994 (Table 7.2). Prescribing in the Northern Region followed a similar
pattern to that of dispensing in England, in that gastrointestinal and central nervous system
medicines together with those for infections accounted for 71.8% of the total number of
prescription items for medicines with prolonged oral clearance dispensed in 1994. However the
proportion of prescription items for central nervous system medicines was higher in the Northern
Region (26%) compared to England (16.7%).
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Over 91% of the prescription items prescribed for Central Nervous System medicines in the
Northern Region were for minor analgesics (Appendix 7.1), and in comparison with other health
authority areas, the Northern Region overall has a lower socioeconomic status, with 9.6% of the
population of the North of England being unemployed compared with an unemployment rate in the
UK of 8.3%, in 1996, as well as the average earnings being considerably lower in the North East,
compared with the averages for England and the UK (Office for National Statistics, 1998). A
higher proportion of patients in the Northern Region may be entitled to exemption from
prescription charges and this may be why patients are being prescribed these analgesics rather
than buying them from pharmacies.
In contrast to minor analgesics, there was a lower proportion of prescription items for
medicines for Infections dispensed in the Northern Region (18.3%) compared to England (2l.4%).
This may be due to local prescribing initiatives to reduce antibiotic prescribing and the use of
formularies.
Of the 2.8 million prescription items prescribed in the Northern Region for all
Gastrointestinal medicines (Table 7.2), 42.9% (l.2 million) were for medicines with prolonged
oral clearance (Table 7.3). For Infections and Central Nervous System medicines the proportions
were lower with 24.2% and 17.9% being for medicines with prolonged oral clearance, respectively
(Table 7.2 and Table 7.3). This reflected the finding in England, that Gastrointestinal medicines
were more likely to have prolonged oral clearance.
InNewcastle, 0.45 million prescription items were prescribed for medicines with prolonged
oral clearance, representing 14.4% of all prescription items prescribed in Newcastle in 1994
(Table 7.3). The pattern of prescribing in Newcastle was very similar to that of the Northern
Region with the Gastrointestinal System (27.3%), Central Nervous System (25.2%) and
Infections (18.8%) Sections of the BNF accounting for 7l.3% of prescriptions dispensed for
medicines with prolonged oral clearance.
Of the 0.27 million items prescribed in Newcastle for all gastrointestinal medicines (Table
7.2), 44% (0.12 million items) were for medicines with prolonged oral clearance (Table 7.3).
Similarly, of the 0.32 milli?n prescription items for infections and the 0.66 million prescription
items for the central nervous system, 25% and 17% were for medicines with prolonged oral
clearance, respectively.
156
Overall Consumption of Medicines with Prolonged Oral Clearance
In summary, in all three areas of the Survey (England, the Northern Region and Newcastle)
approximately 14% of prescription items dispensed or prescribed in 1994 were for medicines with
prolonged oral clearance. Overall prescription data for all medicines dispensed to patients of all
ages in 1994 (Table 7.2) showed that the Gastrointestinal, Cardiovascular, Respiratory, Central
Nervous System and Infections Sections of the BNF were the main areas of medicines use.
However, prescription data for all medicines dispensed to the elderly (Prescription Pricing
Authority, 1995) have shown that the main therapeutic areas of prescribing to the elderly are the
Central Nervous System and the Cardiovascular system. When all medicines with prolonged oral
clearance were considered this pattern of prescribing differed, in that medicines for the
Gastrointestinal System, Infections and the Central Nervous System were the most commonly
prescribed or dispensed, accounting for over 65% of the prescriptions in all areas studied
(England, the Northern Region and Newcastle).
The proportion of prescription items prescribed or dispensed for gastrointestinal medicines
was similar in Newcastle, the Northern Region and England. However, in Newcastle and the
Northern Region the Central Nervous System medicines accounted for a larger proportion and
Infections medicines a smaller proportion, compared with England. Analgesics accounted for
79% and 92% of all CNS medicines in England and the Northern Region respectively. Over 91%
(Appendix 7.1) of these were minor analgesics which can be bought over the counter from
pharmacies, however the prescribing pattern suggested these were more likely to be prescribed in
the Northern Region and Newcastle.
7.2.4.3.3 Number of prescription items dispensed for medicines with prolonged oral
clearance used regularly and long-term by the elderly
The 143 medicines with prolonged oral clearance that were used regularly and long-term by
the elderly identified in the Prescribed Medicines Prevalence Survey, accounted for 49.6% (30.4
million prescription items) of the 61.3 million prescription items dispensed for medicines with
prolonged oral clearance in England, in 1994 (Table 7.3). The top three Sections dispensed were
Gastrointestinal, Cardiovascular and Central Nervous System medicines, accounting for 15.3
million items (50.2%), 6.2 million items (20.3%) and 4.4 million items (14.5%) respectively, and
85% of the total number of prescription items for medicines with prolonged oral clearance used
regularly and long-term by the elderly.
The 15.3 million prescriptions for Gastrointestinal medicines with prolonged oral clearance
potentially used long-term by the elderly accounted for 40.8% of the 37.5 million items for all
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Gastrointestinal medicines dispensed in England (Table 7.2 and Table 7.3). In contrast,
prescriptions dispensed for Cardiovascular and Central Nervous System medicines only accounted
for 7.5% and 5.4% of all prescriptions dispensed for these medicines in England, in 1994. In
addition, less than 1% of all prescriptions dispensed for medicines in the Infections Section of the
BNF were for medicines used regularly and long-term by the elderly.
The Gastrointestinal medicines were mainly antacids (7.5 million items) or laxatives (7.3
million items) which acted locally. Of the 5.4 million items for Cardiovascular medicines, 79%
were for aspirin 75mg effervescent tablets used in the prevention of cardiovascular disease, and of
the 5.4 million items for Central Nervous System medicines, 69% were for minor analgesics.
Antibiotics are normally used for a short duration (5 to 28 days depending on severity of the
infection) and uncommonly used long-term. Only two preparations, cefixime and erythromycin,
were being used regularly and long-term by the elderly.
In the Northern Region during 1994, 2.5 million prescription items were prescribed for
medicines with prolonged oral clearance used regularly and long-term by the elderly. This
represented 56.6% of the 4.47 million prescription items prescribed overall (Table 7.3). Of these
2.5 million items, 89.3% were for Gastrointestinal, Central Nervous System and Cardiovascular
medicines, with these Sections accounting for 1.08 million (42.7%), 0.71 million (28%) and 0.47
million (18.6%) prescription items, respectively (Table 7.3).
In Newcastle, 53.5% of the 0.45 million prescription items for all medicines with prolonged
oral clearance prescribed in 1994, were for medicines used regularly and long-term by the elderly.
The prescribing pattern for Newcastle was similar to the Northern Region with Gastrointestinal,
Central Nervous Systems and Cardiovascular medicines accounting for 90.4% of prescriptions
prescribed for these long-term medicines, with 0.11 million (45.3%), 0.06 million (19.5%) and
0.05 million (25.6%) prescription items prescribed respectively during a one year period (1994).
In summary, the three most common therapeutic areas for medicines with prolonged oral
clearance equivalent to those used regularly and long-term in the elderly, in terms of the number of
prescription items dispensed in 1994 in England, were the Gastrointestinal System,
Cardiovascular System and the Central Nervous System in that order. However in the Northern
Region and Newcastle, Central Nervous System medicines were prescribed more commonly than
Cardiovascular medicines. As for all medicines with prolonged oral clearance there was increased
use of Central Nervous System medication in the Northern Region and Newcastle and most of
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these Central Nervous System medicines were minor analgesics which could have been bought
over the counter from pharmacies.
When comparing the prescribing and dispensing of all medicines with prolonged oral
clearance with medicines with those used regularly and long-term, the major differences were that
very few Infections medicines were used long-term, there was increased use of Gastrointestinal
medicines long-term and Central Nervous System medicines use was similar.
Of the medicines with prolonged oral clearance equivalent to those used regularly and long-
term, antacids and laxatives were most commonly prescribed. Antacids were used to treat excess
acidity leading to heartburn or indigestion; conditions which are common in this age group
(Geokas & Haverback, 1969; Nelson & Castell, 1990). Ageing can reduce the motility of the
gastrointestinal tract and the elderly may often have a diet lacking in fibre which, along with
reduced fluid intake may cause chronic constipation for which laxatives are commonly prescribed.
The elderly also often take medicines such as non-steroidal anti-inflammatory drugs and
anticholinergic medicines which can cause gastric problems or constipation as side-effects and for
which they are often prescribed antacids and laxatives (Finch et al., 1998).
Cardiovascular medicines were also commonly prescribed, representing approximately 20%
of the prescriptions prescribed and dispensed nationally, regionally and locally. The elderly suffer
from more cardiovascular problems than the general population in the UK (Lakatta, 1993;
Williams, 1991), which would account for a large proportion of the Cardiovascular medicines
dispensed. In particular, aspirin 75mg effervescent tablets accounted for 95% of all the
prescription items dispensed in this Section, in all three areas. This drug is now used
prophylactically by the elderly as well as younger individuals suffering from cardiovascular
problems such as angina and hypertension.
7. 2. 4. 4 Dose form of medicines with prolonged oral clearance used regularly and
long-term by the elderly
When the prescription items were analysed by dose form, liquid oral medicines and solids
with prolonged oral clearance were most popular dose types, accounting for over 90% of the
prescription items dispensed in each of the three areas of England, the Northern Region and
Newcastle (Table 7.4).
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Table 7.4 Number of prescription items (Rx) dispensed in 1994, for medicines with
prolonged oral clearance used regularly and long-term by the elderly, by dose type
Dose Type England N. Rezion Newcastle
Rx Items 0/0 Rx Items 0/0 Rx Items 0/0
(xlOOO) (xl000) (xlOOO)
Liquid oral medicine 15363.5 50.5 1037.2 4l.0 102.2 42.9
Solid doses 12170.1 40.0 1304.3 51.5 118.1 49.6
Powders and oral gels 471.1 1.5 33.4 1.3 3.2 1.3
Sachets 2419.3 8.0 155.4 6.2 14.6 6.2
Totals 30424.0 100.0 2530.3 100.0 238.1 100.0
In England, liquid oral medicines were the most common dose form, accounting for 50.5%
(15.4 million) of the prescription items. This was in contrast to medicines dispensed in the
Northern Region and Newcastle, where the solid dose form with prolonged oral clearance
accounted for approximately 50% of the prescription items, compared with approximately 42%
for liquid oral medicines.
Liquid oral medicines are the traditional alternatives to solid oral doses. There are more
preparations with prolonged oral clearance formulated as liquid oral medicines and they are well
established as a suitable dose form especially in children and patients with swallowing problems.
They are also the cheapest dose form with prolonged oral clearance and pressure on prescribers to
cut drug costs may increase their use. Liquid oral medicines, as well as other medicines with
prolonged oral clearance offer the patient a convenient form of administration of medicines where
swallowing is a problem. However, the solid oral dose with prolonged oral clearance offers
advantages over liquid oral medicines in that these dose forms are less bulky and more convenient
for patients, at the same time having the advantages of liquid oral medicines in that they do not
have to be swallowed whole and can offer faster onset of action (e.g. soluble and effervescent
tablets), offer more control over dosing (e.g. buccal and sublingual tablets that may be removed at
any time) and have local effects (e.g. lozenges and pastilles).
The other dose forms, which were not as commonly prescribed as liquid oral medicines and
solid doses, were oral gels and loose powders and powders packaged in sachets. Oral gels and
loose powders, although very different dose forms were analysed in the same category as they
were both measured in gr3:ffis, the significance of which discussed later (Section 7.2.4.5). In
England, the Northern Region and Newcastle the number of prescription items dispensed for
medicines formulated as loose powders or oral gels was only 471,000 (1.5%), 33,400 (1.3%) and
1,300 (l.3%) items respectively, reflecting the small range prescribed regularly. In fact, these
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prescription items were for just four preparations, three of which were different brands of
ispaghula husk, a bulk forming laxative and one was a brand of senna granules, also used for
chronic constipation.
Prescriptions for powders packaged as sachets represented between 6.2% (in Newcastle and
the Northern Region) and 8% (in England) of all prescription items for medicines with prolonged
oral clearance used regularly and long-term, dispensed in 1994. Sachets are more expensive than
liquid oral medicines and loose powders and as a result prescribers are encouraged to reduce their
use, which may be a reason why they are not commonly prescribed.
7.2. 4. 5 Quantities dispensed during a one year period for all medicines with
prolonged oral clearance (Appendix 7.2, 7.3 and 7.4)
To assess the total quantity of medicines dispensed, the four different dose forms of
medicines with prolonged oral clearance, liquid oral medicines, solids, loose powders and oral gels
and sachets, were considered separately according to their units of measurement. Quantities for
liquid oral medicines were measured in litres, and solids and sachets as the number of tablets and
sachets. Loose powders and oral gels were placed in the same category as their units of
measurement were grams (Table 7.5).
As Table 7.5 shows, in England in 1994, 10.6 million litres, 1122.9 million tablets, 191.2
million grams and 307 million sachets for liquid oral medicines, solid doses, loose powders and
oral gels, and sachets (containing powders for reconstitution) respectively, were dispensed.
Table 7.5 Quantities for all medicines with prolonged oral clearance dispensed in England, the
Northern Region and Newcastle during 1994, by dose type
Dose Type Unit Quantity
England N. Region Newcastle
(xt03) (xt03) (xt03)
Liquid oral medicine litres 10569.6 716.4 78.1
Solid doses with prolonged oral clearance number 1122908.4 134152.3 14070.4
Powders and oral gel grams 191234.5 12214.1 109l.2
Sachet (containing powders) number 307022.1 20179.1 1877.2
Of the 10.6 million litr~s of liquid oral medicines dispensed, 5.9 million litres (56%) were for
Gastrointestinal medicines, with 1.7 million (16.4%), 1.3 million (12.8%) and 1.2 million (11.5%)
litres dispensed for medicines in the Respiratory, Central Nervous System and Infections Sections
respectively (Table 7.6). These four BNF Sections accounted for 97% of the quantity of all liquid
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oral medicines dispensed in England in 1994. As with prescriptions, the majority of the quantity
of Gastrointestinal medicines were antacids (3.5 million litres) and laxatives (2.3 million litres),
accounting for 98% of the total volume dispensed.
..:;;~ .
The solid doses with prolonged oral clearance (Rtf example effervescent and chewable
tablets) used in England accounted for 1122.9 million tablets with prolonged oral clearance, with
92.8% of the total quantity being for Cardiovascular (44.7%), Central Nervous System (31.8%)
and Gastrointestinal (16.3%) medicines (Table 7.5 and Table 7.6). Of the 502.5 million
cardiovascular tablets with prolonged oral clearance, 349.4 million (70%) were aspirin 75mg
effervescent tablets. There were 338.1 million solid doses dispensed for analgesics, accounting
for 95% of all Central Nervous System medicines formulated as solid doses with prolonged oral
clearance. As with liquid oral medicines, most solid Gastrointestinal medicines with prolonged
oral clearance were antacids (89%).
Liquid oral medicines prescribed in the Northern Region accounted for 0.7 million litres, of
which 61% were gastrointestinal medicines (Table 7.5 and Table 7.7). These were mainly
antacids (52%) and antacids (36%).
Of the 134.2 million solid doses for all medicines with prolonged oral clearance prescribed in
the Northern Region in 1994,54% were for Central Nervous System medicines, with 72.5 million
tablets prescribed (Table 7.7). The other main areas of use of solids with prolonged oral
clearance were the Cardiovascular System and the Gastrointestinal System where 42.4 million
(31.6%) and 13.5 million (10.l%) tablets with prolonged oral clearance were dispensed,
respectively. Of the Central Nervous System medicines prescribed, analgesics accounted for 71.2
million tablets (98%). Aspirin 75mg effervescent tables accounted for 61% (25.9 million tablets)
of all Cardiovascular medicines prescribed in 1994.
Newcastle followed a pattern similar to regional and national dispensing, with 77,400 litres
of liquid oral medicines being prescribed in 1994 (Table 7.8), of which 65.8% (50,900 litres) were
for Gastrointestinal medicines. Central Nervous System, Infections and the Cardiovascular
medicines accounted for 9,100 (11.8%), 8,300 (10.7%) 8,000 (10.3%) litres of liquid oral
medicines being prescribed, respectively (Table 7.8). The main Gastrointestinal medicines used
were antacids (68%) and laxatives (30%).
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Overall Consumption ofMedicines with Prolonged Oral Clearance
There were 14.1 million solid doses with prolonged oral clearance prescribed in
Newcastle in 1994, of which 46.3% (6.5 million tablets) were for the Central Nervous
System. The Cardiovascular and Gastrointestinal medicines accounted for 4.6 million
(32.4%) and 2.5 million (18.l %) tablets, respectively (Table 7.8). As with numbers of
prescriptions prescribed the main area of prescribing for Central Nervous System medicines
was analgesics (99.6%). Aspirin 75mg effervescent tablets were the main cardiovascular
medicine prescribed.
In summary, of the quantity of liquid oral medicines dispensed in the three areas, a large
proportion was for Gastrointestinal medicines, with the proportion in the Northern Region and
Newcastle (61% and 66% respectively) being slightly higher than England (56%). The
proportion of liquid oral medicines dispensed for Central Nervous System (12%) and
Infections (11%) was similar for England, the Northern Region and Newcastle.
Solid doses with prolonged oral clearance were mainly Gastrointestinal, Cardiovascular
and Central Nervous System medicines and were mainly effervescent or soluble tablets which
are dissolved in water before administration or chewable tablets which are sucked and chewed
before swallowing.
Other solid doses were sublingual and buccal tablets which are placed under the tongue
or in the buccal surface, and the medicine absorbed from the oral cavity. These were mainly
found in the Cardiovascular Section and used for the prevention and relief of angina attacks
and for nausea. Central Nervous System and Cardiovascular tablets with prolonged oral
clearance tended to be effervescent tablets and Gastrointestinal medicines, chewable tablets.
The proportion of use of this dose form varied between England, where 45% of solid doses
with prolonged oral clearance were Cardiovascular medicines and the Northern Region, where
approximately 50% of the quantity of solids with prolonged oral clearance were Central
Nervous System Medicines.
7.2.4.6 Quantities of medicines with prolonged oral clearance used regularly and
long-term by the elderly (Appendix 7.2, 7.3 and 7.4)
The quantity ofliquid ~ral medicines dispensed in England in 1994, equivalent to the 143
medicines identified in the Prescribed Medicines Prevalence Survey was 6.7 million litres
(63.7% of all liquid oral medicines) (Table 7.6). Of these, Gastrointestinal medicines
accounted for 83.1% (5.6 million litres) of this volume, with the only other main area of use
being the Respiratory System, which accounted for 0.7 million litres (11.6%).
166
Overall Consumption ofMedicines with Prolonged Oral Clearance
In England in 1994, solid doses with prolonged oral clearance equivalent to those used
regularly and long-term in the elderly represented 82.5% (926.7 million tablets) of all solids
with prolonged oral clearance (Table 7.6), of which 361.6 million (39%) and 346.2 million
(37.4%) were Cardiovascular system and Central Nervous System medicines, respectively,
with the Gastrointestinal system accounting for 16.3% (172 million tablets). The
Cardiovascular medicines were mainly aspirin 7Smg effervescent tablets (97%), the Central
Nervous System medicines mainly analgesics (94%) and the Gastrointestinal tablets mainly
antacids (92%).
When the Northern Region was considered, of the 0.7 million litres of liquid. oral
medicines prescribed in 1994, 66% (0.48 million litres) were for the 143 medicines equivalent
to those used regularly and long-term by the elderly (Prescribed Medicines Prevalence
Survey). Of these, 0.41 million litres (87%) were Gastrointestinal medicines, of which 61%
were antacids and 37% laxatives.
In the Northern Region, solid doses with prolonged oral clearance equivalent to those
used regularly and long-term by the elderly accounted for 86.4% (11S.9 tablets) of all
medicines formulated in this way. The majority of these tablets were for Central Nervous
System and Cardiovascular medicines which accounted for 71.3 million (61.5%) and 29
million (25%) tablets, respectively. Of the Central Nervous System medicines, 99% were for
analgesics and 89% of the cardiovascular medicines were for aspirin 7Smg effervescent
tablets.
InNewcastle, 67% (SI,800 litres) of the 77,400 litres of liquid oral medicines were used
regularly and long-term by the elderly. Gastrointestinal medicines accounted for 89.5%
(46,400 litres) of these medicines. As with the England and Northern Region these medicines
were mainly antacids (61%) and laxatives (30%).
Solid doses with prolonged oral clearance used regularly and long-term by the elderly,
dispensed in Newcastle, accounted for 79% (11.1 million tablets) of the 14.1 million of these
tablets with prolonged oral clearance dispensed in Newcastle in 1994. The Central Nervous
System, Cardiovascular an~ Gastrointestinal Sections of the BNF accounted for 58.5% (6.5
million tablets), 22.8% (2.S million tablets) and 16.6% (1.9 million tablets) of these tablets
respectively. Central Nervous System medicines were mainly analgesics (99.7%),
Cardiovascular solid doses were mainly aspirin 7Smg effervescent tablets (84%) and
Gastrointestinal solid doses were mainly antacids (97%).
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In summary, in all three areas (England, the Northern Region and Newcastle), the 143
medicines used regularly and long-term, identified by the Prescribed Medicines Prevalence
Survey, were primarily liquid oral medicines and solid doses with prolonged oral clearance.
Of the liquid oral medicines over 80% of the quantities dispensed were for Gastrointestinal
medicines in all three areas studied. Central Nervous System solid doses with prolonged oral
clearance represented a greater proportion of the total quantity of this dose form dispensed
regularly and long-term, in the Northern Region (61.5%) and Newcastle (58.5%), compared
with England (37%).
7.2.4.7 Sugar content of medicines with prolonged oral clearance and the impact
of generic prescribing on the sugar content of dispensed medicines
Earlier sections have discussed the number of prescription items and quantities
prescribed and dispensed for medicines with prolonged oral clearance. Further analysis
determined the numbers of medicines, prescription items and quantities dispensed that were
sugars-free, sugars-containing and variable. Variable medicines were classified as those
generic formulations where the dispensed medicine was sugars-free or sugars-containing
depending on which formulation was being used by the pharmacy.
7.2.4.7.1 Generic and proprietary medicines with prolonged oral clearance
Of the 613 medicines with prolonged oral clearance, 131 were generic and 482
proprietary preparations. The generic medicines were manufactured by 37 different
manufacturers producing a total of 424 formulations. Each manufacturer produced between I
and 57 different formulations and each medicine was manufactured by between 1 and 14
pharmaceutical manufacturers. Of the 143 medicines with prolonged oral clearance used
regularly and long-term, 42 were generic and 101 were proprietary formulations. The 42
generic formulations with prolonged oral clearance used regularly and long-term were
manufactured by 27 pharmaceutical companies producing 144 formulations.
In terms of prescribing in the Northern Region, of the 2.5 million prescription items
dispensed for the 143 medicines with prolonged oral clearance used regularly and long-term
by the elderly, I million (40%) were for proprietary medicines and 1.5 million (60%) were for
generic medicines. This was consistent with the current rate of generic prescribing in
England, which in 1997 was 60% of all prescriptions written, but lower than the rate of
generic prescribing in the Northern Region, which was 66.6% (Department of Health, 1998).
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7.2.4.7.2 Numbers of preparations for all medicines with prolonged oral clearance
identified as sugars-free and sugars-containing
Of the 613 medicines which represented all medicines with prolonged oral clearance,
46% were sugars-free, 34% sugars-containing, 1% variable with no information for 19% of
the medicines. Of the 482 proprietary medicines, 51% were sugars-free and 29.5% sugars-
containing with no information obtained for the remaining 19.5% of the medicines. Of the
131 generic medicines, 27.5% were sugars-free, 50.4% were sugars-containing, 3% variable,
with no information available for 19.1% of the medicines.
The 131 generic medicines were available as 424 generic formulations, 28.5% of which
were sugars-free, 44.8% sugars-containing with no information available for 26.7% of the
generic formulations. The numbers of generic and proprietary medicines with prolonged oral
clearance used regularly and long-term by sugar content has been previously discussed in
Chapter 5 (Section 5.4 .15.1), where a similar distribution of sugars-free, sugars-containing
and variable medicines was found.
The proprietary manufacturers were able to offer more comprehensive information on
sugar content with information being received from 43 manufacturers for 388 (81%) of the
proprietary preparations. Most proprietary manufacturers were major businesses with
medical information departments dedicated to providing information on their product, whereas
generic manufacturers appeared to have more problems in disseminating relevant information
to inquiries from healthcare professionals and researchers.
Although over recent years there has been increased awareness of the threat to dental
health from sugars-containing medicines (Hobson, 1985; Mackie & Bentley, 1994; Maguire et
al., 1996), there still are a large number of preparations that are being manufactured with
acidogenic sugars. This has been particularly true of generic medicines; in a study of liquid
oral medicines used long-term in paediatrics, in the Northern Region of England, of the 160
generically prescribed medicines, 39% were sugars-containing and 41% were variable
(sugars-free or sugars-containing may be dispensed) (Maguire & Rugg-Gunn, 1994). In the
present survey the lack of information from the pharmaceutical manufacturers was of
particular concern, with the- 15 of the 37 generic manufacturers not providing any information
on their products, accounting for 89 (21%) of the 424 generic formulations, with
manufacturers for a further 118 (28%) only providing partial information.
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7.2.4.7.3 Number of prescription items dispensed in the Northern Region, during
1994, for medicines with prolonged oral clearance, used regularly and long-term by
the elderly, by sugar content and dose form
Of the 4.5 million prescription items dispensed for all medicines with prolonged oral
clearance in the Northern Region, 2.53 million (56%) were for medicines with prolonged oral
clearance used regularly and long-term by the elderly. Of these, 73.1 % (l. 85 million
prescription items) were for sugars-free medicines, 20.6% (0.52 million) for sugars-containing
medicines, 5.3% (0.13 million) for variable medicines and 1% (0.02 million) for medicines
with no information on sugar content.
Table 7.9 shows the number of prescriptions dispensed for the 101 proprietary medicines
with prolonged oral clearance used regularly and long-term by the elderly in the Northern
Region, by sugar content of these medicines. Of the l.02 million prescriptions for proprietary
medicines, 0.83 million (81%) were sugars-free, 0.17 million (17%) sugars-containing and
there was no information for the remaining 0.02 million (2%) (Table 7.9). Over 90% of the
prescriptions were for the first four BNF Sections, the main section being Gastrointestinal
medicines which accounted for 73.4% (0.75 million items) of the prescription items, of which
sugars-free accounted for 0.67 million items (89%).
The number of prescriptions dispensed for genenc medicines with prolonged oral
clearance used regularly and long-term by the elderly is shown in Table 7.10. Of the l.52
million prescription items, 1.02 million (67%) were sugars-free, 0.36 million (24%), 0.13
million (8.6%) variable and the remaining 0.02 million (0.4%) prescription items were for
medicines where the sugar content was not known (Table 7.10). Of the 0.34 million
prescription items for Gastrointestinal medicines, only 0.04 million (13%) were sugars-free,
with 0.29 million (87%) items being for sugars-containing medicines (Table 7.10). The
majority of the prescriptions for Cardiovascular medicines (99.5%) were for sugars-free
medicines. Of the 0.63 million prescription items for Central Nervous System medicines, 88%
(0.55 million items) were for sugars-free medicines, with only 9% being for sugars-containing
medicines (Table 7.10).
Table 7.11 and Table ?.l2 show the number of prescriptions for proprietary and generic
medicines by dose form and sugar content. Of the l.02 million prescription items for
proprietary medicines with prolonged oral clearance, liquid oral medicines accounted for 56%
(0.57 million items) with 29% (0.26 million) being for solids with prolonged oral clearance.
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Of the 0.57 million prescription items for proprietary liquid oral medicines, 0.53 million
(93.7%) were for sugars-free medicines, whereas 55.4% of the 0.26 million items for solid
doses with prolonged oral clearance were sugars-free (Table 7.11). The proprietary sugars-
containing solids with prolonged oral clearance were mainly chewable tablets, the sugars-free
solids being effervescent tablets.
Effervescent tablets are formulated with intense sweeteners rather than bulk sweeteners
to prevent bulking during manufacture (Rubinstein, 1988). They have a well established
formulation and are often available generically. In contrast, chewable tablets are a relatively
new dose form and all chewable tablets identified in this study were proprietary brands .. It is
of some concern that new dose forms, like chewable tablets should be formulated with
acidogenic sweetening agents, especially when being used regularly and long-term. In 1987,
Hobson and Fuller (Hobson & Fuller, 1987) reported on the progress of eight
recommendations they had made with regard to sugar based medicines and dental disease in an
earlier paper (Hobson, 1985). One of these recommendations had been that "The
pharmaceutical industry should provide a greater range of sugars-free preparations,
particularly those which are commonly used by children on a long-term basis". The progress
report showed that although a number of sugars-free medicines were being manufactured,
there were still many formulations, especially for adults that were sugars-containing. In
addition their paper reported that The British Pharmacopeia Commission had decided to move
towards an open formula so that manufacturers were able to use alternatives to acidogenic
sugars. It is then regrettable that even though the pharmaceutical industry is aware of the
potential problems of sugar in medicines, they are still manufacturing new medicines as
sugars-containing.
Generic medicines with prolonged oral clearance accounted for 60.1 % of the 4.5 million
prescription items dispensed for all medicines with prolonged oral clearance, in the Northern
Region in 1994. Generic medicines with prolonged oral clearance used regularly and long-
term accounted for 1.52 million items, of which 67.5% (1.02 million prescription items) were
for sugars-free medicines and 23.5% (0.36 million) were for sugars-containing medicines,
with 8.8% (0.13 million prescription items) being for variable medicines (Table 7.12). Of
these 1.52 million prescription items dispensed generically, 0.47 million were for generic
medicines liquid oral medicines, of which 9.7% (0.04 million) were for sugars-free medicines
and 73.8% (0.35 million) were for sugars-containing medicines (Table 7.12).
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Generic medicines are manufactured by a number of pharmaceutical manufacturers and the
regulations for their manufacture do not extend to the type of sweetening agents used as long as
they are inert agents and the bioavailability of the drug is correct. Since sweetening agents are
classed as 'inert', manufacturers can choose to use cheaper sweetening agents such as sucrose.
In contrast, the majority (94%) of generic solid doses with prolonged oral clearance, used
regularly and long-term by the elderly were sugars-free. All these were effervescent tablets which
are routinely formulated with intense sweetening agents such as saccharin, as bulk sweetening
agents such as sucrose and polyols are not suitable for this dose form (Rubinstein, 1988).
Overall, although more prescriptions dispensed for medicines with prolonged oral clearance
used regularly and long-term in the elderly were sugars-free, there was a lot of variation between
the sugar content of preparations depending upon whether a generic or proprietary medicine was
prescribed and between different dose forms. There was a higher proportion of sugars-free
prescription items for proprietary liquid oral medicines compared with generic liquid oral
medicines, which were more likely to be sugars-containing, however, the majority of solids with
prolonged oral clearance used regularly and long-term were sugars-free.
7.2.4.7.4 Quantity of medicines with prolonged oral clearance used regularly and long-
term in the elderly. dispensed in the Northern Region in 1994 by sugar content and dose
form
In the Northern Region ill 1994 the overall quantity of medicines with prolonged oral
clearance used regularly and long-term by the elderly was 0.48 million litres of liquid oral
medicines, 115.9 million solid doses with prolonged oral clearance, 11.1 grams of loose powders
and oral gels and 9.7 million sachets containing powders or granules (Table 7.7).
Of the 0.48 million litres dispensed for liquid oral medicines, 0.29 million (60%) were
sugars-free and 0.18 million (40%) sugars-containing. Proprietary liquid oral medicines used
regularly and long-term by the elderly, accounted for 279,900 litres dispensed in the Northern
Region in 1994, of which, 96.3% (269,400 litres) were sugars-free, with sugars-containing
proprietary liquids accounting for 2.5% (7,000 litres) (Table 7.13). In contrast, of the generic
liquid oral medicines potentially used by the elderly regularly and long-term, dispensed only 8.9%
(17,400 litres) were for sugars-free liquids, with 82.6% (161,600 litres) for sugars-containing
liquids (Table 7.14).
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Table 7.13 Quantity of sugars-free and sugars-containing proprietary medicines with prolonged
oral clearance by dose type
Quantity Dispensed
(xtOl)
LOMl 0/0 Solids % Powders 0/0 Sachets %
(litres) (tablets) & oral (number)
gels
h~rams)
Sugars-free 269.4 96.3 15162.0 59.9 1090.4 9.8 8940.2 94.6
Sugars-containing 7.0 2.5 9677.0 38.3 9979.5 90.2 340.1 3.6
No information 3.5 1.2 454.2 1.8 0.0 0.0 173.7 1.8
Totals 279.9 100.0 25293.2 100.0 11069.9 100.0 9454.0 100.0
lLiquid oral medicine
Table 7.14 Quantity of sugars-free and sugars-containing generic medicines with prolonged oral
clearance by dose type
Quantity Dispensed
(xtOl)
LOM % Solids % Powders % Sachets %
(litres) (tablets) & oral (number)
gels
(2rams)
Sugars-free 17.4 8.9 87032.1 96.0 0.0 - 0.0 0.0
Sugars-containing 161.6 82.6 868.7 1.0 0.0 - 218.5 100.0
Variable 16.7 8.5 2652.2 2.9 0.0 - 0.0 0.0
No information 0.0 0.0 62.5 0.1 0.0 0.0
Totals 195.7 100.0 90615.5 100.0 0.0 - 218.5 100.0..
ILiquid oral medicine
Proprietary solid doses with prolonged oral clearance accounted for 25.3 million tablets
dispensed, of which 59.9% (15.2 million) were sugars-free and 38.3 % (9.7 million) were sugars-
containing (Table 7.13). Nearly all (96%) generic solid doses with prolonged oral clearance were
sugars-free and all were effervescent tablets (Table 7.14).
The quantities of proprietary and generic liquid oral medicines dispensed showed a similar
pattern to the number of prescriptions prescribed and dispensed in terms of sugar content. The
proportion of volume of proprietary liquid oral medicines that was sugars-free was vastly greater
than the proportion of generic sugars-free liquid oral medicines (Tables 7.13 and 7.14).
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7.2.5 Overall summary of Prescribing Analysis Survey
The Prescribing Analysis Survey analysed the prescribing and dispensing of 613 medicines
with prolonged oral clearance in England, the Northern Region and Newcastle. The main findings
of the study were:
• In England, 10.6 million litres of liquid oral medicines and 1122.9 million solid doses with
prolonged oral clearance were dispensed in 1994, of which 6.7 million litres of liquid oral
medicines and 926.7 million solid doses with prolonged oral clearance were for the 143
medicines used regularly and long-term as identified in Chapter 5 (The Prescribed
Medicines Prevalence Survey)
• In Newcastle, 0.08 million litres and 0.05 million litres of liquid oral medicines, and 14.1
million and 11.1 million solid doses with prolonged oral clearance, of all POC medicines
and those used regularly and long-term, respectively were dispensed in 1994 .
• In the Northern Region:
• The 143 medicines with prolonged oral clearance used regularly and long-term
accounted for 2.5 million prescription items, which represented 0.5 million litres of
liquid oral medicines and 115.9 million solid doses with prolonged oral clearance.
• The proprietary medicines represented 0.3 million litres of liquid oral medicines and
0.26 million items were for 25.3 million solid doses with prolonged oral clearance and
the generic medicines represented 0.2 million litres and 90.6 million solid doses with
prolonged oral clearance.
• Of the generic liquid oral medicines, 83% of the 0.2 million litres were sugars-
containing compared with proprietary liquid oral medicines, where only 2.5% of the
0.3 million litres were sugars-containing.
• Of the generic solid doses with prolonged oral clearance, only 1% of the 90.6 million
solid doses were sugars-containing, compared with 38% of the 25.3 million solid dose
units being sugars-containing.
Generic prescribing ~f liquid oral medicines was more likely to be sugars-containing,
whereas proprietary prescribing of liquid oral medicines more likely to be sugars-free. Generic
prescribing accounted for more sugars-free solids with prolonged oral clearance compared with
proprietary solids, where almost half the prescription items and volume for solids with prolonged
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oral clearance were sugars-containing. Sugars-containing solids were mainly chewable tablets
and buccal tablets, whilst all effervescent tablets were sugars-free.
7.3 'OVER THE COUNTER' (OTC) MEDICINES ORDERING SURVEY
7.3.1 Introduction
There is evidence that that OTC medicine use is increasing and, in particular, more OTC
medicines are being used by the elderly (McElnay & Dickinson, 1994). However, there is
currently no information on the overall volume of use of OTC medicines with prolonged oral
clearance and what proportion of these medicines are sugars-containing.
7.3.2 Aim
• To estimate the quantity of OTC products with prolonged oral clearance used over a one
year period (1994) in the Northern Region of England by dose form and sugar content.
7.3.3 Methods
7.3.3.1 Sources of data
Records of sales of OTC medicines from community pharmacies are rarely kept, although
increasingly, some pharmacies operate patient medication record (PMR) systems to record the
purchase of OTC medicines. This allows the pharmacist to monitor what the patient has bought
previously and check any prescribed medication they may be taking.
The pharmaceutical wholesalers who operated in the Northern Region, Unichem pIc and
AAH Pharmaceuticals, were approached for this information. The area covered by these
wholesalers, who provided services to the majority of independent and multiple pharmacies in this
Region, is shown Appendix 7.5. The only two pharmacy groups that did not use these
wholesalers were Boots the Chemists and Lloyds. At an early stage in the study Boots the
Chemists and Lloyds Chemists declined to take part in this survey and therefore another method of
collecting quantity data for 'over the counter' medicines for the Northern Region was required.
International Medical. Statistics (IMS) is a company that collects medical statistics
worldwide. It collects OTC data from pharmaceutical wholesalers and multiple pharmacy groups
who do not use commercial wholesalers, such as Boots the Chemists and collates this information
according to postal codes and television coverage areas. Appendix 7.6 shows the coverage area
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for Channel 3 North East (Tyne Tees Television), in the Northern Region of England. Since this
area covered most of the Northern Region, it was decided that data from this area could be used
for this survey.
IMS was approached for OTC sales data for a one year period (1994) by letter in July 1997.
Following a favourable response from IMS, they were sent a list of OTC drugs with prolonged
oral clearance compiled from the OTC table of the database (Chapter 5, Figure 5.1), together
with the corresponding pack sizes, and information on quantities of medicines with prolonged oral
clearance sold within the Channel 3 North East television coverage area was requested.
IMS were able to run a search on their computer for the number of packs sold for each pack
size for each OTC medicine. The results of this search were provided on a floppy disk as a
spreadsheet file. The spreadsheet was used to calculate the total quantity of each OTC medicine
sold by multiplying the pack volume by the number of packs sold.
7.3.3.2 The OTC database
Using the Proprietary Association of Great Britain's OTC directory 94/95 (Proprietary
Association for Great Britain, 1995), the following information was obtained for all OTC
medicines with prolonged oral clearance and entered into the OTC table (Chapter 5, Figure 5.1):
• BNF category
• Dose type (e.g. liquids, solids etc.)
• Manufacturer
• Active ingredients
• Pack sizes available
The quantity data derived from the information supplied by IMS was entered into this
database table, and a series of queries were run to establish the total quantities of 'over the
counter' medicines with prolonged oral clearance sold in the coverage area for Channel 3 North
East.
7.3.3.3 Sugar content of OTC medicines with prolonged oral clearance
The British National ~ormulary 1995 (British Medical Association & Royal Pharmaceutical
Society, 1995), Data Sheet Compendium (Association of British Pharmaceutical Industry, 1995)
and the OTC directory (Proprietary Association for Great Britain, 1995) were used to obtain
information on the sugar content of OTC medicines. In addition, where necessary, the
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manufacturers of these OTe preparations were contacted and information on the sugar content of
their medicines requested. A list of OTC preparations by manufacturer, along with a cover letter
outlining the study was faxed to the medical information department of each pharmaceutical
company. The company was asked to list the quantity of all sugar and non-sugar sweeteners in
the OTe medicines. They were invited to reply by fax or email.
The information obtained was used to classify each OTe medicine as sugars-free, sugars-
containing or a medicine for which no information was available.
7.3.4 Results and Discussion
7.3.4.1 Sources of data
Sales of medicines bought over the counter (OTC) are rarely recorded by community
pharmacies and no other method of recording OTC medicine use currently existed. However,
pharmaceutical wholesalers recorded their sales to pharmacies, and were felt to be the most useful
potential source of information to allow an estimate of the quantity of OTe medicines used in the
Northern Region. This estimate needed to be interpreted with caution as not all OTC preparations
bought by community pharmacies from wholesalers may have been subsequently sold to the
public, not all pharmacies may have used these wholesalers, and wholesalers may not have been
the pharmacies only source of supply of OTe medicines, as in some instances they may buy
directly from the manufacturer. However, as an estimate of medicine purchases, quantities of
medicines ordered from wholesalers provided a useful estimate. Pharmacies are commercial
institutions and it would not have been in the business interests of a pharmacy to have stock lying
on its shelves for extended periods and perhaps even going out of date before it was sold. This is
why most pharmacies have a strict stock rotation system, only ordering what they expect to sell,
resulting in a rapid turnover of stock.
The two largest pharmaceutical wholesalers in England, Unichem and AAH, were
approached in the study and were very helpful in providing data, however the two pharmacy
chains (Boots the Chemists and Lloyds Chemists), who did not use pharmaceutical wholesalers
declined to offer any OTC sales or ordering data. Since data purely from the two pharmaceutical
wholesalers would not have given an accurate estimate of the total quantities of OTe products
ordered by pharmacies, another method of obtaining these data was required. Through
discussions with Boots the Chemists it became clear that one of the main reasons that they could
not give OTC sales data for this survey was that they already had a contract with a company
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(IMS) that collected prescribing, hospital ordering and OTC ordering data. These data, collated
by IMS, are sorted by postal codes and television area. Through discussions with Tyne Tees
Television it became clear that their television coverage area for Channel 3 North East was
sufficiently similar to that of the Northern Region and the information provided by IMS on the
ordering of OTC medicines by pharmacies from pharmaceutical wholesalers and pharmaceutical
companies, would cover a similar area to the prescribing and hospital data collected. The
television coverage area and the Northern Region were not exactly the same (Appendix 7.5 and
7.6), but this was the best available estimate to provide an overall view ofOTC medicine use on a
regional basis.
7.3.4.2 OTC medicines with prolonged oral clearance
7.3.4.2.1 Number of preparations by BNF Section
There were 323 OTC preparations with prolonged oral clearance identified from the OTC
directory and these are classified according to BNF Sections in Table 7.15. The OTC products
with prolonged oral clearance occupied seven different BNF Sections with 76.8% of the total
number of preparations being Respiratory (35.9%), Gastrointestinal (22.9%) or Ear, Nose and
Oropharynx (18%) preparations.
The OTC preparations in the Respiratory and Ear, Nose and Oropharynx Sections of the
BNF were mainly liquid oral medicines and used for the treatment of minor cold and flu
symptoms. The 74 preparations in the gastrointestinal system were virtually all antacids and
laxative medicines.
The other main BNF sections where OTC preparations were found were the Central Nervous
System (39 preparations) and Nutrition And Blood (30 preparations). The Central Nervous
System preparations were mainly minor analgesics, and preparations in the Nutrition And Blood
section were mainly mineral and nutrient supplements.
The majority of medical complaints which present to a pharmacist are minor aliments such as
upset stomach (e.g. indigestion and heartburn), diarrhoea or cold and flu symptoms. The range of
OTC medicines with prolonged oral clearance available reflected these minor medical complaints,
with concentration in therapeutic areas where the dose form of the medicine is important for
therapeutic efficacy. Pharmaceutical manufacturers are continually changing dose forms and
presentations of OTC medicines to compete with other products in the market place. This has led
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to a number of preparations with similar ingredients but different dose forms being marketed,
usually backed up with television advertising. This, so the manufacturers claim, is to improve
patient compliance and ensure proper use of the medicine, however it may lead to inappropriate
use such as long-term use for medicines that are indicated for short-term use only. It is the role of
the pharmacist to ensure that the OTC medicines are used appropriately and that is why a large
number of such medicines are classed as 'pharmacy' (P) only medicines.
7.3.4.2.2 Number of preparations by dose form
Of the 323 OTC preparations, 183 preparations (57%) were liquid oral medicines, with the
remainder being solid doses with prolonged oral clearance (26%), powders and oral gels (9%) and
sachets containing powders and granules (8%) (Table 7.15). As for prescribed medicines with
prolonged oral clearance, liquid oral medicines and solid doses with prolonged oral clearance were
the most commonly available dose form.
Of the 116 preparations in the Respiratory Section of the BNF, 105 (91%) were liquid oral
medicines. As well as a systemic effect, liquid oral medicines offer a local soothing effect on the
mucous membranes of a sore throat, improving their efficacy and making them a popular choice
for cold and flu medicines. This was also true of the Ear, Nose and Oropharynx preparations,
where the dose form was also of primary therapeutic importance: 25 of the 58 solids with
prolonged oral clearance, were pastilles or lozenges. These exert a local soothing effect on the
mucosa of the throat as their primary action. These preparations are sucked and remain in the
mouth for prolonged periods.
As Table 7.15 shows, solid tablets with prolonged oral clearance accounted for 83 OTC
preparations. These were mainly Gastrointestinal (38.6%), Ear, Nose and Oropharynx (30.1 %)
and Central Nervous System (24.1 %) preparations. The Gastrointestinal medicines were mainly
antacid tablets, which offer quick relief from excess acid symptoms and are a popular alternative
to antacid liquids which are bulky and more difficult to transport. The 20 preparations in the
Central Nervous System section were all minor analgesics, the majority (75%) of which were
formulated as effervescent tablets.
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7.3. 4.3 Quantities of OTC medicines used in the television coverage area for Tyne
Tees Television (Channel3 North East)
As Table 7.16 shows, of the 106,700 litres of OTC liquid oral preparations ordered by
community pharmacies in 1994, 47300 litres (44.3%) and 23800 litres (22.3%) were for
Respiratory and Gastrointestinal medicines, respectively. The other two main sections were Ear,
Nose and Oropharynx. (16700 litres) and the Central Nervous System (15000 litres).
Gastrointestinal and respiratory medicines are both efficacious when in a liquid form and for the
majority of these medicines a direct non-liquid equivalent is neither appropriate nor available.
Overall, 16.9 million solid tablets with prolonged oral clearance were ordered in the area
covered by Channel3 North East television in 1994. The three main therapeutic areas of use were
Central Nervous System, Gastrointestinal medicines and Ear, Nose and Oropharynx medicines,
accounting for 7.2 million (42.6%),5.8 million (34.3%) and 3.5 million (20.7%) solid doses with
prolonged oral clearance, respectively. A large number of OTC solid doses with prolonged oral
clearance tend to be analgesics in the form of effervescent tablets, which are dissolved in a small
volume of water prior to administration. The effervescent solution offers faster pain relief as the
drug is in solution and can readily absorb into the system. Solid formulations have many
advantages; they are chemically more stable than liquid oral medicines as well as easier to
transport and store. This reduces production costs and is more convenient for the pharmacist in
terms of storage and shelf life of the product.
OTC products with prolonged oral clearance formulated as loose powders, granules or oral
gels accounted for 4.9 million grams being ordered by pharmacies, with Gastrointestinal
medicines (antacids and laxatives) accounting for 4.3 million grams (77%). Ear, Nose and
Oropharynx medicines accounted for 0.7 million grams and these were mainly oral gels used for
local application. The main areas of use for the powders packed as sachets (1.1 million) were the
Respiratory System (779,700 sachets) and Central Nervous System (286,000 sachets), which
accounted for the 95% of the total quantity ordered. Sachets are a relatively new form of dosage,
with each sachet containing a powder or granules which are dissolved in water before
administration. All the sachets in the Respiratory section were cold and flu medicines usually
containing a combination of paracetamol and a decongestant. They have similar advantages to
solid doses with prolonged oral clearance in that they are relatively easy to store and are stable. In
comparison with loose powders, they offer consistent dosing each time, taking away the guess
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work involved in measuring such powders. The cold and flu sachets usually make up pleasant
tasting lemon or blackcurrant drinks preferred by patients.
Table 7.16 Quantities of OTC medicines ordered in the Channel3 North East
coverage area, in 1994
BNF Section Quantity of OTC Medicines
Liquid Solids Powders Sachets
Oral with & oral (no.)
Medicines POC gels (xlOl)
(litres) (ne.) (grams)
(xlOl) (xlOl) (xlOl)
o I Gastrointestinal System 23.8 5576.2 4248.4 8.5
02 Cardiovascular System 0.0 0.0 0.0 0.0
03 Respiratory System 47.3 5.4 0.0 779.7
04 Central Nervous System 15.4 6784.5 18.3 286.0
05 Infections 0.1 0.0 0.0 0.0
06 Endocrine System 0.0 0.0 0.0 0.0
07 Obstetrics and Gynaecology 0.0 0.0 0.0 13.0
08 Malignant Disease 0.0 0.0 0.0 0.0
09 Nutrition and Blood 16.7 393.0 0.0 35.9
10Musculoskeletal and Joint Disease 0.0 0.0 0.0 0.0
11Eye 0.0 0.0 0.0 0.0
12Ear, Nose and Oropharynx 3.8 4029.5 656.5 0.0
Total 107.1 16788.6 4923.2 1123.1
7.3.5 Sugar content of OTC medicines with prolonged oral clearance
7.3.5.1 Number of sugars -free and sugars-containing OTC preparations
Overall, of the 323 OTe medicines with prolonged oral clearance identified, 126 (39%) were
sugars-free and 162 (50.2%) preparations were sugars-containing. There was no information
available for the remaining 35 (10.8%) preparations (Table 7.17). The sugar content of
preparations in different therapeutic sections varied considerably; of the 74 Gastrointestinal
medicines, 47% were sugars-free and 47% sugars-containing, whereas of the 116 Respiratory
medicines, only 27.5% were sugars-free and 63.8% were sugars-containing. This related to their
dose form, in that of the Gastrointestinal medicines, 30 were liquid oral medicines (of which 77%
were sugars-free) and 32 solids with prolonged oral clearance (of which only 6% were sugars-
free), whereas 105 of the 116 Respiratory medicines were liquid oral medicines, of which only
30% were sugars-free. In general, the Gastrointestinal liquid oral medicines were sugars-free and
the solids with prolonged oral clearance were sugars-containing. All the sugars-containing
Gastrointestinal medicines formulated as solids with prolonged oral clearance (26 preparations)
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were chewable tablets, which is a relatively new dose form. As mentioned earlier, it is of some
cause for concern that this dose form would appear to be a new source of sugars-containing
medicines. Pharmaceutical manufacturers have been requested to formulate new products as
sugars-free, especially when the product may be used long-term (Hobson & Fuller, 1987).
A similar pattern was seen for Central Nervous System OTC medicines where 74% of the 39
preparations were sugars-free, and 20 were effervescent tablets, a dose form commonly
formulated with artificial intense sweeteners (Rubinstein, 1988). Of the liquid oral medicines in
the Central Nervous System section, all were minor analgesics, with 13 preparations being
formulated for children, of which 10 preparations were sugars-free. This reflected the impact of
pressure for sugars-free medicines for children as a result of research which has linked sugars-
containing medicines with dental caries (Mackie & Bentley, 1994; Mackie et al., 1993; Maguire
et al., 1996; Roberts & Roberts, 1979), and which have persuaded manufacturers to produce
sugars-free paediatric and children's medicines (Maguire & Rugg-Gunn, 1994). Although
paediatric OTC medicines have increasingly become available as sugars-free formulations, a
similar pattern has not been seen by OTC medicines primarily used by adults. This survey has
shown that large numbers of sugars-containing OTC medicines with prolonged oral clearance are
available and being used. The products formulated for adults that have become available sugars-
free have been mainly in response to pressure from diabetic societies and consumer groups, and
probably not in a bid to improve dental health.
Sugar content information could not be obtained for 16 of the 58 Ear, Nose and Oropharynx
medicines. Of the remaining 42 preparations, 23 (39.7%) were sugars-containing and 19 (32.7%)
sugars-free. Of the 30 Nutrition and Blood medicines, 63.3% (19 preparations) were sugars-
containing, and these were mainly vitamins and health tonics.
Analysis of the number of OTC medicines with prolonged oral clearance by dose type (Table
7.18) showed that of the 184 liquid oral medicines, 42.4% were sugars-free and 48.9% were
sugars-containing. Of the solid OTC preparations with prolonged oral clearance 57.5% were
sugars-containing and only 30% were sugars-free. In general, paediatric liquid oral medicines
tended to be sugars-free and those not indicated for children, sugars-containing. Sugars-free
solids with prolonged oral 'clearance were mainly effervescent tablets; chewable tablets, pastilles
and lozenges were usually sugars-containing.
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Table 7.17 Number of sugars-free and sugars-containing OTe preparations by BNF section
BNF Section Sugars-free Sugars- No Total
containing information
No. % No. % No. % No. %
01 Gastrointestinal System 35 27.8 35 2l.6 4 1l.4 74 22.9
02 Cardiovascular System 0 0.0 0 0.0 0 0.0 0 0.0
03 Respiratory System 32 25.4 74 45.7 10 28.6 116 35.9
04 Central Nervous System 29 23.0 7 4.3 3 8.6 39 12.1
05 Infections 1 0.8 2 l.2 0 0.0 3 0.9
06 Endocrine System 0 0.0 0 0.0 0 0.0 0 0.0
07 Obstetrics and Gynaecology 1 0.8 2 l.2 0 0.0 3 0.9
08 Malignant Disease 0 0.0 0 0.0 0 0.0 0 0.0
09 Nutrition and Blood 9 7.1 19 1l.7 2 5.7 30 9.3
10Musculoskeletal and Joint Disease 0 0.0 0 0.0 0 0.0 0 0.0
11Eye 0 0.0 0 0.0 0 0.0 0 0.0
12Ear, Nose and Oropharynx 19 15.1 23 14.2 16 45.7 58 18.0
Total 126 100.0 162 100.0 35 100.0 323 100.0
Table 7.18 Number of sugars-free and sugars-containing OTe preparations with
prolonged oral clearance by dose type (total number of preps=323)
Preparations with prolonged oral clearance
Liquid oral Solids with Powders and Sachets
Dose Form medicines poe oral gels
No. % No. % No. % No. %
Sugars-free 78 42.4 24 30.0 14 46.7 10 34.5
Sugars-containing 90 48.9 46 57.5 9 30.0 17 58.6
No information 16 8.7 10 12.5 7 23.3 2 6.9
Totals 184 100.0 80 100.0 30 100.0 29 100.0
7.3.5.2 Quantity o/OTC medicines with prolonged oral clearance ordered by
community pharmacies, by sugar content and dose type
Of the 107,100 litres of OTC liquid oral medicines ordered, approximately equal volumes
were sugars-free (52,400 litres) and sugars-containing (53,000 litres). However, there were
differences between sugars-free and sugars-containing quantities within BNF Sections, with 94%
of the quantity of all Gastrointestinal medicines sold being sugars-free, whereas 87% of the
quantity of Respiratory liquid oral medicines was sugars-containing. Overall, of the solid doses,
58.7% were sugars-free, 38.4% sugars-containing, with more Central Nervous System solids with
prolonged oral clearance being sugars-free than sugars-containing, but almost equal quantities of
sugars-free (2.7 million) and sugars-containing (2.8 million) solid doses of Gastrointestinal
medicines being sold during 1994.
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Table 7.19 Quantity of sugars-free and sugars-containing OTC preparations ordered in 1994
in the Channel 3 North East area, by dose type
Quantity
(dOl)
Liquids Solids with Powders & Sachets
POC oral eels
Litres % No. % Grams % No. %
Suaars-free 52.4 48.9 9863.3 58.7 1205.7 24.5 270.4 24.1
Suaars-centainina 53.0 49.5 6451.7 38.4 3534.4 71.8 832.6 74.1
No information 1.7 1.6 473.6 2.8 183.2 3.7 20.0 1.8
Total 107.1 100.0 16788.6 100.0 4923.2 100.0 1123.1 100.0
7.3.5.3 Type of sweeteners used in OTC medicines with prolonged oral clearance
Of the 126 sugars-free preparations, 26 (21%) did not contain any sugar, and of these 17
were liquid oral medicines (Table 7.20). The most common sweetening agent for sugars-free
OTC medicines was the intense sweetener saccharin on its own, and this accounted for 41 (33%)
of the 126 sugars-free preparations. Saccharin and sorbitol in combination accounted for 13 of
the 126 sugars-free preparations.
Table 7.20 Types of common sweetening agents found in OTC preparations with
prolonged oral clearance
LOM1 Solids Powders Sachets Total
& oral
_gels
Suzars-free
No Sugar 17 0 7 2 26
Saccharin 19 15 4 3 41
Saccharin + Sorbitol 10 3 0 0 13
Others 32 6 3 5 46
Total 78 24 14 10 126
Susars-ceatainina
Sucrose 34 18 5 5 62
Sucrose + Glucose 7 7 3 0 17
Sucrose + Saccharin 5 8 0 4 17
Sucrose + Glucose + Saccharin 9 0 0 0 9
Sucrose + Sorbitol 12 2 0 0 14
Others 23 11 2 3 48
Totals 90 46 9 12 162
lLiquid oral medicines
Of the 162 sugars-containing OTC preparations with prolonged oral clearance, the most
common sweetening agent was sucrose used on its own or in combination with other preparations.
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Sucrose was the sole sugar in 62 (38%) preparations. It was found in combination with glucose
(17 preparations), saccharin (17 preparations), glucose and sorbitol (9 preparations) and sorbitol
(14 preparations). Appendix 7.7lists all sweetening agents used in all OTe preparations.
In summary, in terms of availability, there were more sugars-containing (50.2%) than
sugars-free (39%) OTe medicines with prolonged oral clearance. In terms of preparations, the
sugar content varied according to dose form with liquid oral medicines, solid doses (with
prolonged oral clearance) and loose powders or oral gels being more likely to be sugars-
containing. A similar pattern followed for quantities ordered, except that in terms of quantities,
more sugars-free (58.7%) than sugars-containing (38.4%) solids with prolonged oral clearance
were ordered. Effervescent tablets tended to contain artificial intense sweeteners which have
better formulation properties (Rubinstein, 1988) and a high proportion of these were analgesics.
In terms of quantities, more sugars-containing than sugars-free OTe medicines with
prolonged oral clearance were ordered by community pharmacies; the sugars-free medicines
ordered were mainly paediatric formulations. There were also more sugars-containing than
sugars-free solid OTe medicines with prolonged oral clearance available, however, greater
quantities of sugars-free medicines were sold to pharmacies. The sugars-containing solids with
prolonged oral clearance were mainly Gastrointestinal medicines in a chewable tablet form and
used to much lesser extent than minor analgesics.
188
Overall Consumption of Medicines with Prolonged Oral Clearance
7.4 HOSPITAL PHARMACY MEDICINES ORDERING SURVEY
7.4.1 Introduction
To provide an overall estimate of the use of medicines with prolonged oral clearance in the
North East of England a survey was necessary to determine the consumption of these medicines in
the secondary healthcare services.
7.4.2 Aims
• To determine the quantity of medicines with prolonged oral clearance used by hospital
pharmacy departments over a one year period (1994), in the Northern Region of England,
by dose form and sugar content.
7.4.3 Methods
7.4.3.1 Data collection
The hospital services do not collect data equivalent to primary care prescribing data (PACT
and PCA), although individual hospitals sometimes collect data on drug dispensing for audit
purposes. However, in the UK International Medical Statistics (IMS) collects information on
drugs ordered by NHS hospitals from the invoices of all drugs ordered by their pharmacy
departments. The raw data from these invoices are entered into a computer for analysis, and are
collated into regional and national statistics.
In order to maintain consistency with the Prescription Analysis Survey and the OTC Survey,
data for 1994 were required for this survey. IMS data for hospital pharmacies in the Northern
Region are purchased by the Regional Prescribing Unit, Newcastle upon Tyne. The unit kindly
gave access to these data for 1994, and provided them as a spreadsheet (MS Excel) file on
computer disk. This file contained pack size, name of formulation and the number of packs of all
medicines ordered during the one year period (1994). As only information for medicines with
prolonged oral clearance was required, the data from the disk were imported into a relational
database (MS Access) and queries were run, using the dose form, to identify all medicines with
prolonged oral clearance. ~ll other products in the database were deleted. This list of medicines
was then checked against the DRUGS table of the database to ensure that all medicines with
prolonged oral clearance used in hospital were accounted for, and imported into MS Excel, where
the number of packs ordered were multiplied by the pack size to give the total quantity of
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medicines with prolonged oral clearance ordered by NHS hospitals in the Northern Region. This
information was entered into the CONSUMPTION DATA table of the database (Chapter 5,
Figure 5.1) to allow further analysis.
7.4.3.2 Sugar content of medicines with prolonged oral clearance used in hospitals
The DRUGS table of the database contained information on the sweetening agent of all
drugs with prolonged oral clearance, collected during the Prescribed Medicines Prevalence
Survey, and this was linked to the CONSUMPTION DATA table. Queries using MS Access
were undertaken to determine the proportion of medicines that were sugars-free and sugars-
containing, as well as the sugar content of the medicines with prolonged oral clearance ordered by
hospital pharmacy departments in the Northern Region.
7.4.4 Results and Discussion
7.4.4.1 Number of preparations ordered by hospital pharmacies in the Northern
Region
Of the 613 medicines with prolonged oral clearance identified from the BNF (British Medical
Association & Royal Pharmaceutical Society, 1995), 212 (34.4%) were ordered by hospital
pharmacy departments in the Northern Region during 1994 (Table 7.21). As with the OTe
survey, the IMS data were ordering data and the assumption was made that all medicines ordered
were subsequently dispensed to and used by the patients. Due to the high cost many of drugs,
hospitals have strict stock management, only ordering and storing medicines that will be used
before they expire.
In an attempt to control spiraling drug costs, hospital drug formularies have been introduced
by most hospital pharmacy departments. Formularies contain a selective list of preparations
based on efficacy and cost from which prescribers may choose an appropriate medicine.
Furthermore, drugs not on the formulary are restricted and generally only consultants can
prescribe them after authorisation from the senior pharmacist. The use of a formulary would
reduce the number of preparations stocked by pharmacies and this would, in part, explain why the
overall number of preparations with prolonged oral clearance (212 preparations) used was low
compared with the range of prescribed medicines with prolonged oral clearance used in general
medical practices in the Northern Region (552 preparations), during the same period. Of these
212 preparations, 75% were for medicines in the Central Nervous System, Infections and
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Gastrointestinal Sections of the BNF, with these sections accounting for 30.2%, 29.7% and
14.6% of preparations with prolonged oral clearance, respectively.
When the 143 preparations with prolonged oral clearance used regularly and long-term by
the elderly as identified by the Prescribed Medicines Prevalence Survey were considered, of the
212 preparations ordered by hospital pharmacy departments, only 58 (27.4%) were equivalent to
those used regularly and long-term in the elderly (Table 7.21). These medicines were mainly
Central Nervous System (32.8%) and Gastrointestinal (29.3%) medicines showing a slight
difference from prescribed medicines dispensed in the Northern Region where of the 143
preparations, 36.4% were Gastrointestinal and 22.4% were Central Nervous System medicines.
Table 7.21 Number of preparations with prolonged oral clearance ordered by hospital
pharmacy departments, by BNF, in the Northern Region during a one year period.
Long-term
poe preps All poe preps'
ordered by Long- ordered by
All hospital term hospital
BNF Sectiom poe pharmacies poe _l)_harmacies
preps No. % prepsl No. %
01 Gastrointestinal System 111 31 14.6 52 17 29.3
02 Cardiovascular System 30 10 4.7 18 7 12.1
03 Respiratory System 60 13 6.1 16 5 8.6
04 Central Nervous System 126 64 30.2 31 19 32.8
05 Infections 167 63 29.7 2 1 1.7
06 Endocrine System 3 1 0.5 0 0 0.0
07 Obstetrics and Gynaecology 5 0 0.0 2 0 0.0
08 Malignant Disease 1 0 0.0 0 0 0.0
09 Nutrition and Blood 51 13 6.1 11 2 3.4
10Musculoskeletal and Joint Disease 23 9 4.2 9 7 12.1
11Eye 0 0 0.0 0 0 0.0
12Ear, Nose and Oropharynx 36 8 3.8 2 0 0.0
Totals 613 212 100.0 143 58 100.0
1Medicines that were identified by the Prescribed Medicines Prevalence Survey as being used
regularly and long-term by the elderly in five districts of the Northern Region
From Table 7.21, it can be seen that for all medicines with prolonged oral clearance and for
medicines with prolonged oral clearance used regularly and long-term the number of preparations
used was considerably lower for all BNF Sections, when compared with the Prescription Analysis
Survey.
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7. 4.4. 2 Dose type
When the 58 preparations with prolonged oral clearance used regularly and long-term by the
elderly were analysed by dose type (Table 7.22), 88% were liquid oral medicines, the remainder
being solid doses with prolonged oral clearance (5%) and powders and granules in sachets (7%).
There were no preparations formulated as loose powders or oral gels ordered by hospital
pharmacies. The 51 liquid oral medicines represented 88% of all preparations with prolonged oral
clearance equivalent to those used regularly and long-term in the Prescribed Medicines Prevalence
Survey. Of these, 74.5% were Central Nervous System (33.3%), Gastrointestinal (29.4%) and
Cardiovascular (11.8%) system medicines.
Of the 17 liquid oral medicine preparations in the Central Nervous System Section of the
BNF, 53% were for antidepressants, analgesics and anti-psychotics. These medicines are given
after careful patient assessment and may require continual dose assessment and change. The use
of liquid oral medicines in these situations is often preferable as it allows the prescriber to
administer a range of different doses which would be difficult with solid oral doses. Of the 15
liquid oral Gastrointestinal medicines, 66.6% were for antacids and laxatives.
7.4.4.3 Quantities of medicines with prolonged oral clearance ordered by hospital
pharmacies
A total of 13490 litres of liquid oral medicines, 44600 solid doses with prolonged oral
clearance and 26300 sachets were ordered by NHS hospitals in the Northern Region, in 1994
(Table 7.23).
Of the liquid oral medicines ordered by hospital pharmacy departments 89.1 % of the total
quantity was for Gastrointestinal (46.3%), Central Nervous System (28%) or Infections (14.8%)
medicines, with antacids (18.7%) and laxatives (76.8%) accounting for 95.5% of the
Gastrointestinal medicines.
Of the 3780 litres of Central Nervous System liquids ordered, 78.8% were for anti-
psychotics (41.4%), anti-epileptics (21.8%) or minor analgesics (15.6%). In acute situations
where the patient may be in pain and not able to swallow, analgesics are often easier to administer
as liquid oral medicines. Minor changes in doses are often required in anti-psychotics and anti-
epileptics and using a liquid oral dose form allows these minor changes to be made more easily.
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Of the total quantity of CNS liquid oral medicines equivalent to those used regularly and
long-term in the Prescribed Medicines Prevalence Survey, 38% was for anti-epileptic medication,
32.2% for anti-psychotics and 24.1 % was for antidepressants. This pattern of ordering differed
from all medicines with prolonged oral clearance ordered by hospital pharmacies in that there
were no liquid oral medicine analgesics ordered equivalent to those used long-term by the elderly
and the proportion of anti-psychotics was lower for long-term medicines. This may have been
because the hospital pharmacy department formularies used cheaper solid oral doses for these
medicines and restricted the use of liquid oral medicines to paediatric use.
Of the 44,600 tablets with prolonged oral clearance ordered by hospital pharmacies, only
5000 tablets (11.2%) were for those medicines identified as being used regularly and long-term by
the elderly. These medicines were from only two BNF sections: the Central Nervous System
(4700 tablets, 94%) and Musculoskeletal and Joint Diseases (300 tablets, 6%) and all were
effervescent tablets.
7.4.4.4 Number of sugars -free and sugars-containing medicines with prolonged oral
clearance used regularly and long-term by the elderly, ordered by hospital pharmacies
in the Northern Region in 1994.
Of the 212 preparations with prolonged oral clearance, 42 were generic and 170 were
proprietary preparations. Of the 170 proprietary medicines, 50% were sugars-free and 35.9%
sugars-containing, the remaining 14.1% was for medicines for which no information on sugar
content could be obtained.
Of the 58 medicines equivalent to those used regularly and long-term by the elderly, 77.6%
were proprietary preparations and 22.4% were generic preparations (Table 7.24 and Table 7.25),
41% were sugars-free and 50% were sugars-containing, with 2% being variable and no
information available for 4 preparations (7%).
The level of generic medicines usage was lower than that for prescribed medicines dispensed
in the general medical and dental services. In hospitals, pharmacists can dispense any brand of a
medicine regardless of what is prescribed and are not obliged to dispense the proprietary brand as
their community colleagues have to. Pharmaceutical companies, being aware of this, often offer
branded products at competitive prices so that hospitals will use their products, in the hope that on
discharge the patient will continue using the branded product in the community.
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Of the 45 proprietary medicines equivalent to those used regularly and long-term by the
elderly, 47% were sugars-free and 44% were sugars-containing, with no information being
available for 4 (8%) preparations (Table 7.24). Of these proprietary preparations, 38 were liquid
oral medicines, of which 47.4% were sugars-free and 44.7% sugars-containing. Of the other 7
proprietary medicines, 3 were solids with prolonged oral clearance, of which 2 were sugars-
containing and 4 were sachets, of which 2 were sugars-free and 1 sugars-containing. Dose forms
other than liquid oral medicines are relatively new and only available for a few preparations.
They also are more expensive and hospitals would probably avoid using them to reduce drugs
costs. This is probably why these formulations represent a minority of those medicines with
prolonged oral clearance ordered into hospital pharmacies.
Of the 13 generic medicines with prolonged oral clearance used regularly and long-term, only
23% were sugars-free, with 69% being sugars-containing and 1 (8%) variable (where the
medicine may be formulated as sugars-free or sugars-containing); all 13 generic medicines with
prolonged oral clearance were liquid oral medicines (Table 7.25).
The pattern previously observed in the Prescription Analysis Survey showing proprietary
liquid oral medicines more likely to be sugars-free and generic liquid oral medicines more likely to
be sugars-containing was also seen in the ordering data for hospital pharmacies in the Northern
Region.
7.4.4.5 Quantities of sugars-free and sugars-containing medicines with prolonged
oral clearance used regularly and long-term ordered by hospital pharmacy
departments in the Northern Region in 1994
The 45 proprietary medicines with prolonged oral clearance equivalent to those used
regularly and long-term by the elderly in the Prescribed Medicines Prevalence Survey accounted
for 3090 litres of liquid oral medicines, 5000 tablets with prolonged oral clearance and 6400
sachets of powders and granules (Table 7.26). In terms of quantities ordered, of the liquid oral
medicines, 46.9% (1450 litres) were sugars-free and 47.9% (1480 litres) were sugars-containing.
Of the 5000 proprietary solid doses with prolonged oral clearance, 94% were sugars-free and
2l.9% of the sachets were sugars-free (Table 7.26).
Of the 4690 litres of generic liquid oral medicines equivalent to those used regularly and
long-term by the elderly and ordered by hospital pharmacies, 93.4% (4380 litres) were sugars-
containing (Table 7.26).
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These results for prolonged oral clearance medicines ordered by hospital pharmacies in the
Northern Region over a one year period, show that generic liquid oral medicines were more likely
to be sugars-containing compared with proprietary preparations. In terms of quantity, the sugars-
free proportion of proprietary medicines ordered was lower than that found for the quantity of
prescribed medicines prescribed. Overall hospital pharmacies tended to use fewer sugars-free
medicines than in the primary care health services.
Table 7.26 Quantities of proprietary medicines with prolonged oral clearance potentially
used regularly and long-term by the elderly, ordered by hospital pharmacies in the
Northern Region in 1994
LOMs 0/0 Solids 0/0 Powders 0/0 Sachets %
(litres) (tablets) & oral (number)
d03 d03 gels d03
(grams)
xl03
Prenrietarv medicines
Sugars-free 1.45 46.9 4.7 94.0 0 - l.4 2l.9
Sugars-containing l.48 47.9 0.3 6.0 0 - 4.1 64.0
Variable 0.16 5.2 0.0 0.0 0 - 0.9 14.1
Total 3.09 100.0 5.0 100.0 0 - 6.4 100.0
Generic medicines
Sugars-free 0.31 6.6 0 - 0 - 0 -
Sugars-containing 4.38 93.4 0 - 0 - 0 -
Variable 0.0 0.0 0 - 0 - 0 -
Total 4.69 100.0 0 - 0 - 0 -
Hospital pharmacy departments, in a bid to reduce costs, try and use the cheapest available
medicines possible, whether these be generics or proprietary medicines at artificially low prices
and it may be that sugars-containing are being used in favour of sugars-free as they tend to be
cheaper. Lack of understanding on the dangers to dental health by hospital pharmacists may be
why sugars-free medicines are not being used.
7.4.5 Summary and Conclusions
To summarise, the use of medicines ID hospitals was assessed by analysing hospital
pharmacy ordering data for hospitals in the Northern Region. The overall use of medicines with
prolonged oral clearance w~ lower than in primary care, with hospitals only using 212 of the 613
medicines with prolonged oral clearance, of which only 58 were used regularly and long-term by
the elderly. The main findings from the survey were:
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Overall Consumption of Medicines with Prolonged Oral Clearance
• The 212 medicines with prolonged oral clearance accounted for 13490 litres of liquid oral
medicines and 44600 solid doses with prolonged oral clearance.
• Of the 58 medicines with prolonged oral clearance equivalent to those used regularly and
long-term by the elderly, 51 were liquid oral medicines and 3 were solids with prolonged
oral clearance, accounting for 7780 litres and 5000 solid doses being ordered respectively.
• Of the liquid oral medicines, 3090 litres were for proprietary medicines, of which 47%
were sugars-free and 48% sugars-containing. Generic liquid oral medicines accounted for
4690 litres of which 7% were sugars-free and 93% sugars-containing.
• Of the solid doses with prolonged oral clearance, all were proprietary medicines, with
94% being sugars-free and 6% being sugars-containing.
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APPENDIX 7.2
Quantity of all medicines with prolonged oral clearance and those used long-
term, dispensed in England, during a one year period (1994).
All Medicines with prolonged oral Long-term medicines with prolonged oral
clearance clearance
Powders and Powders and
BNF Liquids Tablets oral gels~~ Sachets Liquids Tablets oral gels») Sachets
Section I (litres d O~ (no. dO) (2ramsdO (no. dO) (litres xlO) (no. dO) I (I!rams dO (no. x10~
1.1 3454.0 162490.0 - - 3232.2 159026.5 - -
1.2 116.1 - 1938.3 3643.0 93.6 - - 3643.0
1.3 60.7 11314.8 - - 39.8 3874.8 - -
1.4 31.8 - - - - - - -
1.5 3.2 - - - 3.2 - - -
1.6 2253.3 9056.3 182284.3 150533.9 2225.1 9056.3 178165.0 127759.5
1.7 - - - - - - - -
1.8 - - - - - - - -
1.9 - - 236.3 68.5 - - - -
2.1 1.1 - - - 1.1 - - -
2.2 12.0 - - - 7.2 - - -
2.3 - - - - - - - -
2.4 5.5 - - - - - - -
2.5 0.6 - - - 0.6 - - -
2.6 2.4 153129.1 - - 2.3 12236.7 - -
2.7 - - - - - - - -
2.8 - - - - - - - -
2.9 - 349359.7 - - - 349359.7 - -
2.10 - - - - - - - -
2.11 0.2 - - - - - - -
2.12 - - - 13822.7 - - - 10206.8
2.13 - - - - - - - -
3.1 134.7 - - - 36.4 - - -
3.2 - - - - - - - -
3.3 4.5 - - - - - - -
3.4 198.0 - - - 22.2 - - -
3.5 - - - - - - - -
3.6 - - - - - - - -
3.7 - - - - - - - -
3.8 - - - - - - - -
3.9 1400.2 - - - 720.2 - - -
3.10 - - - - - - - -
4.1 67.4 - - - 48.4 - - -
4.2 104.5 - - - 5.0 - - -
4.3 24.7 - - - 10.7 - - -
4.4 - - - - - -
4.5 - - - 228.0 - - - -
4.6 31.7 3464.1 - 1849.6 - 3464.1 - 1849.6
4.7 675.1 338051.2 - 2844.0 - 334490.8 - 203.0
4.8 142.5 10364.3 - 541.3 70.7 5993.4 - -
4.9 9.5 4908.2 - - 1.1 2286.9 - -
4.10 293.1 - - - - - - -
5.1 1184.5 2240.2 - 108656.8 4.1 - - 100.3
5.2 15.2 - - - - - - -
5.3 2.5 3176.3 - - - - - -
5.4 2.2 - - - - - - -
5.5 6.4 553.8 - 272.2 - - - -
6.1 - - - 436.8 - - - -
6.2 - - - - - - - -
6.3 - 9256.5 - - - - - -
6.4 - - - - - - - -
6.5 - - - - - - - -
6.6 - - - - - - - -
6.7 - - - - - - - -
7.1 - - - - - - - -
7.2 - - - - - - - -
7.3 - - - - - - - -
7.4 18.5 685.8 - 6.6 17.0 5.3 - -
8.1 - - - - - - - -
8.2 2.8 - - - - - - -
8.3 - - - - - - - -
9.1 54.1 - - - 38.8 - - -
9.2 1.5 - - 17278.3 - 6737.2 - -
9.3 - 8865.3 - - - - - -
9.4 - - - . - - - - -
9.5 6.0 31710.4 ...........?~~:~ - 27634.3 - -......................... ................................................................... ........................ ......................................................................
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APPENDIX 7.2 (continued)
All Medicines with prolonged oral Long-term medicines with prolonged oral
clearance clearance
BNF Powders and Powders and
Therapeutic Liquids Tablets oral gels Sachets Liquids Tablets oral gels Sachets
Section I (litres xt 0) (no. xtO) (eramsxtO) (no. xt!O_ _{litres xt!O_ _{no. xtO) l_{g_ramsxt!O_ _(no. xt!O_
9.6 1.4 1650.6 - - 0.6 1650.6 - -
9.7 27.1 - - - - - - -
9.8 - - - - - - - -
10.1 122.3 8134.7 - 6060.4 95.1 5445.8 - -
10.2 11.9 - - - 11.9 - - -
10.3 - - - - - - - -
ILl - - - - - - - -
11.2 - - - - - - - -
11.3 - - - - - - - .
11.4 - - - - - - - -
11.5 - - - - - - - -
11.6 - - - - . - - -
11.7 - . - - - - - -
11.8 - - - - - - - -
11.9 - - - - - - - -
12.1 - - - - - - - -
12.2 - - - - - - - -
12.3 86.5 14497.1 6775.6 59.5 0.1 5431.9 - -
Total 10569.6 1122908.4 191234.5 307022.0 6732.2 926694.3 178165.0 143762.2
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APPENDIX 7.3
Quantity of all medicines with prolonged oral clearance and those used long-
term, dispensed in the Northern Region, during a one year period (1994).
All Medicines with prolonged oral Long-term medicines with prolonged oral
clearance clearance
BNF Powders and Powders and
Therapeutic Liquids Tablets oral gels Sachets Liquids Tablets oral gels Sachets
Section I ilitres xl 0") (no. xlO") (eramsxlO") (no. xlO") (litres xl 0") (no. xlO,,) (erams dO,,) (no. dO")
1.1 266.1 11651.8 - - 252.7 11252.7 - -
1.2 5.4 - 31.8 239.5 4.2 - - 239.5
1.3 5.4 1270.9 - - 2.7 427.9 - -
1.4 2.4 - - - - - - -
1.5 0.2 - - - 0.1 - - -
1.6 157.1 607.3 11571.5 11204.3 152.7 607.3 11069.9 8723.7
1.7 - - - - - - - -
1.8 - - - - - - - -
1.9 - - - 0.8 - - - -
2.1 0.1 - - - - - - -
2.2 0.6 - - - 0.4 - - -
2.3 - - - - - - - -
2.4 0.3 - - - - - - -
2.5 - - - - - - - -
2.6 0.2 16485.6 - - 0.2 3136.5 - -
2.7 - - - - - - - -
2.8 - - - - - - - -
2.9 - 25871.2 - - - 25871.2 - -
2.10 - - - - - - - -
2.11 - - - - - - - -
2.12 - - 30.6 722.0 - - - 596.9
2.13 - - - - - - - -
3.1 17.2 - - - 12.0 - - -
3.2 - - - - - - - -
3.3 0.6 - - - - - - -
3.4 10.3 - - - 0.1 - - -
3.5 - - - - - - - -
3.6 - - - - - - - -
3.7 - - - 1.0 - - - -
3.8 - - - - - - - -
3.9 60.8 - - - 33.5 - - -
3.10 - - - - - - - -
4.1 5.0 - - - 3.4 - - -
4.2 4.6 - - - 2.7 - - -
4.3 1.7 - - - 0.3 - - -
4.4 - - - - - - - -
4.5 - - 3.1 32.3 - - - -
4.6 2.0 206.6 - 110.7 - 206.5 - 88.9
4.7 64.5 71244.2 - 233.2 - 70585.6 - 19.5
4.8 7.1 90.0 - 63.9 3.7 365.2 - -
4.9 0.5 238.9 - - 0.1 97.6 - -
4.10 3.5 - - - - - - -
5.1 78.9 139.2 - 6577.1 0.2 - - 4.0
5.2 1.0 - - - - - - -
5.3 0.2 207.5 - - - - - -
5.4 - - - - - - - -
5.5 0.4 33.0 - 10.8 - - - -
6.1 - - - 9.5 - - - -
6.2 - - - - - - - -
6.3 - 538.9 - - - - - -
6.4 - - - - - - - -
6.5 - - - - - - - -
6.6 - - - - - - - -
6.7 - - - - - - - -
7.1 - - - - - - - -
7.2 - - - - - - - -
7.3 - - - - - - - -
7.4 0.9 26.7 - 0.6 0.7 2.6 - -
8.1 - - - - - - - -
8.2 0.1 - - - - - - -
8.3 - - - - - - - -
9.1 2.3 - - - 1.6 - - -
9.2 0.1 - 30.6 866.5 - 763.8 - -
9.3 - 860.4 - - - - - -
9.4 - - - - - - - -
9.5 0.4 1806.5 - 40.9 - 1535.3 - -
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APPENDIX 7.3 (continued)
All Medicines with prolonged oral Long-term medicines with prolonged oral
clearance clearance
BNF Powders and Powders and
Therapeutic Liquids Tablets oral gels Sachets Liquids Tablets oral gels Sachets
Section I (Utres xl 0) (no. xlO') lJg_rams xlO') (no. xlO') (litres xl 0') (no. xlO) (gramsxlO') _Lno. xlCl2
9.6 0.1 269.6 - - - 269.6 - -
9.7 0.8 - - - - - - -
9.8 - - - - - - - -......................... ...................... ..................... ........................ .................... ........................ ........................ ......................... .....................
10.1 6.1 872.2 - 62.9 4.0 395.7 - -
10.2 1.3 - - - 0.3 - - -
10.3 - - - - - - - -
11.1 - - - - - - - -
11.2 - - - - - - - -
11.3 - - - - - - - -
11.4 - - - - - - - -
11.5 - - - - - - - -
11.6 - - - - - - - -
11.7 - - - - - - - -
11.8 - - - - - - - -
11.9 - - - - - - - -
12.1 - - - - - - - -
12.2 - - - - - - - -
12.3 8.2 921.7 546.5 2.9 - 391.1 - -
Total 716.4 134152.3 12214.1 20179.1 475.6 115908.6 11069.9 9672.4
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APPENDIX 7.4
Quantity of all medicines with prolonged oral clearance and those used long-
term, dispensed in Newcastle, during a one year period (1994).
All Medicines with prolonged oral Long-term medicines with prolonged oral
clearance clearance
BNF Powders and Powders and
Therapeutic Liquids Tablets oral gels Sachets Liquids Tablets oral gels Sachets
Section (litres dO') (no. dO) (grams dO) (no. xlO) {litres dO,) (no. dO,) (erams xlO,) (no. dO')
1.1 34.5 2447.4 - - 31.0 1805.7 - -
1.2 0.4 - 1.0 5.3 0.3 - - 5.3
1.3 0.4 85.6 - - 0.2 30.5 - -
1.4 0.2 - - - - - - -
1.5 - - - - - - - -
1.6 15.4 11.0 1062.2 1084.6 14.9 11.0 1028.9 810.1
1.7 - - - - - - - -
1.8 - - - - - - - -
1.9 - - - - - - - -
2.1 - - - - - - - -
2.2 - - - - - - - -
2.3 - - - - - - - -
2.4 - - - - - - - -
2.5 - - - - - - - -
2.6 - 2440.8 - - - 408.3 - -
2.7 - - - - - - - -
2.8 - - - - - - - -
2.9 - 2124.9 - - - 2124.9 - -
2.10 - - - - - - - -
2.ll - - - - - - - -
2.12 - - 1.0 61.7 - - - 52.3
2.13 - - - - - - - -
3.1 1.5 - - - 1.1 - - -
3.2 - - - - - - - -
3.3 - - - - - - - -
3.4 0.9 - - - - - - -
3.5 - - - - - - - -
3.6 - - - - - - - -
3.7 - - - - - - - -
3.8 - - - - - - - -
3.9 5.6 - - - 2.9 - - -
3.10 - - - - - - - -
4.1 0.4 - - - 0.2 - - -
4.2 0.5 - - - 0.4 - - -
4.3 0.1 - - - - - - -
4.4 - - - - - - - -
4.5 - - - 2.4 - - - -
4.6 0.2 15.3 - 1.5 - 13.2 - 1.4
4.7 7.3 6485.6 - 12.3 - 6480.9 - 0.8
4.8 1.0 1.1 - 5.9 0.3 - - -
4.9 0.1 8.8 - - - 4.3 - -
4.10 0.1 - - - - - - -
5.1 8.1 22.9 - 586.8 - - - 1.6
5.2 0.1 - - - - - - -
5.3 - 19.4 - - - - - -
5.4 - - - - - - - -
5.5 - - 0.1 0.9 - - - -
6.1 - - - 0.1 - - - -
6.2 - - - - - - - -
6.3 - 38.0 - - - - - -
6.4 - - - - - - - -
6.5 - - - - - - - -
6.6 - - - - - - - -
6.7 - - - - - - - -
7.1 - - - - - - - -
7.2 - - - - - - - -
7.3 - - - - - - - -
7.4 0.1 0.5 - - 0.1 - - -
8.1 - - - - - - - -
8.2 - - - - - - - -
8.3 - - - - - - - -
9.1 0.2 - - - 0.1 - - -
9.2 - - - 112.7 - 58.2 - -
9.3 - 75.8 - - - - - -
9.4 - - - - - - - -
9.5 - 117.3 - - - 85.7 - -
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APPENDIX 7.4 (continued)
All Medicines with prolonged oral Long-term medicines with prolonged oral
clearance clearance
BNF Powders and Powders and
Therapeutic Liquids Tablets oral geIs~) Sachets Liquids Tablets oral geIs)~ Sachets
Section I (titres d O~ (no. dO) (Er&mS xlO (no. xlO~ (titres xlO) (no. xlO) I(Er&mS xlO (no. xlO~
9.6 0.1 33.4 - - - 33.4 - -
9.7 0.1 - - - - - - -
9.8 - - - - - - - -......................... ...................... ..................... ...-.................... .................... ........................ ........................ ......................... .....................
10.1 0.4 83.9 - 2.8 0.3 41.3 - -
10.2 0.2 - - - - - - -
10.3 - - - - - - - -
ILl - - - - - - - -
11.2 - - - - - - - -
11.3 - - - - - - - -
11.4 - - - - - - - -
11.5 - - - - - - - -
11.6 - - - - - - - -
11.7 - - - - - - - -
11.8 - - - - - - - -
11.9 - - - - - - - -
12.1 - - - - - - - -
12.2 - - - - - - - -
12.3 - 58.5 26.9 - - 15.9 - -
Total 78.2 14070.4 1091.2 1877.1 51.8 11113.3 1028.9 871.5
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APPENDIX 7.5
Map of the Northern Region Health Authority Boundary in 1994
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APPENDIX 7.6
Map of the Tyne Tees Television Coverage Area
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APPENDIX 7.7
Types of common sweetening agents found in OTC preparations with prolonged
oral clearance
Sugars-free OTe Medicines
Liquids Solids Powders & Sachets Total
oral gels
No Sugar 17 0 7 2 26
Saccharin 19 15 4 3 41
Saccharin+Sorbitol 10 3 0 0 13
Sorbitol 1 1 2
Lycasin 3 3
Glycerol 2 2
Aspartame 1 1 2
Saccharin+Malitoi 1 1
Saccharin+Maize Starch 0
Saccharin+Lactose 1 1
Saccharin+ Aspartame 0
Sorbitol+Malitol 2 2
Sorbitol+Isomalt 1 1
Lycasin+Sorbitoi 5 5
Lycasin+Saccharin 5 5
Glycerol+Saccharin I 1 2
Glycerol+ Aspartame 1 1
Acesulfame+Isomalt 0
Saccharin+Glycerol+Sorbitol 1 1
Saccharin+Lactose+Cyclamate 1 1
Sorbitol+Saccharin+ Xylitol 3 3
Sorbitol+Glycerol+Cyclamate 1 1
Sorbitol+Saccharin+Cyclamate 4 4
Lycasin+Saccharin+Glycerol 3 3
Lycasin+Saccharin+Cyclamate 2 2
Glycerol+Lycasin+Sorbitol+Cyclamate+ 4 4
Acesulfame
Total 78 24 14 10 126
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APPENDIX 7.7 (continued)
Sugars-containing OTe Medicines
Liquids Solids Powders & Sachets Total
oral gels
Sucrose 34 18 5 5 62
Sucrose+Glucose 7 7 3 0 17
Sucrose+Saccharin 5 8 0 4 17
Sucrose+Glucose + Saccharin 9 0 0 0 9
Sucrose+Sorbitol 12 2 0 0 14
Glycerol+Sorbitol+Cyclamate I 1
Sucrose+Glucose Syrup+Saccharin 1 1
Sucrose+Glucose+Sorbitol 1 1
Sucrose+Glucose+Saccharin+Sorbitol 1 1
Sucrose+Saccharin+Cyclamate 3 3
Sucrose+dextrose+Dried Starch 1 1
Sucrose+Sorbitol+Saccharin 1 1
Glucose+Sucrose+Fructose 3 3
Glucose+Cyclamate+Acesulfame 1 1
Glucose+Treacle+Cyclamate+ Acesulfame 1 1
Lactose+Galactose+Epilactose+Fructose+ 1 1
Lactulose
Lactose+Galactose+Epilactose+Lactulose 1 1
Lactulose+Galactose+Lactose 1 1
Glucose+Saccharin+Cyclamate 1 1
Glycerol+Sorbitol+Sucrose 1 1
Sucrose+Glucose Syrup 3 2 1 6
Sucrose+Treacle 2 2
Cyclamate+Sucrose 1 1
Sucrose+ Aspartame 1 1
Glucose+Saccharin 2 1 3
Glucose+Treacle 1 1
Dextrose+Saccharin 2 2
Glucose Syrup+Saccharin 2 2
Glucose I 1 2
Dextrose 1 1
Glucose Syrup 3 3
Total 90 46 9 17 162
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CHAPTERS
OVERALL DISCUSSION AND IMPLICATIONS
8.1 INTRODUCTION
The series of five observational surveys conducted in this study focused on an assessment of
the use of medicines with prolonged oral clearance in the elderly in the U.K. These medicines with
a prolonged clearance from the oral cavity included liquid oral medicines, chewable tablets, buccal
and sublingual tablets and pastilles and lozenges. If these formulations include an acidogenic
sweetening agent, they could pose a risk to dental health and it was important that an estimate of
this risk was made. Many elderly take large numbers of medicines to alleviate the age-associated
increase in morbidity: in 1997 they were dispensed 49% of all 500 million prescription items
dispensed in the UK (Department of Health, 1998). As the population of elderly individuals in the
UK increases, with more elderly retaining natural teeth into old age (Todd & Lader, 1991), the
extent of use of prolonged oral clearance medicines and their sugars content could potentially
become a significant problem. In view of this there was a need for this aspect of medicines
utilisation to be quantified on an individual and population basis. Many studies have looked at
medicine use and dental health, whether it be sugars and liquid oral medicines (Burt et al., 1988;
Hobson, 1985; James & Parfitt, 1953; Maguire et al., 1996; Roberts & Roberts, 1979) or
medicines with specific oral effects (Baker et al., 1991; Bertram et al., 1979; Peters, 1989),
however no studies have looked at a collective group of medicines with prolonged oral clearance
from the oral cavity.
The surveys were carried out as an assessment of prevalence of long-term use of prescribed
and over-the-counter liquid oral medicines in five Districts within the Northern Region, an
analysis of prescriptions dispensed in the general medical and dental services on a national,
regional and local basis, together with an analysis of hospital pharmacy use and community
pharmacy supply on a regional basis. Medicines are obtained by consumers within the UK's
health care system by fairly diverse means and it was important that the planning of these surveys
took this into account, along with the equally diverse means by which data on supply of medicines
are collated by various b.odies within the National Health Service as well as the commercial
sector.
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This chapter combines an overall critical review of the project and interpretation of the
important results, with a consideration of the implications and suggestions for future research.
8.2 CRITIQUE OF METHODS
To assess the overall of use of medicines with prolonged oral clearance, five surveys were
undertaken. Two of these were concerned with estimating the prevalence of use of medicines with
prolonged oral clearance in the elderly in the North East of England and three surveys assessed the
overall consumption of medicines with prolonged oral clearance in England, the Northern Region
and Newcastle.
Having assessed what the data sources were and which might be accessible to carry out the
surveys, the methods described used the most comprehensive which were available and retrievable
with the manpower and time available for the study.
The Prescribed Medicines Prevalence Survey and OTC Medicines Prevalence Survey were
both general medical practice based and both used personal medical information. The use of these
data required Ethics Committees' permission with assurance that all the data collected would
remain completely confidential and that no individuals details would be discussed. The need to
maintain strict confidentiality took high priority in the methodology used. All patients in the
Prescribed Medicines Prevalence Survey and OTC Prevalence Survey were given a code which
identified the practice where they were registered and their practice medication record number.
This ensured that no data could be traced back to the patient. Commercially sensitive information
was also treated with strict confidentiality; all prescribing data and those obtained from
commercial sources were aggregated by therapeutic section only and no reference made to
individual medicines in these surveys.
8.2.1 Sampling
In the Prescribed Medicines Prevalence Survey, the practices chosen were selected from a list
of practices received from the Family Health Services Authorities (FHSAs) for the five districts.
Due to the vast amount of data that it was anticipated would be collected, it was decided that ten
general medical practices would be selected from a sampling frame containing only
comprehensively computerised practices. In the event all the general medical practices in the five
districts of the Northern Region selected met this inclusion criterion and all practices at the time of
sampling had list sizes of 5,000 patients or more.
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The main aim in both the Prescribed Medicines Prevalence Survey and OTC Medicines
Prevalence Survey was to identify regular (once daily or alternate day) and long-term (3 months
or longer) use of medicines with prolonged oral clearance. Regular use was defined as at least
'once daily' or 'alternate day', however all instances of use identified were at least 'once daily'.
The time period of three months was chosen as minimum length of treatment to define long-term
use as most medicines used for acute conditions such as infections would not be used for longer
than this time period, and this was also the time scale chosen by a similar prevalence survey
undertaken with children (Maguire & Rugg-Gunn, 1994).
The methodology used in the two prevalence surveys varied in that the survey for prescribed
medicines looked at all 20,371 elderly patients registered at the 10 practices and details of those
patients taking medicines with prolonged oral clearance were entered onto a database. In contrast,
the prevalence survey for OTC medicines used a sub-sample of 50% of the elderly patients often
general medical practitioners at the ten general medical practices, producing a total sample of
2322. These patients were sent questionnaires and asked to list their medication, which was then
entered into the database and analysed. Statistical advice on sample size confirmed that 2322
patients would form an adequate sample for the OTC Medicines Prevalence Survey.
The surveys of overall consumption of medicines with prolonged oral clearance looked at
prescribing, dispensing and ordering data for prescription and OTC medicines within the primary
healthcare service (Prescription Analysis Survey and OTC Medicines Survey), and ordering data
for prescribed medicines within the secondary healthcare service (Hospital Drug Ordering
Survey). The surveys used 100% samples of these data; prescribing data was from 100% of all
prescriptions dispensed in primary care, 'over the counter' data recorded 100% of all OTC
medicines ordered by pharmacies in the Channel 3 North-East TV area and the hospital ordering
data included 100% of all medicines with prolonged oral clearance ordered by hospitals.
Although the coverage for Channel 3 North East and the Northern Region Health Authority were
not identical, it was felt the two areas coincided sufficiently well to provide a reasonable estimate
of OTC medicine use in the Northern Region.
8.2.2 Data collection
The study looked at the use of medicines with prolonged oral clearance used regularly and
long-term by the elderly as well the overall use of medicines with prolonged oral clearance.
Careful consideration was given to the data collection methods of each survey to ensure that the
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most accurate data could be retrieved. However, since the surveys have been completed, with the
advance in computing technology, it would now be possible to improve and speed up data
collection if a similar study were carried out in the future. Data collected from a practice could
now be downloaded straight from the computer system of the general medical practice, rather than
printing it off and then manually transferring the data to a database. The surveys looking at the
overall use of medicines with prolonged oral clearance used PACT and PCA prescribing data
which were also entered into a database manually. PACT and PCA data are now available
electronically and such a format would have considerably reduced the time taken to collect and
analyse these data. PCA data took less time to analyse than PACT and they were used for
England. Unfortunately PCA data were not available for the Northern Region nor Newcastle,
requiring the use of PACT which involved additional calculations before data entry. The formats
of data varied slightly in that PCA data, which were used for England were based on where the
prescription was dispensed and PACT data, which were used for the Northern Region and
Newcastle were based on the location of the prescriber. PCA data are dispensing data (i.e. what
was actually dispensed) and PACT data are prescribing data (i.e. what was actually prescribed).
In most cases these two are identical and the data provided by the two formats would be
comparable, however for some drugs there may be slight discrepancies between PCA and PACT
data. PCA data for England included data on overall quantities already calculated. In view of the
volume of data involved, it was felt that this was the most appropriate use of the manpower
available. As an electronic version of PACT is now available, this could be used in any future
surveys of this nature as all national, regional and district level data would be of the same format.
The data collection for the surveys, although time consuming, was relatively straightforward.
The general medical practices were very helpful in providing access to the computerised patient
records, as well as giving permission to contact their patients for the questionnaire survey.
Likewise, the Prescription Pricing Authority and Prescribing Unit were very helpful and gave full
access to PACT and PCA data, as well hospital drug ordering data. The major problem
encountered in the data collection was access to overall use of 'Over the Counter' medicines data.
This was originally to be collected from pharmaceutical wholesalers, who were happy to provide
good quality data for all sales of OTC medicines to community pharmacies. This had already
been proved to be a su~cessful method of data collection (Maguire & Rugg-Gunn, 1994).
However in this study, these data from two multinational companies was not made available even
after many attempts to contact these companies. It was unfortunate to have to reject the data
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provided by the pharmaceutical wholesalers, and find another source of data that could provide an
overall estimate of the use of OTC medicine with prolonged oral clearance.
Another area where the data provision was poor was the generic manufacturers regarding the
sugars content of generic medicines with prolonged oral clearance. Proprietary manufacturers
provided concise information on the types and amounts of sweetening agents in medicines with
prolonged oral clearance, whereas the generic manufacturers were only able to state that the
medicine was sugars-free or sugars-containing for most cases and were not able to provide
information on the actual sugars content.
In the analysis of these surveys two assumptions had to be made and taken into consideration
when looking at the results. Data collected for the overall use of medicines in hospitals in the
Northern Region and the overall use of OTC medicines were ordering data. It was assumed that
these ordered medicines were subsequently dispensed to, or bought by the patient and then
consumed by the patient and not lost through wastage due to poor stock control in pharmacies.
The second assumption was patients' compliance was good and that all medicines prescribed and
dispensed were ultimately consumed by the patient. However, research has shown that patient
compliance in the elderly may be poor (Robertson, 1985; Salzman, 1995), and this is currently an
issue the Royal Pharmaceutical Society of Great Britain is investigating further following the
publication of their report 'From compliance to concordance' (Royal Pharmaceutical Society of
Great Britain, 1997). This report suggests that up to 50% of the elderly may not be complying
with their medication and that compliance is further reduced with increased number of tablets
taken and increased frequency of dosing. The Society recommends that the issue of compliance be
included in the NHS research and development programme.
8.3 OVERALL FINDINGS
8.3.1 Prevalence of use of medicines with prolonged oral clearance in the elderly
The literature review in Chapter 3 revealed no published information on the prevalence of
long-term use of medicines with prolonged oral clearance in the elderly, and the possible effects on
dental health. This study was the first known determination of the prevalence of use of these
medicines in the elderly population.
To ensure that an overall picture of prevalence of all medicines was obtained, two surveys,
one looking at prescribed medicines (Chapter 5) and the other at 'over the counter' (OTC)
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medicines (Chapter 6) were undertaken. These surveys showed prevalence rates of 9.8% and
1.1% for regular and long-term use of prescribed and OTC medicines with prolonged oral
clearance in the elderly population sampled. Of the 2002 elderly patients taking prescribed
medicines regularly and long-term, 68% were female, which was higher than the proportion of
females in the Northern Region and England which was approximately 58% in 1995 (Office for
National Statistics, 1995). Of the 2002 patients, 46% were ~75 years, which was higher than
proportion of ~75 year olds registered at the ten practices which was 34%. Statistical analysis
showed that females aged 75 years and over were more likely to be taking medicines with
prolonged oral clearance regularly and long-term (p<0.0001). Extrapolated to the five districts
and regionally, the number of elderly patients taking prescribed medicines of this nature regularly
and long-term would be 24588 and 60544 elderly patients respectively based on the elderly
population of the 5 districts and the Northern Region being 250900 and 617800 respectively, in
1995 (Office for National Statistics, 1995). Extrapolation of the data for England and the UK
could be made but the regional differences in medicine use may result in this being inaccurate.
The numbers of patients identified in the OTC Medicines Prevalence Survey were too low to carry
out any statistical analysis; 1.1% prevalence accounted for 17 patients. However, if these OTC
sales were indicative of the rest of the five Districts and the Region, then the number of elderly
patients taking OTC medicines regularly and long-term would be 3021 and 7261 patients
respectively.
In addition, the OTC Medicines Prevalence Survey showed that 46% of all the respondents to
the questionnaire had some natural teeth. This would indicate that up to 13500 elderly patients in
the five districts and 34400 regionally may be at risk from dental caries if the medicines with
prolonged oral clearance were sugars-containing.
8.3.2 Medical problems for which medicines with prolonged oral clearance are
commonly used long-term
The two prevalence surveys showed that prescribed medicines were more likely to be used
regularly and long-term than over the counter (OTC) medicines. Prescribing instances recorded
for regular long-term use of a medicine prescribed for an elderly patient showed that of the total of
2796 long-term prescribing instances, over half (54%) were for gastrointestinal medicines, in
particular, laxatives and antacids. The Prescription Analysis Survey confirmed this finding with
the majority of prescriptions dispensed for prolonged oral clearance medicines nationally,
regionally and locally being for gastrointestinal medicines. Of all medicines dispensed in 1994 to
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the elderly, 10.5% were for gastrointestinal problems (Prescription Pricing Authority, 1995),
which would suggest that gastrointestinal medicines are more likely to be prescribed as medicines
with prolonged oral clearance. This most likely related to the dose form: most gastric conditions
are a result of excess acidity and a liquid oral medicine or chewable tablet can neutralise this acid
more effectively than a solid oral dose form designed for immediate swallowing since a greater
surface area of medicine is produced for contact with the gastric acid.
8.3.3 Overall prolonged oral clearance medicine consumption: long- and short-
term
Overall, there were no great differences in the prescribing of all prolonged oral clearance
medicines, and those medicines with prolonged oral clearance likely to be prescribed long-term in
the elderly. However, there was some indication that those medicines commonly prescribed which
were also available 'over the counter'; for example, minor analgesics such as paracetamol, were
more likely to be prescribed than bought in the more socially deprived district of Newcastle
compared with the Northern Region and nationally. The scale of use of 'over the counter' (OTC)
prolonged oral clearance medicines, in terms of quantities, was previously unknown. In a study of
overall use of medicines by children by Rylance et al (Rylance et al., 1988), 55% of medicines
dispensed to children were on prescription, however there was no indication as to whether all these
were Prescription Only medicines. The remaining 45% of medicines used were OTC medicines,
with 40% purchased in pharmacies. No similar research has previously been described in the
elderly.
The present survey of overall consumption of 323 General Sales List and Pharmacy Only
OTC products with prolonged oral clearance, indicated that the quantity purchased over the
counter; 0.11 million litres, and 16.8 million solid oral doses with POC in the Northern Region,
was equivalent to approximately 14% of the quantity of all prolonged oral clearance medicines
dispensed within the general medical and dental services in the Northern Region.
Once the hospital pharmacy consumption figures were included, the prolonged oral clearance
medicine market (both long- and short-term) amounted to approximately 0.73 million litres of
liquid oral medicines plus 134.25 million solid doses with prolonged oral clearance, dispensed in
primary and secondary care, in the Northern Region. If these figures are extrapolated in terms of
the ratio of Regional to National prescribing found in the Prescription Analysis Survey, which
was 1:14 in terms of number of prescriptions dispensed, and assuming all dispensed medicines
were consumed, the national consumption rate of liquid oral medicines was approximately 10.22
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million litres plus 1879.43 million solid doses per year. However, this is obviously an over-
estimate of actual consumption rates since compliance with medication is variable; between 25%
and 50% of elderly patients do not to take their medicines as prescribed (Robertson, 1985;
Salzman, 1995).
As medicines with prolonged oral clearance formed four distinct categories in terms of dose
form (liquids, solids, powder/oral gels and sachets), it was necessary to analyse the quantity data
according to the different units of measurement (e.g. litres for liquid oral medicines compared with
number of units for solids with prolonged oral clearance). This form of analysis, by dose unit has
only previously been reported for liquid oral medicines in relation to their use in children (Maguire
& Rugg-Gunn, 1994; Roberts & Roberts, 1979). This analysis by dose form was important as it
highlighted major differences in the prescribing of sugars-free and sugars-containing medicines
between dose forms, which is discussed in the next section (8.3.4). In addition, this analysis by
dose form also highlighted a potential problem which was not considered during the planning
stages of the study. Of the 134.3 million solid doses with prolonged oral clearance used overall in
the Northern Region, 94.8 million (71%) were effervescent tablets. Prior to administration, these
tablets are dispersed in water, where an acid-base reaction explodes the tablet into the solution.
Most tablets contain an excess of a weak acid (usually citric acid) to ensure the reaction is
completed as well as giving the final solution a pleasant flavour. The resulting solution is quite
often acidic and therefore may put the patient at risk of dental erosion if consumed regularly and
long-term. Other studies have looked at the potential of medicines to cause dental erosion. In a
survey looking at juvenile arthritis (Sullivan & Kramer, 1983) and two groups of children, one
chewing aspirin and the other swallowing aspirin whole, dental erosion was reported in those
children taking the chewable form of aspirin. A case study looking at a women taking a chewable
vitamin has also described dental erosion (Giunta, 1983). No studies have described the long-term
effects of effervescent tablets in the elderly in terms of dental health and this is one area which
would benefit from further research.
8.3.4 Sugars content of medicines with prolonged oral clearance used regularly and
long-term
The studies carried out here indicated that 49% of all OTC liquid oral medicine consumption
and 59% of all solid O'I'C'medicine consumption in the Northern Region was sugars-free in terms
of quantity, whereas the long-term prescribing data show that 71% of prescribing instances for
long-term prolonged oral clearance preparations (identified in the Prescribed Medicines
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Prevalence Survey) were definitely sugars-free. In terms of prescriptions suitable for long-term
use dispensed in the Northern Region, 73% were for sugars-free medicines and, as far as
quantities were concerned, 60% of liquid oral medicines and 88% of solid doses with prolonged
oral clearance dispensed were sugars-free.
Overall it appeared that sugars-free medicines with prolonged oral clearance were being used
more than sugars-containing and it may be that manufacturers have responded to the increasing
pressure from health professionals and reformulated existing sugars-containing medicines,
producing new sugars-free products. In particular, manufacturers of paediatric medicines have
increased their range of sugars-free medicines accordingly, providing an expanding range for the
prescriber and purchaser to choose from, particularly for minor analgesics and cough and cold
remedies. However, choosing the form that an alternative sweetener should take is important, and
problems have been encountered when formulating sugars-free products for international markets.
The regulatory status of an alternative sweeteners varies between countries, and where there are
few manufacturers of a sweetener, bulk transportation over large distances may be necessary,
often leading to considerable practical problems.
The data from the Prescription Analysis Survey showed that in 71% of the prescribing
instances for the 143 preparations identified as being used regularly and long-term by the elderly,
sugars-free medicines were being prescribed. However closer examination of the data showed that
there were major differences between dose forms and between generic and proprietary prescribing.
Of all formulations of generic liquid oral medicines, 81% were sugars-containing compared with
only 8% of proprietary liquid oral medicine preparations and for liquid oral medicines, 52% of all
prescribing instances were for generic medicines with prolonged oral clearance, 48% for
proprietary liquid oral medicines. This has very important implications for prescribing as
medicines prescribed generically were more likely to be dispensed as sugars-containing, and if
used long-term, as the medicines in this survey were, the potential risk to dental health is
increased.
In terms of the patients actually at risk, approximately 46% of the elderly patients surveyed
in the OTC Medicines Prevalence Survey were dentate. If this proportion was extrapolated to the
20371 elderly in the ten general medical practices surveyed in the Prescribed Medicines
Prevalence Survey, then this would indicate 921 dentate elderly (approximately 4.5%) were taking
medicines with prolonged oral clearance regularly and long-term. From the Prescribed Medicines
Prevalence Survey, 26% of the prescribing instances were for sugars-containing medicines,
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increasing the risk of dental caries in these patients. However when generic prescribing and dose
form was considered, the risk was greater, with 80.6% of prescribing instances for generic liquid
oral medicines being sugars-containing.
This aspect is of particular concern as more and more medicines are running out of patents
and are being formulated by generic manufacturers. If reformulation of these medicines with
acidogenic sweetening agents is permitted and the pressure on general medical practitioners to
prescribe generically continues, then patients taking these medicines regularly and long-term may
be at increased risk. Generic manufacturers are not bound legally to produce sugars-free
medicines, in fact, as long as the medicine is bioequivalent, any 'inert' excipient can be included
(Hobson & Fuller, 1987).
8.3.5 Generic and proprietary medicines
Generic prescribing, that is prescribing medicines by their chemical name, continues to
increase in the UK, so that almost 60% of all medicines dispensed in 1997 were generics
(Department of Health, 1998). This aspect of prescribing was explored further in the prevalence
and prescription analysis surveys. Of the 143 medicines with prolonged oral clearance used
regularly and long-term, 42 were generics which accounted for 144 different formulations
manufactured by 27 different pharmaceutical companies. This had a great impact on dispensing
as the formulation of medicine varied depending on who manufactured it and what the pharmacy
stocked.
Data from the Prescribed Medicines Prevalence Survey showed that 52% of the prescribing
instances were for generic medicines. Even proprietary medicines not available as generics were
being prescribed generically as was the case for ispaghula husk sachets which were prescribed
generically 33% of the time. This rate is slightly lower than average rate of generic prescribing in
England and the Northern Region which currently stands at 60% and 67%, respectively
(Department of Health, 1998). This lower rate of generic prescribing may be partly due to the
fact that of the 143 medicines with prolonged oral clearance many were proprietary
gastrointestinal medicines (antacids). Although these medicines have been on the market for many
years, there is no direct generic equivalent for them due to their complex mixture of ingredients.
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All OTC preparations with prolonged oral clearance identified during the setting up of the
OTC database were proprietary preparations, however, OTC generic medicines with prolonged
oral clearance are being developed. A number of solid dose OTC generics have been on the
market for a few years and recently medicines such as paracetamol suspension have started to be
marketed and sold as OTC generics. This production commenced after action by pharmaceutical
manufacturers in response to large non-pharmacy supermarkets insisting on breaking Resale Price
Maintenance (RPM) rules. These rules state that all OTC medicines should be price-fixed to
discourage competition over pharmaceuticals between pharmacies and other retail outlets. The
supermarkets disagreed with this and arranged for their 'own brand' generic OTC medicines to
overcome this price fixing. This move has raised the public profile of generic manufacturers.
Previously, in the dispensing process the manufacturer of the generic formulation was normally
not identifiable from the prescription dispensed to the patient, which is usually dispensed in a
brown bottle from a large dispensing pack. The European Community is urging pharmaceutical
manufacturers to introduce prepackaged patient packs containing one months supply of a
medicine where the manufacturer will be clearly identified. As the generic manufacturer is more
clearly identifiable as a result of these changes, they may be forced to formulate more dental
'friendly' products if the consumer demands it.
8.3.6 Prescribing of medicines with prolonged oral clearance
The two prevalence surveys have shown that the prevalence of use of prolonged oral
clearance medicines in the elderly, especially generic medicines may pose a threat to dental health
of dentate elderly.
The greatest threat is from generically prescribed liquid oral medicines, the majority of which
were sugars-containing. The main therapeutic areas of use of these generic liquids were for
gastrointestinal problems and in particular laxatives. This aspect of use should become a focus
for dental health promotion in the elderly. Rather than going through the costly process of
reformulating the medicine, rational prescribing may improve the situation, such as reducing the
use of laxatives by ensuring the patient is given good dietary advice and avoiding taking medicines
that cause constipation where possible. Where laxatives are used, their prescribing could be
monitored to restrict them to short-term use.
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8.4 IMPLICATIONS AND RECOMMENDATIONS
The results of the surveys presented here have a number of implications as far as prolonged
oral clearance medicines and their use in the elderly is concerned. These can be most
comprehensively discussed as they affect the professional bodies concerned.
8.4.1 For government
Tougher legislation by government with regard to the manufacture of generic medicines is
required in terms of regulation of the incorporation of sugars in medicines destined for long-term
use. There is also a need for generic manufacturers to compile accurate drug information with
regard to the sugars content of medicines which is readily available for professional use. This
would show commitment to cost-effective, efficacious drug therapies and to dental health. Sugars
contained in a preparation should no longer be treated as inert ingredients but rather as active
substances which can cause dental caries.
The government could possibly influence the use of sugars-free medicines in a number of
ways. It could offer general medical practitioners inducements to prescribe sugars-free, reimburse
pharmacists the difference in price for dispensing sugars-free, or it could help generic
manufacturers by subsidising the production of sugars-free medicines.
8.4.2 For manufacturers
Pharmaceutical manufacturers have a central role in the issue of medicines and dental health:
they need to ensure that all new medicines with prolonged oral clearance are available sugars-free
especially if the data sheet indicates possible long-term use. Secondly, there is a need to continue
the reformulation of older sugars-containing prolonged oral clearance medicines as sugars-free
and phase out the production of sugars-containing medicines. This might be achieved through the
development of alternative dose forms which are more readily formulated with an alternative
sweetener. This move from sugars-containing to sugars-free formulations has been seen in the
actions of manufacturers of proprietary medicines but generic companies have been slow to
follow. The main reason appears to be cost as in the competitive market place companies are
continually trying to reduce overheads to offer the cheapest products.
Progression to sugars-free from sugars-containing medicines with prolonged oral clearance is
not a simple process and there many issues to be considered. Sucrose has a number of properties
which make it an ideal excipient in the production of pharmaceuticals. It has a preservative
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action, good bulking properties and prevents crystallisation in liquids. In addition there are
certain problem areas with regard to the manufacture of sugars-free medicines with prolonged oral
clearance. Firstly, manufacturers have not always been aware of which POC medicines are
prescribed long-term. Secondly, it has been proprietary pharmaceutical manufacturers who have
made the most progress in moves to provide sugars-free medicines with alternative sweetening
agents. In contrast, generic manufacturers, by trying to produce the cheapest drug available have
not been able to provide prescribers and dispensers with suitable range of sugars-free alternatives.
This difficulty has been due partly to the discrepancy between the costs of using EC subsidised
sugars-based sweetening agents rather than more expensive alternative sweetening agents which
are the non-subsidised (Bonds & Fields, 1991). Governments' failure to provide incentives to
make necessary regulatory changes have compounded the problem as old habits die hard and
manufacturers are reluctant to replace best sellers with new products where there would appear to
be no demand. Some newer dosage forms such as effervescent tablets have been introduced to
replace the more traditional liquid oral medicines in recent years. Their longer shelf life and
reduced bulk provide many advantages over liquid oral medicines. However, with some of these
alternative dose forms a potential new risk to dental health has emerged due to the high acid
content of some of these products. This threat may put dentate individuals who need regular and
long-term medication at risk from dental erosion.
8.4.3 For prescribers
The prescribing of medicines with prolonged oral clearance is ultimately the responsibility of
the general medical practitioner (who may be acting on the recommendations of a consultant).
However, the nature of the formulation received by the patient in terms of its sugars content is
controlled by a number of organisations and professions all of whom have an integral
responsibility to the patient to ensure that they receive a medicine which is safe and effective.
Prescribers of medicines are under pressure to control their drug budgets tightly and therefore the
present degree of use of generic medicines is unlikely to decrease. However, prescribers should be
aware of the risks to dental health posed by the long-term use of liquid oral medication, and
consider the following points when prescribing to the elderly:
1. Where possible, the elderly should be prescribed solid dosage forms.
2. Where a medicine with prolonged oral clearance is necessary long-term, if available a
sugars-free equivalent should be used.
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3. Specificity when prescribing long-term is crucial; failure to state 'sugars-free' when
prescribing generically may result in a sugars-based preparation being dispensed where an
equivalent sugars-free proprietary form is available. Computer systems in general
medical practices could be programmed to automatically place the words 'sugars-free'
every time a medicine with prolonged oral clearance is prescribed.
4. Dentate patients taking a medicine with prolonged oral clearance which is sugars-based
should be encouraged to brush their teeth using a fluoride toothpaste after taking the
medication, providing the medication is not highly acidic. They should attend for regular
dental care to ensure that comprehensive dental preventive measures can be undertaken as
an adjunct to medical management.
Since the majority of prescriptions for medicine with prolonged oral clearance used
regularly and long-term in the elderly are provided by general medical practitioners, with or
without the advice of hospital physicians, practical information and support regarding the use of
sugars-free alternatives, especially in long-term therapy, should be provided by the medical, dental
and pharmacy professions.
8.4.4 For dispensers
If a medicine is prescribed generically without 'sugars-free' being specified on the
prescription the pharmacist can decide which preparation to dispense and can choose a sugars-free
or sugars-containing preparation. As pharmacies are businesses and sugars-free preparations are
usually more expensive than sugars-containing, then the pharmacist may opt to give sugars-
contammg. Pharmacists may also dispense sugars-containing preparations if they fail to
understand about sugars-containing medicines with prolonged oral clearance and the risk to dental
health. However, studies have shown a reasonable level of knowledge and awareness of the
sugars-free option amongst pharmacists (Maguire et al., 1999).
Most community pharmacies now keep patient medication records and are encouraged to do
so by the Pharmaceutical Society by Great Britain, which through the Pharmacy Services
Negotiating Committee offer remuneration for offering this service (Royal Pharmaceutical Society
of Great Britain, 1998). In addition, a pick-up service from general medical practices for repeat
prescriptions which has been recently introduced will ensure that a particular pharmacy will
dispense for the same patient all the time. In this situation the pharmacist has the opportunity to
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identify sugars-based medicines with prolonged oral clearance and provide advice with regard to
suitably equivalent solid dose forms or sugars-free alternatives. However, unless pharmacists are
aware of the potential they have to monitor and intervene in the dispensing of sugars-containing
medicines with prolonged oral clearance the situation is unlikely to change. Repeat prescriptions
are a particular problem; they could be treated separately and a special payment made to
encourage pharmacists to optimise sugars-free dispensing, allowing the pharmacist full
reimbursement for providing a sugars-free proprietary equivalent to a medicine generically
prescribed, if the medicine was for long-term use. In addition, pharmacists should be encouraged
to 'persuade' prescribers to use sugars-free medicines where possible and even contact the
prescriber if they identify a problem. This need only be in the short-term until the generic
manufacturers were able to produce more sugars-free alternatives. The use of 'over the counter'
(OTC) medicines with prolonged oral clearance is an opportunity for pharmacists to provide
advice to consumers regarding sugars-free medicines. Many of these OTC products are taken on
a regular basis (e.g. cough medicines and analgesics) subjecting a significant proportion of the
purchasing population to an increased sugar intake. The elderly users, and carers administering
these medicines may not be aware of this source of sugar and maybe unaware of the increased risk
of dental disease.
Pharmacists could request more information from manufacturers regarding the constituents
of medicines, and act as an informed source to advise medical practitioners on the sugars content
of products. The National Pharmaceutical Association has not updated its newsletter on sugars
content of liquid medicines since December 1995 (Personal Communication, NPA Information
Department, 1998) and this information is no longer current as many medicines have since been
formulated as generics.
A national database, perhaps maintained by the Department of Health, which included
information on the sugars-content of all medicines with prolonged oral clearance and was updated
regularly, by perhaps electronic links to pharmaceutical companies, should be available to all
health professionals. Such a database could be made available on-line over the Internet to allow
easy access by the relevant professions.
8.4.5 For health promoters
Health promotion in the UK involves the health promotion departments of the health
authorities, pharmacies, general medical practices, dental practices and hospitals. Health
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promoters need the proper resources and information on the risks associated with sugars-
containing medicines, the types of medicines involved and the advice to give in order to work
effectively. A team approach is needed to dealing with this issue, involving all health
professionals and health promotion teams. Their main target group is the consumer whose
knowledge and attitude must be changed. Patients must be educated on the potential risk and
what they might do to minimise risk. If patients start to demand sugars-free medicines then the
health professions and manufacturers will have to listen.
8.4.6 For the consumer
The outcome of health care issues is influenced considerably by consumers whether they be
patients, purchasers or carers. They can however only act on existing knowledge and raising their
level of awareness with regard the forms of medication available must be the initial step. The
targeting of specific groups such as carers of the chronically ill elderly would concentrate these
efforts more effectively. Patients rely on health professionals for advice and may look to
pharmacists, general medical practitioners and dentists for information on the risks to dental
health from sugars-containing pharmaceuticals. Patient groups such as the Consumers
Association may also have a role to play, seeking information from the relevant health
professionals and relaying this to the patient. Existing attitudes are often hard to change and it
may be difficult to persuade an elderly person who lacks understanding on the risks associated
with sugars-containing medicines to actively ask for sugars-free medicines. Many of the
comments made on the questionnaires returned by the elderly in the OTC Medicines Prevalence
Survey, showed that the elderly were not aware that sugars-free medicines were available nor
were they aware of any problems associated with sugars-containing medicines.
8.5 FURTHER WORK
The research in this study has concentrated on the elderly aged 60 years and over. Future
work is needed to assess that 16 to 60 year olds are not at risk from sugars-containing medicines
with prolonged oral clearance.
Another area of interest is the use of effervescent tablets which form an acidic solution upon
dissolution and may contribute towards dental erosion. Future work is required to assess the risk
of these medicines to dental health and the prevalence of their use, especially in light of the
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increase in the use of medicines such as aspirin 75mg effervescent tablets for prevention of
coronary heart disease.
The increase in the use of generic 'over the counter' medicines should be investigated to
monitor their formulation with regard to sugars content. It is important that they do not follow the
path of prescribed generics being formulated as sugars-containing medicines.
The increasing number of generic formulations and the rapid change of ownership of generic
manufacturers introduces continual change in the generic market and the sugars content of
formulations of medicines with prolonged oral clearance should be monitored. A database of
these medicines should be devised, perhaps using a database similar to the one created in this
study and this should be kept current. With advances in information technology and the internet,
this database could be made available to all relevant professionals and provide up to date
information on all medicines with prolonged oral clearance.
Research into the change in patterns of use of sugars-free medicines with prolonged oral
clearance in the elderly and other groups of the population should be ongoing, to record and
monitor progress, in the quest for optimal dental health.
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CHAPTER9
CONCLUSIONS
The study had one main aim and four subsidiary aims. Using two prevalence surveys and
three surveys looking at overall use of medicines with prolonged oral clearance, these aims were
addressed and the following conclusions can be drawn:
9.1. Main aim
• The prevalence of use of prescribed medicines with prolonged oral clearance used
regularly and long-term by the elderly in ten practices in five districts of the Northern
Region of England was 9.8%, representing 2002 patients aged ~60 years who were taking
143 medicines with prolonged oral clearance 2796 times overall.
• The prevalence of use of 'over the counter' (OTC) medicines with prolonged oral
clearance in a sub-sample of patients in 10 practices in 5 districts of the Northern Region
was 1.1% representing 17 patients aged ~60 years taking 13 OTC medicines with
prolonged oral clearance 17 times overall.
9.2. Subsidiary aims
9.2.l. Of the 2002 patients taking prescribed medicines with prolonged oral clearance regularly
and long-term, 68% were female and 54% aged 60 to 74 years, and of the patients taking
OTC medicines with prolonged oral clearance, 47% were female and 77% aged 60 to 74
years.
9.2.2. The main medical problems of patients taking prescribed medicines with prolonged oral
clearance regularly and long-term and patients responding to the questionnaire in the
OTC Medicines Prevalence Survey were cardiovascular and musculoskeletal. The main
therapeutic areas for the prescribed medicines with prolonged oral clearance used
regularly and long-term were Gastrointestinal, Cardiovascular and Central Nervous
System. The main therapeutic areas for OTC medicines were Gastrointestinal and
Nutrition and Blood.
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9.2.3. In terms of sugar-content, 81% of the prescribing instances for prescribed generic liquid
oral medicines were for sugars-containing medicines, compared with only 8% of the
prescribing instances for proprietary liquid oral medicines (Prevalence Survey of
prescribed medicines). Of all 909 prescribing instances for generic solids with prolonged
oral clearance, 94% were sugars-free; 44% of 342 prescribing instances for proprietary
prescribed poe solids. Of the 17 instances of regular and long-term use of OTe
medicines with prolonged oral clearance, identified in the OTC Prevalence Survey, 41%
were sugars-containing.
9.2.4. The volume of medicines with prolonged oral clearance supplied overall (in primary and
secondary care) in the Northern Region was 0.73 million litres and 134.3 million solid
doses of prescribed medicines with prolonged oral clearance and 0.11 million litres and
16.8 million solid doses or OTC medicines, over a one year period (1994).
9.2.5. Generic prescribing was substantial with 52% of the 2796 prescribing instances for
medicines with prolonged oral clearance used regularly and long-term by the elderly, and
60% of all 2.51 million prescriptions dispensed for medicines potentially used regularly
and long-term by the elderly in the Northern Region (in 1994) were generically prescribed.
In terms of quantity, 41% of liquid oral medicines and 78% of solid doses with prolonged
oral clearance and potentially used regularly and long-term by the elderly, dispensed in the
Northern Region over a Oneyear period (1994) was generically prescribed.
This study, through a series of surveys has shown that the elderly, of whom almost 50% were
dentate, are taking medicines with prolonged oral clearance regularly and long-term, with
prescribed medicine use being greater than OTe medicine use. These medicines with prolonged
oral clearance, especially generically prescribed liquid oral medicines are likely to be sugars-
containing and pose a threat to the dental health of these dentate elderly.
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